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Abstract 
Counter current chromatography (CCC) is a form of liquid liquid chromatography, which 
the Brunel Institute for Bioengineering (BIB) team have developed to process scale. In this 
thesis, its application has been successfully extended to the rapid, scalable purification of 
monoclonal antibodies (mAb) from mammalian cell culture, using aqueous two-phase 
systems (ATPS) of inorganic salts and polymer. A polyethylene glycol (PEG) and sodium 
citrate system was found to be the most appropriate by robotic phase system selection. The 
search for an economical alternative to protein A HPLC is a substantial bioprocessing 
concern; in this work CCC has been investigated.  
Initial studies showed that unpredictably, despite separation from impurities being 
achieved, some loss in the IgG‘s ability to bind to Protein A was seen, as confirmed by 
Protein A BiaCore analysis. CCC machines were seen to adversely affect IgG 
functionality. This led to a systematic investigation of the effect of CCC phase mixing on 
IgG functionality in a number of different CCC instruments, allowing direct comparisons 
of modes of CCC (hydrodynamic and hydrostatic CCC) and their associated mixing (wave-
like and cascade, respectively). The varying g forces produced within the CCC column 
were determined using a recently developed model to calculate g force range. The effect of 
interfacial tension was also studied using a custom built ‗g‘ shaker. 
 The optimum CCC mode was identified to be the non synchronous CCC, 
operated in a hydrodynamic mode but allowing bobbin to rotor speed (Pr ratio) to be 
controlled independently. In a normal synchronous J type centrifuge a Pr of 1 is fixed, this 
is where the bobbin and rotor speed are identical I.e. one bobbin rotation (where mixing 
occurs) to one rotor revolution (where settling occurs). Constraints were seen with this 1:1 
ratio and the separation of mAb using ATPS. This work has shown with the use of the non 
synchronous CCC at a Pr of 0.33, mixing is reduced and rotor rotations increased. 
Consequently the associated g force range is decreased. Furthermore, by the extension of 
settling time, the clear separation of the mAb from impurities has been achieved with 
retention of biological activity.   
 This thesis demonstrates the importance of settling time for ATPS in 
phase separation and documents the fundamental requirements for the successful 
separation of biologics. Purified non synchronous CCC samples have additionally 
undergone rigorous quality control testing at Lonza Biologics by their purification 
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scientists.  This work has ultimately showed that with optimisation, the non synchronous 
CCC can be used to produce biological samples that are of industry standard.  
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1.1.1  Monoclonal antibody discovery  
Monoclonal antibodies (mAbs) are therapeutic proteins, naturally manufactured by the 
body‘s B cells, with a typical molecular weight of 150kDa. They were discovered in 1975 
by Kohler and Milstein using hybridoma technology. A hybridoma is defined as a 
biologically constructed hybrid of a mortal antibody producing lymphoid cell with a 
malignant or immortal myeloma cell (Marx et al., 1997). Hybridoma technology has 
allowed the limitless production of antibodies from a single clone, thereby named 
monoclonal antibodies. All resulting antibodies were thus identical and highly specific, 
creating a major advance in biotherapeutics. Initially, in vivo production of mAbs was in 
mice and rats. The immune system of the animals was primarily suppressed, a hybridoma 
was injected and multiplication occurred in the peritoneal cavity. Ascetic fluids produced 
were rich in secreted antibody. Following an appropriate incubation interval, the animal 
was killed and ascites drained. Despite very high antibody yields being produced in the 
range of 1-20mg/ml, ethical concerns were raised due to the manner of their production. 
Additionally, as mAbs were produced in animals, they showed reduced immunoreactivity 
of around 60-70% (Marx et al., 2007) in humans, lowering their ability to induce human 
responses (Figure 1.1.1). 
 
Figure 1.1.1: In vitro and in vivo human antibody production. b) Primarily based on hybridoma 
technique, monoclonal antibodies were produced using mouse models. These genetically 
engineered mouse produce humanized immunoglobulins, immortalization is by fusion with the 
myeloma cell line. A)  Due to the demand for human antibodies, libraries can now be used to 
improve specificity by irrelative selection using a specific target antigen. The library of antibodies 
can be panned against a target. Antibodies are amplified with Escherichia coli and selection 
rounds continue until the antibody of correct specificity is obtained (Brekke et al., 2003).  
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 Investigations showed the FC constant region of the IgG structure was 
murine in origin, therefore affecting dosing in humans. Patients were seen to develop 
human-antimouse antibodies (HAMAs) which adversely complexed with murine mAbs, 
leading to unwanted sickness e.g. acute anaphylactic (Binyamin et al., 2006). Research 
was prompted into a transition from mouse monoclonal antibodies to mouse-human 
chimaeras (Weiner et al, 2010). Previous immunogenicity issues were overcome by 
substitution of mouse constant domains with that of human heavy constant domains 
(Baker, 2005; Trikha et al., 2002). 
 As the necessity and demand for mAbs has increased, sufficient pressure 
has been placed on the large scale production of humanized monoclonal antibodies. The 
majority of monoclonal antibodies now produced use mammalian cell expression systems, 
for example Lonza uses Chinese Hamster Ovary (CHO) cells. The CHO cell line is 
typically used due to its relative similarity to the human glycolyasation pattern and stability 
as an expression system. Cell line stability of an expression system is critical in the 
production of the desired protein. Generation of the product is only possible when cells 
accept foreign DNA, in which all antibody information is stored (Sommerfield et al., 
2005). Due to the need for the highest possible production rate by the cells, an 
amplification system is typically used. At Lonza (Lonza Biologics, Slough, UK, this 
company is particularly referred to as they are the industrial sponsors of the CASE 
studentship) they use the glutamine synthetase (GS) system (Birch et al., 2006; Birch et al., 
2005).  
1.1.2 mAb cell culture production 
 Cell productivity has greatly increased over the past decade, generating 
high yields of mAbs.  Batch feeding with nutrient fortification has been a major factor in 
achieving these titres (Trebak et al., 1999) (Figure 1.1.2.1). Serum, which is of animal 
origin, is generally used to provide essential nutrients for growth. Although cutting edge 
mammalian cell culture proteins are serum free and use chemically defined media. This 
simplifies purification and reduces regulatory concerns about potential pathogens. Batch 
feeding has been found to maximise final mAb yield by increasing cell culture longevity 
and mAb secretion rate (Bibila et al., 1995). 
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Figure 1.1.2.1: Representation of batch feeding which has resulted in hugely improved cell culture 
titres. Improvements have been made to previous batch culture (left), where no nutrients were 
supplemented. In fed-batch culture, nutrients are fed at specific time intervals during the 
fermentation process (Birch et al., 2006). 
 
 Purification of mAbs that follows the fermentation process requires the 
removal of a variety of protein products secreted by the cells into the fermentation broth 
(Figure 1.1.2.2). Additionally cell culture medium e.g. amino acids, inorganic salts, 
vitamins and supplements added for example calf serum must be separated from the 
product protein. Also DNA, viruses and lipids present in fermentation broth as by products 
from cell lysis must be removed along with host cell proteins. A vast range of proteins are 
required to be separated from the protein of interest (mAb), making purification extremely 
challenging (Somerfield et al., 2005). 
 
Figure 1.1.2.2: Fermentation tank. On the left hand side all components needed to produce mAb 
are shown. By-products from cell lysis and the fermentation process must also be removed. Also 
the mAb must be removed from other proteins, making purification extremely challenging 
(Sommerfeld et al., 2005).   
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1.1.3 Mab structure 
Antibodies (IgG) are therapeutic molecules with a well defined biochemical structure. 
Their structure is the major determinant of their resulting specificity to a range of targets 
(Shukla et al., 2007). Immunoglobulins are defined by four covalently linked polypeptide 
chains, which are subject to varying degrees of glycosylation. Two distinct functional units 
make up an antibody; these are known as the fragment of antigen binding (Fab) and the 
constant fragment (Fc). Of these four polypeptide chains, two chains are heavy and two 
chains are light and are held together by an intermolecular disulfide bonds (Hinge). All 
chains are folded into immunoglobulin domains. The Fab contains the variable domains, 
consisting of three hypervariable complementarily determining regions (CDRs) at the 
amino terminal part of the molecule. These CDRs form the antigen binding site of the 
antibody. The binding site is formed where light chain variable domain (VL) and heavy 
chain variable domain (VH) meet, and antigen specificity and resulting affinity is 
conferred here (Weiner et al, 2010). The light chain has one constant domain (CL) and one 
variable domain (VL). The heavy chain, however, has one variable domain (VH) and three 
constant domains (CH1,CH2,CH3) (Tabrizi et al., 2006). The remaining part of the 
antibody is composed of a ‗constant domain‘, which varies only between classes and 
serves to bind varying effector molecules (Brekke et al., 2002). The heavy and light chains 
are held together by a combination of non covalent and covalent interactions to the 
disulfide hinge region (Figure 1.1.3.1).   
  
Figure 1.1.3.1:  The 4 chain basic structure of Immunoglobulins is shownn (left). Heavy and light 
chain produce a complete molecule of 150 kDa (Steinmeyer et al., 2008). On the right hand side, 
Fc and Fab portions are labelled. The resulting inter-chain disulfide bonds and non-covalent 
interactions can be seen.  Specificity is conferred in the CDR loops of the variable region. (Brekke 
et al., 2002).   
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There are five different classes of antibodies that exist: IgA, IgD, IgE, IgG and IgM, which 
are distinguished by the type of heavy chain they contain. It is this difference in heavy 
chain polypeptide that gives rise to differing structure and therefore biological activity of 
the classes. The difference is found within the Fc fragment; in addition to this some classes 
such as IgG, can be further divided into subclasses e.g. IgG1, IgG2, IgG3 and IgG4. The 
IgG monomer is the most abundant class in human serum; and is the only class to cross the 
placenta in humans during birth (Figure 1.1.3.2). IgGs are usually used as therapeutics due 
to the biological response they elicit. Both its abundance and specificity make it an 
extremely attractive molecule for both research and clinical diagnostics (Pierce scientific). 
Molecular weight 150kDa Total size 
55kDa for each heavy chain 
25kDa for each light chain 
Serum concentration 10-16 mg/ml 
Percent total Ig 75% 
Figure 1.1.3.2:  Table summarising IgG properties 
 
1.1.4 Monoclonal antibody market 
Monoclonal antibodies due to their specificity represent a multibillion pound industry 
(Reichert et al., 2008). The therapeutic properties of mAbs for the treatment of a range of 
diverse diseases have established them as the biggest selling biotherapeutics, known as a 
blockbuster. mAbs are an equally attractive molecule for diagnostics and are used in a 
number of differing assays e.g. virus assays. Over 20 mAbs have currently been FDA 
approved as shown in Figure 1.1.4.1. Their unique selling point of specificity has allowed 
their applications to grow from biotechnology and diagnostics to most recently the human 
proteome (Roque et al., 2007). It has been reported, that 3200 pharmacological target in 
the body out of a possible 5200 in the human genome are susceptible to protein 
intervention (Steinmryer et al., 2009). 
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Figure 1.1.4.1: mAb currently FDA approved and their corresponding indications. (Sommerfield et 
al., 2005). 
 
The therapeutic indications for mAbs are growing and now encompass oncology, arthritis, 
infectious disease and immune and inflammatory disorders (AIID) (Reichert et al., 2004). 
More recently they have been seen to provide customised affinity against drug abuse e.g. 
prevention of relapse for nicotine addiction (Peterson et al., 2006). Moreover, due to their 
incredible specificity and limited side effects they remain popular in cancer therapy 
(Alkan, 2004). Other cancer therapies are well known for their inability to distinguish 
healthy cells from those of the target tumour cells, hence resulting in toxicity to the 
patients. Minimal toxicity is seen with mAbs as they can be designed to selectively target 
the tumour cells and elicit anti-tumour effects. Their mode of action is either by 
complement mediated cytolysis, cytotoxicity, delivery of radiation or blocking receptors or 
growth factors (Zhang et al., 2007). The targets used by mAbs in oncology treatment are 
shown in Figure 1.1.4.2. 
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Figure 1.1.4.2: Overview of oncology treatment targets with the use of mAbs 
1.1.5 Modes of action 
The ultimate aim of mAbs is to eliminate or neutralise infection or to treat disease targets. 
It is this biological activity that is exploited therapeutically. 
 
 
Figure 1.1.5.1: Overview of mAb therapeutic modes of action. Characterized into three modes: (1) 
blockage of specific molecules,(2) targeting of specific cells or (3) functioning as signalling 
molecules. 
 
Therapeutic antibodies: Mode of action 
1Block action of specific molecules 
Prevent growth factors, cytokines or 
soluble mediators reaching target. 
Achieved by antibody binding to either 
molecule or receptor. 
  
2) Target specific cells 
For example with cancer cells 
Antibodies engineered to carry effector 
molecules e.g. toxins or radiation 
3) Functioning as signalling molecule 
Natural effector function of antibodies 
By antibody dependent cell cytotoxicity 
(ADCC) or complement dependent 
cytotoxicity (CDEC) 
Oncology treatment with mAbs 
                                Targets: 
Against antigens expressed by tumour 
cells 
 E.g. Her-2 (breast cancer) 
 Or antigens shared with cancer 
and normal cells e.g. differential 
antigens CD20,CD52 
Stroma-tumour interaction 
 Neutralisation of growth 
factors e.g. VEGF 
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1.1.6 Upstream/ Downstream processing of mAbs 
The standard commercial purification protocol for mAbs is shown in Figure 1.1.6.1. The 
principle purification step used is Protein A (PA) chromatography and this platform 
approach will be discussed further in later sections.  
 
 
Figure 1.1.6.1: Platform approach typical used in mAb purification using Protein A purification 
Cell culture supernatant is typically purified by the capture step Protein A chromatography. . In 
order to remove all contaminates post Protein A capture and to obtain purity to regulatory 
compliance, two additional chromatographic polishing steps are employed.  
 
Vast improvements upstream in cell culture titres have been achieved; however this has not 
been directly translated into downstream success, creating a processing bottleneck. 
Upstream productivity has increased greatly due to previous challenges of bioreactor size, 
cell culture cycle time and low expression level being overcome. Significant improvements 
in growth medium and feeding strategies have been made (Swinnen et al., 2007) (Figure 
1.1.6.2). Further improvements upstream are still being investigated and include the 
manipulation of genotypes to produce more stable cell lines and also the use of differing 
expression systems as opposed to mammalian cells. Recent work has suggested future 
trends will involve the use of E.Coil and yeast with a less expensive and less complex 
processing time (Birch et al., 2006; Farid et al., 2007; Jiang et al., 2010) 
 Concerns, however, have shifted downstream; high titres of mAbs now 
produced by cell culture cannot be processed downstream at the equivalent rates. 
Downstream processing accounts for 50-80% of total manufacturing costs. The need for a 
balance between upstream and downstream processing has never been so important. The 
following costs are encompassed in downstream processing: equipment, consumables, 
labour, waste treatment, raw material and disposal. Of these costs, the PA resin accounts 
for 80%, due to its high cost. Despite platform approaches being seen as advantageous in 
terms of streamlining and costs, manufacturing constraints can still be a problem. Due to 
the price of the PA resin companies routinely use smaller columns with repeat cycling, 
increasing the time to process (Low et al., 2007). A need for a replacement that is 
economically viable, therefore allowing future sustainability, is a major bioprocessing 
issue. Industrial priorities have now shifted from not only replacing Protein A, but also 
Cell culture 
supernatant  
Protein 
A  
Viral 
inactivation 
Chromatographic 
polishing steps x2 
Viral 
filtration 
Ultra 
filtration 
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reducing unit operations. Integration is required that will reduce loss in yield between each 
unit operation (Somerfield et al., 2005).  
  
Figure 1.1.6.2: Bioprocessing bottleneck created by mAb purification by Protein A. As 
fermentation titres have increased, the cost per gram of mAbs would have been predicted to 
decrease in a linear manner. Plant throughput issues due to cost and processing constraints by PA 
have resulted in the cost per gram of mAbs to plateau off (Left graph). With the production of mAbs 
(steps represented by single purple boxes) an increase in titres has significantly increased plant 
purification time (Right graph). Pictures courtesy of Lonza biologics.  
 
1.1.7 Protein A: Structure 
The natural affinity between Protein A and IgG forms the basis of Protein A purification. 
Protein A is derived from gram-positive bacterium Staphylococcus aureus. It is a cell wall 
associated protein domain that resides on the bacterium surface. Sequencing of the 
staphylococcus protein A (SPA) was conducted by Uhleh et al (1984) this was to predict 
the gene encoding Protein A was composed of three distinct regions. These being: S for 
signal sequence, five homologous IgG binding domains, E, D, A, B and C, and a cell wall 
anchoring region XM (Hober et al., 2007) (Figure 1.1.7.1). It is the five IgG binding 
domains which allow affinity binding of the Fc portion of IgG1, IgG2 and IgG4. 
 
Figure 1.1.7.1: Protein A structure. Protein A has a molecular weight of around 42kDa. Domains 
E,D,A,B,C define the Fc binding site to the mAb.  Specificity offered by protein A to IgG has made 
it a hugely studied molecule. An engineered domain termed ‘z’ has been produced and is used in 
affinity resins (e.g. Mabselect SURE). (Hober et al., 2007).   
 
 20 
 
1.1.8    Protein A chromatography 
Monoclonal antibody purification by Protein A is the gold standard capture method in 
biopharmaceutical manufacturing. It is used due to its incredible specificity. Due to the 
affinity interaction of the mAb with protein A, a reduced level of non specific binding is 
seen, thereby increasing operational yields. The ability of protein A to tolerate crude 
extracts from the cell culture starting supernatant, allows a one step purification to a 
specificity of > 99.5%.  Polishing steps remove host cell proteins, DNA and aggregated 
IgG to an acceptable level. The uniform platform approach offered by Protein A 
purification allows manufacturing harmonization, where all additional steps have been 
investigated to allow efficient mAb production (Follman et al., 2004). 
 Cuatrecasas et al in 1968 introduced this form of affinity chromatography 
for antibody purification. Protein A ligands are covalently immobilised onto a solid 
(agarose) support and packed into a chromatographic column.  Cell culture supernatant is 
loaded onto the column and IgG is retained by its interaction with protein A. Further 
washing allows unbound non specific species to be washed away with other impurities. 
Final elution is with a low pH elution buffer, which causes the protonation of histidine 
residues on the mAb and PA, which are next to each other in the binding area. This leads to 
charge-charge repulsion and elution (Figure 1.1.8.1). The column is then regenerated for 
further use.  
 
Figure 1.1.8.1: Schematic of protein A HPLC purification. The Protein A ligand is immobilised on 
to the column. Following crude sample loading, the mAb is retained by affinity binding to protein 
A. Washing is employed to remove non specific binding. Elution of the mAb is with a low pH 
elution buffer.  (Roque et al., 2007). 
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Additional chromatographic modes are subsequently employed to allow a final level of 
acceptable pharmaceutical purity to be reached. Polishing steps are conducted in an 
orthogonal mode. Hydrophobic interaction chromatography (HIC) and anion exchange 
chromatography are routinely used based on their differing removal specifications. Anion 
exchange allows the removal of DNA and endotoxins following Protein A capture, whilst, 
HIC allows the final removal of aggregates post purification.  
1.1.9 Protein A purification issues   
The low pH column elution needed for IgG elution from Protein A can cause protein 
aggregation issues. The need for low pH is due to complementary histidyl residues on both 
the Protein A and IgG that must be protonated to allow IgG release. Structural changes 
occur in the Fc region of the IgG and can result in a high weight molecular aggregate 
content. In turn this affects column eluate turbidity and ultimately creates immunogenicity 
concerns, hence the need for additional polishing steps. The pH required for elution can be 
raised by the addition of NaCl (0.1-1M) thereby reducing the adverse effects of using a low 
pH elution in Protein A purification, but this can reduce yield from the column. Ethylene 
glycol can also be used to reduce strong hydrophobic interaction between Protein A and 
IgG, increasing the elution pH required (Shukla et al., 2007). 
 Protein A leaching is also a serious issue in mAb purification. The 
Protein A ligand has been seen to co-elute with the antibody, as it dissociated from the 
column. Additional polishing steps are thus critical for the removal of this leached Protein 
A which must be cleared for regulatory acceptance. Carter-Franklin et al (2007) reported 
that leaching could possibly be reduced by the addition of EDTA, suggesting that 
proteinases may be a factor. Cleaning in place and column saturation with Protein A is also 
an issue; the ligand cannot withstand harsh alkaline conditions. In order to remedy this, 
high concentrations of chaotropes i.e. urea are used, which pose an environmental removal 
challenge. The engineered two domains can be used with 0.1M NaOH, Mabselect SURE is 
used at Lonza. 
However, the major disadvantage of Protein A is its high cost, which is non 
comparable to any other chromatographic resin.  Possible solutions have been the design of 
small molecule ligands with a similar binding affinity of mAbs to Protein A. Hober et al 
2007, detailed how less sensitive Staphylococcus aureus Protein A molecules have been 
designed where sensitive amino acids are replaced, allowing cleaning in place to therefore 
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be conducted. However, this resin is even more expensive that normal PA. Ligands to 
mimic binding pockets of Protein A for Fc region interaction have also been developed. 
These protein mimetic resins (Mabsorbent A1p) have been seen to be effective; however 
they have a much lower affinity than Protein A and are not widely used in industry. 
1.2 Chromatographic alterative to Protein A 
The need to find an alternative to Protein A purification has previously been highlighted 
(Lyddiatt, 2002). Ideal features for protein chromatographic separation are high selectivity, 
high binding capacity, low nonspecific absorption, reusability and low cost (Jungbauer et 
al., 2005). Follman et al in 2004 demonstrated that a platform approach can be 
successfully applied with the use of three chromatographic steps, which do not include 
Protein A affinity chromatography. Previously, direct technology comparisons have been 
made with Protein A purification and differing technologies. Other technologies simply 
cannot compete with the incredible specificity offered by Protein A (>99% impurity 
removal directly from cell culture supernatant). As this group highlighted there is a need to 
ensure that following complete purification (all three individual steps) adequate 
purification is reached and each step should not be viewed as a single entity. By varying 
combinations of the methods of cation exchange, anion exchange, hydrophobic charge 
induction and small molecule ligand resin chromatography, host cell proteins (HCPs) could 
be removed from CHO-derived monoclonal antibodies, to a level comparable to Protein A 
purification. The order in which chromatographic steps were performed was seen of 
significant importance. Capture steps that removed the highest amount of HCPs from the 
cell culture starting material (e.g. mixed mode) did not ultimately yield the lowest HCP 
level. It was hypothesised that binding competition between HCP species was evident with 
overloading of initial capture chromatographic steps that would ultimately affect overall 
HCP removal. The most appropriate chromatographic step combination in terms of 
removal of the highest amount of HCPs was demonstrated as hydrophobic interaction 
chromatography, anion exchange chromatography and finally mixed mode ion exchange.  
1.2.1 Cation exchange chromatography 
 The chromatographic capture step which has been seen with the greatest potential 
to rival protein A purification of mAbs is cation exchange chromatography (CEX). It has 
been demonstrated with the commercially available mAbs Synagis (Medimmune) and 
Humira (Abbott). The robustness of cation exchangers, prevention of ligand leaching and 
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relatively lower costs when compared to Protein A purification, makes it an attractive 
option. Strong cation exchangers developed by Merck known as Fractogel have shown 
yields and host cell removal that are comparable to Protein A purification (Stein et al., 
2007). 
 CEX utilizes the basic isoelectric point of mAbs and allows the removal 
of negatively charged impurities i.e. residual DNA and some host cell proteins. Futhermore 
it has the ability to discriminate varying antibody variants from target proteins. Previously, 
elution using CEX was with acidic conditions using sodium chloride which required 
dilution and moreover was implicated in metal corrosion issues during manufacturing. 
Zhou et al (2007) showed the development of a pH-conductivity hybrid gradient elution 
with a cation exchange column. Elution was possible without the need for large 
concentrations of inorganic salts. It was seen that with the use of selected pH values and 
sodium acetate as a buffering salt, hybrid gradient CEX exhibited host cell protein removal 
data comparable to PA purification. Furthermore, scalability to 200L was possible, where 
resolution and separation were not compromised (Zhou et al., 2007). 
 Work by Clausen et al (1999) again used a linear salt gradient CEX but 
focused on the use of Zicronia, creating a novel ion-exchange matrix. Zicronia with its 
incredible chemical stability relative to other silica and polymer supports, allowed harsh 
cleaning procedures to be used. Ethylenediamine-N, N‘tetra (methylene phosphoric) 
(EDTPA) acid was used to modify zicronia based columns, preventing any nonspecific 
binding at Lewis acid sites on Zirconia surface. A purity of >95% and a yield of 92-98% 
from cell culture supernatant was achieved. A disadvantage with this technique however 
comes with scalability. It is predicted that as EDTPA modified Zirconia particle size are 
increased, decreased column efficiency would result.  
 Most recently Muller-Spath et al, (2010) have investigated the use of 
cation-exchange chromatographic capture in a continuous mode. By the use of linear 
gradient interconnected columns are able to recycle side products. High yield and high 
purity of single variant mAbs have been produced (Muller-Spath et al., 2009). Continuous 
mAb loading, with cell feeding and also cleaning in place have been demonstrated. Huge 
benefits have been seen which include time saving, reduction in mAb variants for 
regulatory approval and a continuous mode of operation. Moreover a model was recently 
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proposed (Muller-Spath et al., 2011) that showed great potential to rival Protein A  
purification. At present however, host cell protein removal data has not been considered. 
 A patented technology known as countercurrent tangential 
chromatography has also been described. It avoids complications seen with packed bed 
columns by the use of resins that are flowed through mixers and membranes. The 
membrane retains target molecules and is then eluted with an elution buffer. Separation has 
been investigated with Myoglobin and Bovine serum albumin to a purity of > 99% and 
94% recovery (Shinkazh et al., 2010). Continuous operation mode is possible, which again 
has a distinct advantage to PA affinity purification that can only be operated in batch 
mode. 
 The downside of ion exchange chromatography however, is the 
requirement for the samples to be of a low ionic strength before loading. An additional 
buffer exchange step in most cases is hence required. Due to the large amount of salts used, 
corrosion of the metal instruments can also be a problem, therefore there is a requirement 
for buffer exchange prior to samples being used in any biological assay (Stanton, 2003). 
Uncontrolled pH during elution can also affect protein stability and cause precipitation. 
With the use of CCC however, despite the need for buffer exchange prior to assays being 
conducted, no high pH elution is required, hence the conditions offered by the high water 
content in the phase system is predicted to be much milder.   
1.2.2 Hydrophobic interaction chromatography 
 Another alterative chromatographic method that could possibly be used 
for the purification of mAbs is hydrophobic interaction chromatography (HIC). Due to the 
low concentration of mAbs in cell culture supernatant, separation by membrane 
hydrophobic interaction chromatography has been investigated. The benefit of HIC is 
selectivity due to high anti-chaotropic salt concentrations required. Ghosh et al, (2006) 
showed the separation of humanised monoclonal antibody from mammalian cell culture 
using HIC membranes, composed of a stack of microporous polyvinylidine (PVDF) pore 
size 0.1µm to a purity and recovery of >97%. Further attempts to improve HIC for mAb 
capture have focussed on increasing resin pore size to maximise mAb transport. Novel 
hydrophobic charge induction (HCIC) mixed mode ligands have also been used to allow 
possible capture of mAbs under low salt conditions. The need for high salt has been seen to 
cause manufacturing concerns, which are exacerbated at larger scale. An ideal alternative 
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to Protein A would allow desorption under milder conditions and binding without the use 
of large quantities of salt. The HCIC technique works based on these fundamentals and by 
the use a pH dependent ionisable ligand.  Schwartz et al (2001) showed by the use of an 
antibody selective ligand, binding by HCIC was possible, with lyotrophic salts and 
desorption at a mild pH 4. Chen et al, (2007) further demonstrated the use of HCIC 
mercapto-Ethyl-Pyridine (MEP) resin which allowed capture comparable to Protein A. 
1.2.3 Affinity chromatography 
 In addition to PA HPLC there are other affinity chromatography methods 
that can be used; these are desired due to the specificity they offer. A downside however 
seen with affinity chromatography is the clogging of column matrices with complex feeds. 
Work using expanded bed affinity chromatography, monolithic chromatography and 
stabilized fluidized bed has hence been conducted (Hober et al., 2007; Holschuh et al., 
2005; Huse et al., 2006). All these options are with the objective of increasing cell titre 
loading and resulting reusability of the resin. Alternative affinity ligands include other bio 
affinity ligands, which are naturally occurring and bind to antigens and lectins etc. Protein 
G and L have the ability to bind to immunoglobulin but not to the same degree or 
specificity as Protein A. They do however withstand the harsh sanitation condition needed 
in production plants. Lectin (jacalin agarose) affinity chromatography has been used for 
the purification of IgA with the benefits of elution at a neutral pH. However, as Jacalin is a 
biologically active lectin its implications in immune responses need to be highly regulated, 
and leaching cannot be tolerated. 
 Pseudo specific ligands, as opposed to naturally occurring ligands (lectin, 
Protein A,G,L etc), are tailor made and mimic natural ligands. They are alternatives to 
natural ligands with reduced binding affinity. Harsh elution conditions are hence not 
required to release molecules. Disadvantages and advantages can be seen with this 
technique. With the use of these pseudo specific ligands, problems associated with 
biological ligands are avoided whilst specificity to the IgG is high. However, this has been 
outweighed by low scale up potential, high production costs and the continual issue of 
ligand leaching (Roque et al., 2006).  
Hydrophobic, thiophilic, hydroxyapatite, chelating metal ion and mixed mode 
affinity ligands can all be used for mAb purification (Roque et al., 2007) (Table 1.2.3.1). 
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Type of 
Pseudo 
biospecfic 
ligand 
Name Mode of action Purity achievable 
Thiophilic 
absorbents 
T-gel  Absorption at neutral pH 
with high lyotrophic salt. 
 Elution by lowering the 
salt concentration. 
100% recovery of entire 
immunoglobulin fragment 
from the crude extract. 
Hydroxyapatite Hydroxyapatite 
crystals 
 Positively charged 
proteins retained by 
hydroxyapatite stationary 
phase. 
 Increasing ionic strength 
gradient used for the 
release. 
Used only after PA HPLC, 
recovery of >80%. 
Chelating 
metal ions 
IDA-Ni2+ 
(IMAC) 
 Iminodiacetic acid 
covalently bound onto 
solid support to trap 
nickel ions (affinity 
ligands for proteins). 
>95% IgG recovery from 
goat serum. 
 
Mixed mode 
ligands 
MEP HyperCel  Ligand has a 
hydrophobic core with 
hydrophilic groups 
attached. 
 Elution is by a pH 
change. 
 85% process yield from 
crude cell culture. 
 Optimisation however 
required: by pH and 
conductivity (Toueille et al., 
2011). 
 Unable to compete with 
protein A HPLC for 
selectivity. 
Table 1.2.3.1: Details of pseudo biospecfic ligands available. Commercially available examples 
are listed along with their mode of respective action and the purity achievable in comparison to 
protein A purification (Roque et al., 2007). 
 
 
Apart from naturally occurring and pseudo specific ligands, a new generation of 
synthetic ligands have been produced. These have been based on a need for improved 
stability, reduced production costs, an increasing cycling time and allowance of cleaning in 
place. Most procedures have been based on increasing the stability of the ligand by the use 
of mini Z-domain of Protein A, an example being affibodies (Roque et al., 2007). These 
antibody mimetics are composed of just alpha helices with no disulphide bridges. Their 
unique structure allows them to withstand high temperatures and acid and alkaline 
conditions respectively (Gebauer et al., 2009). By the use of molecular modelling and 
protein engineering significant advances have been made in the discovery of small 
molecule ligands that mimic Fc-Protein A interaction. Fassina et al (2001) initially 
identified Protein A mimetic peptide (PAM) TG191318. Its inverso derivative (D-PAM), 
where all the amino acids are in the D configuration, has also been developed (D‘Agostino 
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et al., 2008). Host cell protein (HCP) removal comparable to PA purification has been 
demonstrated. The peptide can be easily immobilised onto solid surfaces, withstand harsh 
cleaning procedures and does not require low pH elution.  
 With the use of X-ray crystallography the dipeptide motif Phe-132: Tyr 
133 was seen vital in the Protein A, Fc IgG interaction. The motif was mimicked and 
synthesised by Li et al. Work by this group has culminated in the commercialization of two 
synthetic non-peptide Protein A mimetic ligands: Mabsorbent AIP and A2P from proMeric 
Bioscicences (Ghoush et al., 2008). These ligands can be immobilised onto cross-linked 
agarose and function as normal at high pressure for column purification. 
 The use of tags to modify mAbs instead of the search for specific binding ligand 
has also been proposed (Huse et al., 2002). Fusion of recombinant proteins to peptide 
sequence was thought to simplify purification; however clearance of tags after purification 
was thought to be problematic (Low et al., 2007). 
 With respect to finding a chromatographic alterative to PA purification, 
another affinity ligand which has been chemically modified to deal with drawbacks of PA 
would be ideal. Despite synthesis of pseudo specific ligands being valuable, at present they 
are still unable to match Protein A in terms of specificity. The problem of ligand leaching 
still also persists. For large scale purification, CEX allows greatly improved titre loading at 
nearly 100g/l, providing a very economical alternative to PA at a fifth of the price (Chon et 
al., 2011). As detailed previously much investigation has focussed on improving process 
parameters and even continuous operation modes demonstrated. As an alternative 
chromatographic method CEX is most suited in terms of cost and capacity, however 
significant optimisation to match PA purification is required (Low et al., 2007). 
1.3 Non chromatographic alternatives 
Bioseparations using column chromatography have dominated the biopharmaceutical 
industry for many years.  A need for change has been highlighted by the requirement for 
continuous processing and faster operational times. These needs however have been 
outweighed by the level of specificity and resolution offered by column chromatography. 
These factors are fundamental for biotherapeutics, which ultimately are injected or 
ingested by patients.  
 As documented by Przybycien et al (2004), three chromatographic 
alternatives exist: bulk, field based and absorptive separation techniques (Table 1.3.1).  
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Non chromatographic 
method 
Examples 
Bulk separations  Aqueous two phase extraction (ATPE) 
 Three phase partitioning 
 Precipitation 
 Crystallization 
Field based separation  Membrane filtration 
 Preparative electrophoresis 
Absorptive separation  Monoliths 
 Membrane chromatography 
Table 1.3.1: Overview of non chromatographic alternatives available, examples are categorised 
into bulk, field based and absorptive separations (Przybycien et al., 2004). 
 
1.3.1 Bulk separations 
 Protein precipitation has been used for many years at lab scale. 
Historically ethanol precipitation was used; however recovery was low at 50-60%. In order 
to prevent protein denaturation, processing was carried out at 5˚C, which significantly 
increased operational cost. Ammonium sulphate precipitation is commonly used also for 
protein purification but suffers from low yield and purity (Wang et al., 2009). In order for 
protein precipitation to be applied to monoclonal antibody purification, significant 
improvements in specificity are needed. Investigations have been with the use of charged 
polyelectrolytes, such as caprylic acid or poly-ether sulfone (Shukla et al., 2010). Ma et al 
(2010) showed by the use of polyamine precipitation target proteins can be selected, the 
protein products remain in solution and impurities are removed. By the use of the 
polyelectrolytes these insoluble complexes can further be charged to form large clusters. It 
was seen by the use of this procedure, removal of host cell proteins and DNA were similar 
to that of Protein A purification and product quality was maintained (Ma et al., 2010). The 
disadvantage of this technique nonetheless is lack of viral clearance data. Furthermore 
process integration investigation has not been sufficiently conducted to allow comparisons 
to be drawn.  
 Affinity precipitation has also been considered as a substitute to 
conventional column chromatography. Magnetic beads are coated with Protein A and 
immobilised. As demonstrated by Holschuh et al (2005) with the use of magprepprotein A, 
an IgG binding capacity of 50-100 mg per gram is possible. When compared to the column 
and expanded bed chromatography, adsorption time of the IgG through the matrix is 
greatly decreased. Column size and the volume of solution applied are limiting factors in 
Protein A column batch mode purification. With magnetic particles, separation is within 
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minutes and particulates can be tolerated hence there is no need for additional filtration and 
centrifugation prior to sample loading. The major disadvantage of this technique however 
is that only low antibody concentrations can be bound by the beads (around 50mg/L) 
(Holschuh et al., 2005). Again other immunomagentic beads such as thiophilic magnetic 
polymer beads have been investigated. Despite their ease of use, efficiency and reusability, 
binding capacity is a major problem. Larger beads would be needed to reach required 
packing density to support the sample load. A higher flow rate would therefore be needed 
which ultimately effects antibody bioactivity (Qian et al., 2009). Protein crystallization 
also benefits from low running costs but many factors such as protein concentration, pH, 
temperature and engineering issues make optimization challenging (Przybycien et al., 
2004) 
1.3.2 Field based separations 
 Membrane separation has been achieved by charged ultra filtration (UF) 
membranes and high performance tangential flow filtration (HPTFF). Separation is reliant 
on pH solution and ionic strength. Separation of closely similar biomolecules in terms of 
size is possible. Membrane stacks have been used to further improve separation 
(Przybycien et al., 2004).  A downside of this technique is its low ability to remove 
aggregates or host cell proteins. It can therefore only be used as a first step bulk 
purification tool (Shukla et al., 2010). 
 Preparative electrophoresis can also been used for the purification of 
monoclonal antibodies based on charge and size based strategies. Lim et al, 1998 used the 
gradiflow technology, which uses a set of polyacrylamide separating membranes, to 
separate molecules based on their size and charge. With the use of pH and differing pore 
sizes, separation their by isoelectric points is possible. The technology is both scalable and 
cost efficient. However the recovery of antibody activity was only 80% (Lim et al., 1998), 
consequently affecting overall product yield.  
1.3.3 Absorptive separation  
 Adsorptive separations have been shown by the use of monoliths. 
Monoliths are macroporous stationary phase with the material cast into columns as a block 
composed of channels. Molecule transport is by convection as opposed to diffusion 
(Jungbauer et al., 2005). These varying channel sizes and shape can be formulated by 
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polymerization chemistry. With the use of monoliths differing sizes can be designed, 
allowing an increased flow rate and resulting throughput, with less product degradation. 
The major disadvantage comes with scale up and obtaining regulatory acceptance due to 
the non-uniform pore sizes (Przybycien et al., 2004).  
 Membrane chromatography allows high mass transport of large 
molecules, thereby significantly increasing throughput. Mass transfer is improved by the 
elimination of pores with long diffusion pathways. Membrane binding sites are located on 
the surface and convection is used rather than diffusion. Knudsen et al (2001) 
demonstrated the use of ion exchange membranes that offer increased specificity and 
function independent of flow rate. Removal of low level impurities has also been seen. The 
downside of this technology however is low selectivity. Wang et al (2006) showed the 
possibility of using a hybrid technology, with the high resolution monoclonal antibody 
separation offered by membrane chromatography coupled with ammonium sulphate 
precipitation. Ammonium sulphate precipitation suffers from the inverse effect of high 
processing capacity but low resolution. Hybrid separation was designed based on 
ammonium sulphate precipitation of the mAb followed by hydrophilic interaction using 
membrane absorption of dissolved mAb. The retained mAb was removed from the 
membrane module by a single change in solution to promote mAb dissociation from the 
membrane (Wang et al., 2006). Auxiliary improvements to this work, involving salt 
induced precipitation, microfiltration and membrane adsorption by the use of caprylic acid 
for precipitation, resulted in a purity >95%.  
1.4 Aqueous two phase system (ATPS) extraction 
The ability of two immiscible aqueous solutions to form two phases when mixed over a 
certain concentration is termed aqueous two phase system (ATPS). ATPS were discovered 
by Beijernick in 1886 and require structurally different polymers e.g. Polyethylene glycol 
(PEG) and dextran or a polymer and salt, typically PEG phosphate. The importance of 
ATPSs for the separation of biomolecules however was not recognised until work by 
Albertsson in 1950s (Ferreira et al., 2008). The benefits of these systems were 
biocompatibility, phase systems were typically composed of 80-90% (w/w) water, 
providing a very mild system with low interfacial tension (Dallora et al., 2007; Merchuk et 
al., 1998; Raghavarao et al., 1995). It was therefore considered that biological activity 
could thus be retained during separation (Figure 1.4.1).  
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Figure 1.4.1: ATPS extraction. By the combination of a polymer polymer or polymer salt above a 
certain concentration an aqueous two phase system(ATPS) is formed. The product of interest is 
added and partitioning between the phases occurs. Ideally all containments should partition to one 
phase (lower phase) and target molecules to another (upper phase). (Benavides et al., 2008).  
 
 
 Sulk et al, (1992) carried out initial monoclonal antibody purification 
using low molecular weight PEG 1540Da and 22% phosphate. Extraction was coupled 
with thiophilic absorption chromatography. The antibody was targeted to the upper phase 
producing an overall IgG yield of 71% and 90% IgG recovery in the ATPS step. Asenjo et 
al (1996) demonstrated murine IgG purification, again using low molecular weight salt 
(1450Da) but a lower phosphate concentration of 14% and 12% NaCl.  Initial purification 
was into the PEG rich phase and then back extraction into a fresh phosphate solution. 
(Andrews et al., 1996). 
  Despite the promise in this work, successful protein purification using 
ATPS as a primary capture step required critical understanding of the partitioning process 
(Huddleston et al., 1991). Limited predictability of the partition behaviour of proteins was 
a serious issue, additionally all proteins behaved differently. Classical polymer 
thermodynamics, such as Bronstead relationship, Flory-Huggins theory and Diamond and 
Hsu relationship, were based on polymer polymer systems typically PEG-Dextran 
(Luechau et al., 2010; Maderia et al., 2005). Huddleston et al (1996) reported that protein 
partition in PEG salt systems was dependent on solubility in concentrated salt solutions. 
The lack of a predictive model with PEG salt systems however was attributed to their 
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complexity (Samatou et al., 2007).  In order for industrial adoption this needed to be 
addressed, so the full economic benefits of ATPS in monoclonal antibody purification 
could be explored.  
 Partitioning of proteins in aqueous two phase systems (K) is dependent 
on physicochemical properties of the target protein and contaminates and the PEG-salt 
phase system (Andrews et al., 2005; Qu et al., 2009). A large array of variables is thus 
responsible for protein partitioning; including isoelectric point, surface hydrophobicity, 
protein molecular mass, polymer molecular mass, pH, salt type and respective 
concentration (Tubio et al., 2004; Johansson et al., 1998; Saravanan et al., 2008). 
Zaslavsky et al (1987) also stressed the importance of water as a factor in two phase 
formation. Salts, especially at high concentrations, modify water structure (Farruggia et al., 
2004). These factors are yet to be fully understood. It is however this quantity of variables 
and flexibility that allows selective partitioning and targeting of proteins to be achieved by 
the ATPS (Selber et al., 2004).  
 Up until 2006, the ATPS investigation focus was divided into molecular 
understanding of solute partitioning in ATPS and its practical implementation (Rito 
Palomares et al., 2000). Advances in ATPS implementation came with polymer recycling, 
as demonstrated with yeast proteins (Dembczynski et al., 2010). Reduced direct costs of 
consumables and also waste treatment costs for the removal of salt were seen. Recycling of 
the top PEG-rich phase by back extraction for up to 5 cycles following ATPS extraction 
was possible. Furthermore the addition of fresh material compensated for any negative 
effects seen with the continual recycling of upper phase (Rito-Palomares et al., 2000). It 
was clear that for industrial take up a continuous mode of operation was needed with the 
equipment to support this. Process reproducibility and robustness was also key to allow 
ATPS process integration for high value products. (Rito-Palomares et al., 2004) 
 Despite protein partitioning seen as that of a complex one, Tubio et al 
(2004) investigated the relationship of protein surface hydrophobicity to partitioning. The 
partition coefficient (K) was known to be dependent on hydrophobicity, charge and size.  
K= KhphobKelKsizeKpolymer        
Figure 1.4.2: Equation to determine factors affecting partition coefficient K. Where Khphob 
is hydrophobicity, Kel is isoelectric point, Ksize is charge and size and Kpolymer is molecular 
weight of the PEG.  
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All factors were thought to function independently. Previous correlations using the above 
equation (Figure 1.4.2) were investigated with hydrophobicity. Differing hydrophobicity 
however resulted in differences in molecular mass, hydrophobicity and isoelectric points. 
A correlation was seen between partition coefficients and surface hydrophobicity when 
higher PEG molecular weights were used. Higher levels of hydrophobicity at these PEG 
molecular weights affected partitioning (Tubio et al., 2004). Pico et al (2006) further 
showed the differences in partition coefficients of proteins and impurities could be 
exploited. Varying polymer molecular mass showed separation of model proteins with very 
similar isoelectric points.  
 A selection of example ATPS is shown in Table 1.4.3. Four main types 
of ATPS exist, as formed by two hydrophilic phases:  
1) Polymer salt 
2) Polymer-polymer 
3) ATPS constructed with alternative compound e.g. varying co- polymers ethylene oxide 
and propylene oxide (EOPO) 
4) Thermoseparating polymers e.g. EOPO and dextran, allow temperature induced phase 
separation, by heating of a polymer above its cloud point. These polymers have seen much 
potential in recycling hence making them a greener technology (Persson et al., 2000) 
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Phase system Protein Yield (%) Purification 
factor 
Recovery of 
activity 
Assay used Biomass 
loaded 
Reference 
Ucon 50-HB-500 benzoyl-dextran 3-phosphoglycerate 
kinase from baker‘s yeast 
47 2 100% Coomassie 
brilliant blue G at 
595nm. 
Not 
mentioned 
Lu et al., 
1996 
PEG-phosphate ester, 16% (w/w) 
potassium phosphate +3% (w/w) 
NaCl 
Intracellular human 
recombinant interferon 
99.6 25 Not 
mentioned 
Coomassie 
brilliant blue G-
250 method 
10% w/w Guan et 
al., 1996 
PEG 8000 phosphate system pH 
9.4 
 
Small inclusion bodies 87 1.6 Not 
mentioned 
SDS PAGE 
analysis 
2% w/w Walker et 
al., 1999 
EO50PO50/HM-EOPO system 
(50% ethylene oxide (EO) + 50% 
propylene oxide (PO) 
 
Bovine serum albumin, 
Lysozyme, apoloprotein 
A-1. 
78 5.5 Not 
mentioned 
SDS PAGE 
analysis 
10% w/w 
AP-1 
Persson et 
al., 1999 
PEG 1450 24.9% (w/w) phosphate 
12.6% (w/w) pH 8 
ß-phycoerythrin 77 2.9 Not 
mentioned 
545-280 nm 
absorbance 
Not 
mentioned 
Benavides 
et al., 2004 
13.4% (w/w) PEG 3400 18% 
(w/w) potassium phosphate 
ß-glucuronidase 74 20 Not 
mentioned 
SDS PAGE 
analysis/ BCA 
Not 
mentioned 
Ross et al., 
2010 
PEG 8000 16.1% (w/w) + 10% 
phosphate 
Human recombinant 
protein 
88 na Not 
mentioned 
SDS PAGE and 
Bradford assay 
Not 
mentioned 
Ibarra-
Herera et 
al., 2011 
Table 1.4.3: Selected examples of ATPSs extraction of proteins from various feed stocks. Purity achieved, analytical methods used and any noted retention of biological activity 
are shown. 
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1.4.1 Monoclonal antibody purification by ATPS extration 
It has been reported that the aqueous environment offered by ATPS allows the preservation 
of the native structure of proteins, fundamental to biological activity (Benavides et al., 
2008). Azevedo et al (2009) credited the recent re-emergence of ATPS extraction for 
monoclonal antibody purification with the drive to find alternatives to Protein A. The two 
groups working most directly within this research area are the Platis and Laubrou group in 
Athens and the Aires-Barros group in Lisbon. These will be detailed separately.  
 The Platis and Laubrou group have focussed on transgenic plants, namely 
tobacco plants. Tobacco plants have the same glycosylation pattern as humans; production 
of humanised monoclonal antibodies is thus possible. Additional benefits of these 
transgenic plants are low production costs and low risk of human contamination (as it is 
not a food product) (Balasubramaniam et al., 2003). ATPS provide a benefit for a plant 
protein purification system that are otherwise typically based on many chromatographic 
steps i.e. ion exchange chromatography, gel filtration and affinity chromatography. 
Previously, product loss was seen at each stage. ATPS also allow larger quantities of 
biomass to be tolerated and can withstand particulates. Platis et al (2006) demonstrated the 
purification of mAb 2F5 using 12% (w/w) PEG 1500, 13% (w/w) phosphate buffer at pH 
5. A 3-4 fold purification of the mAb was seen with 95% recovery in the bottom phase. 
Furthermore potentially harmful secondary metabolites of the tobacco plant were removed. 
Previously this was a challenge in conventional chromatographic methods, with strong 
binding to matrices that resulted in them exhibiting ion exchange characteristics (Platis et 
al., 2009).  
 Moreover in 2008 they coupled this purification method, vital for 
polyphenol removal, with cation exchange chromatography and metal affinity 
chromatography. Purification was increased to 162 fold to 97.2% with a 65% yield (Platis 
et al., 2008). This group have shown the ability of ATPS for bulk purification, whilst 
highlighting its limitations in terms of specificity. All work within this group however was 
carried out as a single step extraction. All preparations were also claimed to be fully active, 
as tested by SDS PAGE using Coomassie blue stain and ELISA with goat anti human IgG.  
 A significant contribution to monoclonal antibody purification by ATPS 
has been made by the Aires-Barros group. They have demonstrated successful single 
extraction through to multiple equilibrium modes (Rosa et al., 2009). Recently they have 
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also reported the costing as a direct comparison to Protein A purification. Through the 
series of papers  they have shown the successful use of PEG-phosphate systems for IgG 
purification from CHO supernatant (Azevedo et al., 2007). Due to environmental reasons 
associated with the use of phosphate, they have further investigated alternatives, namely 
PEG-citrate (Rosa et al., 2007; Azevedo et al., 2008). An IgG yield of 99% and final purity 
of 96% have been demonstrated. To further improve the specificity previously seen as a 
problem with ATPS they investigated the use of ligands such as functionalised PEG e.g.  
PEG diglutaric (Rosa et al., 2007; Ferreira et al., 2008; Avevedo et al., 2008). The use of 
these ligands has allowed specificity to be comparable to PA purification. Additionally 
thermoseparating polymers and back extraction can be employed, allowing polymer 
recycling (Kumar et al., 2007). Finally process integration was demonstrated by aligning 
ATPS extraction with other purification steps e.g. hydrophobic interaction chromatography 
and size exclusion chromatography (Avevedo et al., 2008; Azevedo et al., 2009). Success 
achieved by this group has again been demonstrated by single batch extraction with results 
comparable to PA purification. 
 In order for ATPS extraction to be adopted as a viable downstream 
capture method, a scalable technique with commercial potential was required. In all papers 
documented by the Aires-Barros group agitated vessels were used where gravity phase 
separation of over 14 hours was employed. In terms of cost, production time and 
commercial scalability potential this would not be feasible. These papers by the Aires-
Barros group have been summarised in Table 1.4.1.1. The drawbacks and the problems in 
their approaches have also been listed, particularly in terms of the benefits that CCC can 
offer.  
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Paper title/ 
Year 
Aqueous two phase 
extraction system 
Results Assays/ techniques used to 
determine IgG recovery 
Comparison to Protein A purification/ 
drawbacks of approach 
Application of 
central 
composite 
design to the 
optimisation of 
aqueous two 
phase extraction 
of human 
antibodies 
(2007) 
 PEG 3350 8% (w/w), 
10% (w/w) phosphate 
pH6 + 15% (w/w) NaCl. 
 Carried out with an 
artificial mixture of 
1mg/ml IgG, 10mg/ml 
serum albumin and 
2mg/ml Myoglobin. 
 Yield of 
101±7%  
 Purity 99±0%. 
Protein A chromatography used 
and a recovery of 97±4% seen. 
 With back extraction into fresh phosphate 
phase, higher yields were possible (10% 
phosphate buffer pH 6), 76% yield and 100% 
purity.  
Drawback: Large amounts of NaCl needed to 
improve specificity. Further back extraction 
needed to obtain high yields and purity.  
Optimisation of 
aqueous two-
phase extraction 
of human 
antibodies 
(2007) 
 12% PEG, 10% 
phosphate, 15% NaCl pH 
6. 
 IgG recovery from CHO 
cell supernatant. 
 Recovery of 
yield 88%, 
 Purification 
factor 4.2. 
 Purity 100% by 
SEC. 
 PA HPLC for IgG 
concentration 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity 
 The conditions seen to maximise extraction 
were high concentration of NaCl and PEG, 
low phosphate concentration and low pH 
values. 
  Improved yield of 88% from previous 76% 
with 100% purity. 
Drawback: Large amounts of NaCl needed to 
improve specificity. 
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Paper title/ 
Year 
Aqueous two phase 
extraction system 
Results Assays/ techniques used to 
determine IgG recovery 
Comparison to Protein A purification/ 
drawbacks of approach 
Affinity 
partitioning of 
human 
antibodies in 
aqueous two 
phase 
systems.(2007) 
 Functionalised PEG 
(PEG-COOH) added to 
PEG phosphate and PEG 
dextran systems.  
 PEG phosphate: 12% 
(w/w) PEG 3350 + 10% 
(w/w) phosphate. 
 PEG dextran: 8% (w/w) 
PEG 3350 + 8% (w/w) 
dextran 500. 
 60 fold increase 
in selectivity 
with 
functionalised 
PEG.  
Best purification in 
dextran systems, 
93% yield, 
purification factor 
1.9, IgG selectivity 
11. 
 PA HPLC for IgG 
concentration. 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity 
 
 Diglutaric acid was used to functionalise 
PEG, showed yield and specificity 
comparable to PA purification.  
Drawback: In order to make extraction by ATPS 
more predictable and selective (previously 
highlighted as a problem), a ligand with affinity 
for IgG was attached. The ligand however has a 
significant cost implication.   
Purification of 
human 
immunoglobulin 
G by 
thermoseparating 
aqueous two 
phase systems 
(2008) 
10% UCON (ethylene 
oxide/propylene oxide). 
5% dextran + 20% TEG-
COOH (Triethylene 
glycol-diglutaric acid) 
Yield of 85% and 
purity 100%. 
 PA HPLC for IgG 
concentration. 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity 
 
 By the use of thermoseparating polymers and 
TEG-COOH, IgG partitioning was shifted 
from the bottom to UCON rich phase.  
 Offers specificity comparable to affinity 
chromatography by PA purification.   
Drawback: The ligand to improve specificity has 
a significant cost implication. 
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Paper title/ 
Year 
Aqueous two phase 
extraction system 
Results Assays/ techniques used to 
determine IgG recovery 
Comparison to Protein A purification/ 
drawbacks of approach 
Integrated 
process for the 
purification of 
antibodies 
combining 
aqueous two 
phase extraction, 
hydrophobic 
interaction 
chromatography 
(HIC) and size 
exclusion 
chromatography 
(SEC). (2008) 
 
 10% (w/w) PEG 3350 
+12% (w/w) citrate at 
pH6. 
 Bottom phase then 
loaded directly onto 
phenyl-sepharose HIC 
column. 
 Polishing by SEC. 
 After ATPS, 
IgG yield of 
97%, 41% 
HPLC purity 
and 72% protein 
purity. 
 Following HIC: 
99% antibody 
recovery, 86% 
HPLC purity 
and 91% protein 
purity. 
After SEC: 100% 
IgG and 90% yield. 
 PA HPLC for IgG 
concentration. 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity 
 
 Showed promise for use of ATPS extraction 
in downstream purification which is in line 
with other technologies.  
Drawback: High level of purity obtained is 
dependent on SEC and HIC as oppose to ATPS 
extraction. No mention of end biological activity 
of IgG.  
Partitioning of 
human 
antibodies in 
polyethylene 
glycol-sodium 
citrate aqueous 
two-phase 
system (2008) 
 8% (w/w) PEG 3350, 
8% (w/w) citrate + 15% 
(w/w) NaCl at pH 6. 
 99% IgG yield, 
44% HPLC 
purity.  
 Further re-
extraction into 
citrate phase at 
5% NaCl  
 99% yield, 76% 
HPLC purity. 
 PA HPLC for IgG 
concentration. 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity 
 
 The use of citrate as opposed to phosphate 
avoids environmental disposal issues 
associated with phosphate. 
Drawback: Back extraction requires the use of 
further NaCl.  
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Paper title/ 
Year 
Aqueous two phase 
extraction system 
Results Assays/ techniques used to 
determine IgG recovery 
Comparison to Protein A purification/ 
drawbacks of approach 
 
Affinity 
enhanced 
purification of 
human 
antibodies by 
aqueous two 
phase extraction 
(2008) 
 PEG molecules with 
different molecular 
weight modified with 
different ligands and 
screened for their ability 
to bind to IgG in CHO 
supernatant. 
 5% dextran, 8% PEG 
diglutaric acid, 10 mM 
phosphate buffer pH 7 
used. 
 97% IgG yield 
in upper phase 
and 94% purity. 
 PA HPLC for IgG 
concentration. 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity 
 
 By the use of affinity extraction, specificity 
was retained even at large scale. 
 The process can be operated continuously as 
opposed to PA HPLC. 
Drawback: Dextran used in this system is costly 
hence would affect scale up potential. 
Additionally there is the cost of the ligand.  
Downstream 
processing of 
human 
antibodies. 
Integrating an 
extraction 
capture step and 
cation exchange 
chromatography. 
(2009) 
 Functionalised PEG: 
PEG diglutaric acid 
(PEG GA). 
 50%(w/w) PEG-GA, 
25% (w/w) dextran and 
phosphate buffer  pH 7.  
 With the use of 
a cation 
exchange 
following ATPS 
extraction, 89% 
yield and 100% 
purity.  
 PA HPLC for IgG 
concentration. 
 BCA, size exclusion 
chromatography, 
electrophoresis-SDS PAGE+ 
sliver stain. 
 No mention of the retention of 
biological activity. 
 
 Again it was seen ATPS capture can be 
substituted for PA HPLC. 
 A high specificity with the definite potential 
for process integration was demonstrated.  
Drawback: The cost of the functionalised PEG 
would make scale up challenging.  
Table 1.4.1.1: Summary of work conducted and progress made by the Aires-Barros group (Lisbon) with respect to mAb purification from CHO cell 
supernatant.  
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 Rosa et al (2009) attempted to address the issue of a continuous system 
by the use of connected mixer- settler battery systems (Figure 1.4.1.2). The number of 
transfer stages was increased by the use of multi-stage equilibrium (maximum 6). Greater 
separation of IgG from impurities was possible without the need of high concentrations of 
NaCl to favour partition; potential manufacturing precipitation problems were therefore 
avoided.  
 
Figure 1.4.1.2: Multi-stage equilibrium ATPS extraction. By replacing the PEG phase and 
repeated extraction, greater concentration of purified mAb is attained. (Rosa et al., 2009). 
 
An IgG yield of 89% and a purity of 75% was demonstrated following multiple 
extraction with a PEG phosphate system, as opposed to 61% recovery yield and 55% 
purity seen with single stage extraction. Further to this, when functionalised PEG -
triethylene glycol diglutaric acid (TEG-COOH) was used in a multi-stage extraction a yield 
of 95% and protein purity of 95% was noted, in comparison to a single extraction of 43% 
purity. With the use of multiple extractions the final IgG concentration obtained due to 
product enrichment was 1.04mg/ml as compared to 0.21mg/ml (Rosa et al., 2009). The 
potential of ATPS in mAb purification was previously shown by the Aires-Barros group.  
Furthermore the use of multi-step extraction allows greater IgG selectivity, product 
enrichment and increased throughput. The use of ligands also greatly helps with 
specificity. The attachment of actual protein A to PEG has been trialled but due to high 
costs of the ligands was not appropriate (Andrews, 1990). Rosa et al (2009) have detailed 
the use of alternative ligands. Glutaric acid was seen to be the most appropriate, allowing 
improved specificity in ATPS extraction. In addition Rosa et al (2011) published a direct 
comparison of mAb purification in ATPS extraction to that by PA. They reported by the 
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use of ATPS, cost can be reduced by at least 39%. This cost reduction was valid even with 
the use of new generation protein A binding resins with much improved dynamic binding 
capacities.  
 The protein concentration limit within ATPS is a huge issue; 
precipitation issues due to solubility have been seen. Asenjo et al (2011) in a recent review 
reported that partitioning behaviour which is independent of protein concentration can only 
occur at low concentrations. Typically around 5% w/w of the system volume of biological 
feedstock can be processed. Selvakumar et al (2010) have investigated the construction of 
systems in monophasic regions of phase diagram. Phase components are added directly to 
the feedstock, allowing intensification of loading to nearly 70%, reducing ATPS costs with 
the scope for further work. 
 The work by the Aires-Barros group has shown the potential for ATPS 
extraction for mAb purification. It is, however, apparent that a continuous mode of 
operation where greater mixing stages with improved separation efficiency is needed. By 
the use of Counter Current Chromatography (CCC), separation can occur continually by 
the use of centrifugal forces hence functionalised PEG or huge concentrations of additional 
salts are not required to improve selectivity. CCC is thus more efficient allowing high 
resolution separation in a single, shorter run time. As reported in a review by Avevedo et al 
(2009), the speed of phase separation is critical in enhancing process throughput. With 
CCC this is directly achievable by the use of gravitational force to aid separation and 
mixing, which is at a far greater rate that an ATPS extraction. Unlike ATPS extraction, 
CCC uses the theory of aqueous extraction but is assisted by CCC processing, ultimately 
achieving a considerably higher magnitude of extraction steps. 
1.4.2 CCC machines for separation of proteins  
The need for multi-stage extraction has long been demonstrated by Albertsson with initial 
work using counter-current distribution (CCD) (Albertsson et al., 1970). Separation was 
achieved by a series of mixing, settling and transfer stages (Sutherland et al., 2008). 
Despite high resolution separation being achieved it was both laborious and time 
consuming. The first high speed CCC machine using a J type centrifuge was invented by 
Ito in the 1980s. Unlike previous models (droplet CCC and helix CCC) it allowed 
improved resolution, separation time and sample loading. Continuous liquid- liquid 
partitioning was possible along a length of tubing, governed by either gravitational or 
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centrifugal forces to retain stationary phase (Ito, 2005). As both phase are liquid, the need 
for stationary phase retention to allow an adequate high resolution separation of target 
components is of paramount importance.  
The CCC columns are divided into hydrostatic and hydrodynamic instruments 
(Conway, 1991). These modes are further divided into respective machines. Hydrodynamic 
machines include J type multi layer and non synchronous CCC, with two axis of rotation 
resulting in a variable centrifugal force (Conway, 2000). The continual tubing is wound 
onto a bobbin. During planetary motion the part of the coils closest to the axis of rotation 
undergo mixing where the g-fields are lowest, whilst settling occurs at the part of the coils 
furthest from the axis of rotation, hence the area of highest g-field (Sutherland, 2007).  
Rotation also occurs around the sun gear, which causes wave like mixing and has been 
applied for many successful separations with small molecules (Chen et al., 2007; Wood et 
al., 2007). A planetary rotor rotates in a synchronised motion to the main axis of rotation in 
a multi layer centrifuge, with a fixed 1:1 ratio. With the non synchronous machine 
however, this 1:1 ratio can be changed.  
The hydrostatic CCC mode includes the centrifugal partitioning centrifuge (CPC) 
and toroidal coil (TC CCC). A constant gravitational force is produced by a single axis of 
rotation. The column is composed of interconnected chambers that trap stationary phase. 
Mobile phase is pumped through the stationary phase, cell to cell, in a cascade ―waterfall- 
like‖ manner (Sticher et al., 2007). Mobile phase thus penetrates the stationary phase in a 
more vigorous manner than that of the hydrodynamic mode. Previously the need for 
hydrostatic columns to allow adequate mass transfer by vigorous mixing and sufficient 
stationary phase retention was reported (Ito et al., 2009). Previous protein separation runs 
were consequently focused on the CPC and Toroidal coils (Sutherland, 2010). 
 CCC is based on two immiscible liquid phases in a coiled column. The 
absence of a solid support permits separation between two phases based on partitioning 
differences of compounds within a sample. A continuous cycle of mixing, settling and 
separation occurs. Phase interchange simultaneously occurs with every turn (Ito et al., 
1970). Retention of the stationary phase within the coil against the flow of the mobile 
phase is due to the centrifugal force field applied. 
 The choice of solvent system is of critical importance to CCC 
development (Dubant et al., 2008). CCC is an extension of ATPS extraction which is aided 
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by CCC processing. The ultimate benefit of CCC is continuous extraction along a given 
column length over a shorter period of time when compared to single extraction based on 
gravity separation. Due to multiple issues seen with solid phase chromatography, CCC is 
providing an exciting new opportunity, most importantly as a purification tool for 
biological products.  The mild conditions employed are predicted to preserve protein 
integrity and allow total recovery of sample. There is a great need within industry to 
maximise column loading whilst minimizing product aggregation. CCC also shows low 
solvent consumption and a reduction in economic costs (Marston et al., 2006). When 
reviewing the literature on the use of CCC, the mild conditions offered by ATPS and 
absence of a solid support had lead to assumptions that sample denaturation is unlikely 
(Sutherland, 2007; Sticher, 2008). This assumption is challenged within this project with a 
study of the retention of biological activity as detailed by examples.  
1.4.3 CCC vs. Protein A affinity chromatography 
 Protein A affinity chromatography CCC 
Advantages High level of specificity Versatile technique 
Greatly studied technique Low levels of contamination 
Fast Economical- lower buffer cost, reuse of coil 
High yield and throughput Particulates and crude samples accepted 
Total sample recovery 
 
Drawbacks 
Highly expensive Narrow polarity range 
Limited number of  cycle reuse Difficult optimisation  
Column leaching hence additional 
purification steps required 
Labour-intensive 
Low pH elution/ aggregate 
production 
Physical properties can be changed by 
sample injection. 
Lower efficiency 
Table 1.4.3.1:  The advantages and drawbacks of both Protein A and CCC for protein purification.  
 
1.4.4 CCC column design for protein separation  
Since the advent of CCC in the 1960s there have been many improvements to initial 
models. Machine performance has been improved with greater technical knowledge, 
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leading to many successful separations using proteins (Ito, 2005). Successful protein 
separation using high speed CCC (HSCCC) is dependent on stationary phase retention 
(Menet et al., 1993). Due to the multi layer coils used in J-type centrifuges, unpredictably 
low stationary phase retention was seen. Stationary phase retention is dependent on the 
Archimedean screw force created by the planetary motion (Cao et al., 2008). The 
Archimedean screw force ensures both phases are continuously mixed whilst one is kept 
within the coil. A number of factors such as viscosity, interfacial tension, spin speed, coil 
bore, temperature and density differences, etc, between the phases determine stationary 
phase retention (Ito, 2010). Despite some successful purifications being reported with the 
use of J-type HSCCC, extremely broad peaks are generally recorded. Most specifically 
Shinomiya et al (1996) reported unusual peaks following Ovalbumin separation containing 
both natural and denatured products. It was not mentioned whether CCC was seen to 
exacerbate product degradation; they merely attributed the broad peak to heterogeneity of 
the sample proteins. 
 Purification using HSCCC was also seen with alpha amylase (Zhi et al., 
2005) and horseradish peroxidase (Margi et al., 2003). Despite purification in both 
demonstrated by SDS PAGE electrophoresis, a loss to biological activity was reported. 
Horseradish Peroxidase activity recovery was seen at ≥45% whilst 30% with alpha 
amylase. The use of CaCl2 as a protective agent with the alpha amylase was seen to 
improve retention of activity.  
 Guan et al (2007) reported that, despite the need for a new coil design 
with improved stationary phase retention, the multi layer CCC (HSCCC) was more 
scalable, hence more industrially attractive. The Brunel CCC group demonstrated the 
importance of column design for protein separation (Guan et al., 2007). They reported that 
the wave like mixing offered by the multi layer J type HSCCC was insufficient to allow 
mass transfer of high molecular weight proteins between viscous phase systems. Lysozyme 
and Myoglobin and a PEG 1000 12.5%/12.5% potassium phosphate system were used to 
demonstrate that the greater mixing vigour with hydrostatic instruments was needed to 
achieve the separations. Vigorous cascade like mixing could also be attained with spiral 
columns for J type centrifuges, as demonstrated by Ito. Ito‘s group, with the use of 
barricaded spiral disks or spiral tube assembly (Guan et al., 2009); demonstrated protein 
separation could be enhanced from that of conventional multi layer coils. These spiral 
designs allowed the centrifugal force gradient to be generated along the radius of the spiral, 
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thus trapping and retaining stationary phase (Ito, 2010). These spiral tubes interfered with 
the laminar phase flow, improving phase mixing.  Improvements have further been made 
with the addition of 1cm presses perpendicularly along the length of tubing, thus increasing 
spiral layer numbers and reducing dead space (Ito et al., 2009). Knight et al (2011) have 
shown, by using a spiral tubing support rotor, that a range of protein separations is possible 
with various polymer systems (Knight et al., 2007; Knight et al., 1995). In addition, 
multiple spiral disk assemblies have been seen to produce large interface areas with mixing 
achieved by barricaded channels. Glass beads have been placed in mixing sections and 
separations occur in subsequent settling sections, providing a mixer-settler CCC in 
HSCCC. This was demonstrated with Myoglobin and Lysozyme using a PEG 1000 
12.5%/12.5% potassium phosphate system (Knight et al., 2011). 
 Centrifugal partition chromatography (CPC) uses a hydrostatic mode of 
operation (Murayama et al., 2009). High resolution separation is hypothesised by increased 
stationary phase retention. Chen et al (1999) used the CPC with a PEG 6000- potassium 
phosphate system for the separation of bovine serum albumin (BSA) and Lysozyme.  A 
high resolution separation was not seen however, due to the need for separation 
optimisation. The effect of mobile phase flow rate, rotational speed, direction of coil 
revolution and the pH of solvent (Shinomiya et al., 2004) all required consideration.  
 High resolution separation however was demonstrated by Ikehata et al 
(2005) with the construction of a CPC made with toroidally wound tubing, mounted 
circumferentially (eccentrical) on a disk that was rotated in a centrifugal field (Sutherland, 
2010). Mixing comparable to a toroidal coil was seen with a higher partition efficiency 
than a standard CPC model. Separation was demonstrated using a PEG 8000 4% (w/w) 5% 
(w/w) dextran T500 system and showed improved Myoglobin and Lysozyme separation 
(Shinomiya et al., 2000).  
 To allow the further understanding of mixing, much work has been 
conducted by Van Buel and Marchal 2000 with stroboscopic studies. They demonstrated 
the importance of column efficiency, which was determined by sufficient dispersion of the 
mobile phase between that of the stationary phase. The flow path of the mobile phase 
needed to be adequately broken early in a run, which was dependent on Coriolis force. The 
Coriolis force was resultant from flow shape which was shown to be related to rotational 
speed and flow rate (Marchal et al., 2000). The effect of the Coriolis force was 
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demonstrated by Ito et al (1998). Sufficient mass transfer was dependent on the Coriolis 
force acting parallel to the coil segment (Ikehata et al., 2004). Column designs have now 
been created based on this knowledge e.g the Partitron 25. Cells are linked under the 
rotation of the rotor such that mobile phase is adequately mixed by the Coriolis force 
against the cell wall therefore increasing mass transfer efficiency (Margraff et al., 2005). 
The Partitron 25 has a 25 litre capacity, thus is ready for industrial uptake. Additionally, 
downsizing of the model X-1.5L, (Shinomiya et al., 2006) allowed predictions of improved 
biological separations.  
The linear scale up of Lysozyme and Myoglobin separations were shown by 
Sutherland et al (2008), using a CPC and PEG 1000 12.5%/12.5% potassium phosphate 
system. Separation was achieved with scaling from 176mg sample load using a 500ml 
column to 2.2g with a 6.25 litre column. The potential for industrial take up was 
demonstrated with a possible throughput of 40g/day.  Due however to complications with 
the cleaning of interconnected chambers and rotary seals, which are prone to leakage, the 
use of toroidally wound continual tubing was preferred. 
 The toroidal coil CCC (TC CCC) used at Brunel is based on the use of 
multilayer toroidal coils wound around a drum that is rotated in a planetary motion. Unlike 
the CPC it doesn‘t contain rotating seals and has a variable force field. Vigorous cascade 
mixing was known due to its hydrostatic mode. Sutherland et al (2011) carried out a direct 
comparison of the CPC and TCCCC using Lysozyme and Myoglobin and a PEG 1000 
12.5%/12.5% potassium phosphate system. A throughput of 0.67g/h was demonstrated 
with the TC CCC as opposed to 0.14g/h with the CPC. It showed the potential of the TC 
CCC for serial injections with no loss of stationary phase. 
 Initial work to observe the fundamentals of the TC CCC and the loss in 
the resolution of protein partitioning in comparison to small molecules, was studied by Ito. 
He demonstrated that mass transfer through the interface was directly correlated with 
molecular mass (Ito et al., 1998). Proteins with a larger molecular mass exhibited a lower 
mass transfer. The appropriate use of the Coriolis force however could prevent peak 
broadening. He also elucidated that possibly the protein 3D-structure, or partially 
denatured components, could be responsible for peak widening. In following work 
however, this was not reinvestigated, as sample analysis was just based on 430nm 
absorbance assays. He merely stated this mode of CCC, with longer or narrow toroidal 
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coils, would allow successful separation of biological active compounds (Matsuda et al., 
1998). Following this work, Shinomiya et al (1999) investigated the separation of 
Myoglobin and Lysozyme using a PEG 1000 12.5%/12.5% dibasic potassium phosphate 
system. Elution mode was highlighted as critical as only partially purified Myoglobin was 
seen by SDS-PAGE. Again there was no mention of recovery.  
 Within the Brunel University CCC group, toroidal coil construction was 
based on existing, commercially available CCC apparatus (Dynamic Extraction 
centrifuges).  An analytical TC CCC however was investigated by Ito‘s group. It was 
reported by Guan et al in 2010 that separation of Lysozyme and Myoglobin was possible to 
a maximum of 7.4% sample loading of the column volume. Constraints with the TC CCC 
were also seen with mass transfer; however more promise of industrial scale up was seen 
than with the CPC.  Maintenance of stationary phase retention is vital to allow the partition 
of molecules hence result in a separation. Various new column designs, such as Zigzag, 
Saw tooth and Figure 8, were suggested by Yang et al (2010). The potential of using 
longer columns to improve the resolution were suggested.   
 Limited work on the non synchronous CCC for protein separation has 
been carried out by research groups. By the separate control of bobbin to rotor rotations, 
mixing and settling can be independently controlled. It was seen that rotor rotations at 
800rpm (Kobayashi et al., 2005) were sufficient for mixing of the phase system. More 
importantly, settling time could be increased, which was vital to allow partitioning between 
the viscous phase systems. Successful separations have been seen with Lysozyme and 
Myoglobin and also cytochrome C (Shinomiya et al., 2003). A PEG 8000-dextran T500 in 
5mM potassium phosphate and a PEG 1000-dibasic potassium phosphate system (12.5%) 
was used.  The PEG phosphate system was seen to be the most appropriate in terms of the 
separation efficiency. Again these experiments were conducted with extremely stable 
model proteins and there was no assay of biological activity used.  
 In 2010, Ignatova et al, published work highlighting that previous issue 
with mechanical complexities of the non synchronous CCC had been overcome. They 
suggested there was great promise for future work with biologics, predicting a step change 
of 30% in resolution and 90% in plate efficiency.  
 Liquid- Liquid extraction can also include the application of reverse 
micelles (Liu et al., 1998). Reverse micelles are formed when a surfactant is mixed in a 
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non-polar organic solvent. Proteins from micellar solution migrate to aqueous solutions. 
The partition is reliant on electrostatic interaction, manipulated by pH gradients. Work by 
Shen et al (2007) demonstrated the combination of reverse micelle enrichment and CCC 
processing, using Cytochrome C and Lysozyme. Further work has been demonstrated by 
Becker et al, 2009 with the use of additional magnetic absorbents in micellar ATPS. A 
Lysozyme purity of >80% was seen. The combination of techniques has great potential for 
protein enrichment for aqueous solutions.  
 In addition, the use of alternative solvents namely ionic liquids have been 
considered (Pei et al., 2009). Their low melting points (extremely close to room 
temperature) and ‗green‘ characteristics along with high thermal and chemical stability for 
CCC separations are promising (Berthod et al., 2008). Previously ionic liquids were not 
suitable for CCC extraction due to their high viscosity. By the addition of acetonitrile to 
these systems these issues have been addressed. Ruiz Angel et al (2007) have considered 
the use of BM1M C1 ionic liquid (1-butyl-3-methylimidazolium chloride) which has a 
lower density than that of a typical upper PEG phase. The density difference allows greater 
stationary phase retention and Ovalbumin partitioning was investigated. Greater 
partitioning was reported than with a PEG salt system due to intrinsic hydrophobicity. 
Extensive studies however, have been limited, with loading capacity (due to phase 
saturation) anticipated as an issue. A need for this to be addressed before scale up is 
critical.  
 The table below (Table 21) shows a selection of protein purifications 
conducted using various CCC machines. In this work the retention of biological activity is 
critically observed. 
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Protein/ 
Feedstock 
ATPS CCC conditions Purity Biological activity Reference 
Analytical techniques 
used 
Retention 
biological 
activity (%) 
Horseradish 
Peroxidase (HRP) 
from Armoracia 
Rusticana 
10% (w/w) PEG 
1540 + 14.8% w/w 
phosphate 
 HSCCC 
 0.8ml/min 
 1000rpm 
Factor 6  BCA assay + SDS page ≥45% Magri et al., 
2003 
Alpha amylase 
from supernatant of 
recombinant 
Bacillus Subtilus 
 PEG 4000 + 
citrate 2% (w/w) 
sodium chloride. 
 0.56 (w/w) CaCl2 
as protective 
agent 
 HSCCC 
 0.4ml/min 
 880rpm 
Not mentioned  Alpha amylase activity 
measured by starch 
iodine method 
 Bradford assay 
 SDS PAGE + 
Coomassie blue stain. 
From 30 to 
73.1% with 
protective agent 
Zhi et al., 2005 
Ovalbumin from 
hen egg white 
16% (w/w) PEG 
1000 17% (w/w) 
potassium phosphate 
pH 9.2 
 HSCCC 
 1.8ml/min 
 850rpm 
 
 
 
95% Not mentioned Not mentioned Zhi et al., 2005 
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Protein/ 
Feedstock 
ATPS CCC conditions Purity Biological activity Reference 
Analytical techniques 
used 
Retention 
biological 
activity (%) 
C-phycocyanin 
from Spirulina 
platensis 
 Phase A: 0.05 
mol/L sodium 
phosphate buffer 
pH 4 + 0.2mol/L 
KCL. 
 Phase B: 
0.05mol/L sodium 
phosphate pH 8 + 
0.4 mol/L KCL 
 Reverse micelle 
HSCCC 
 1.5ml/min 
 850rpm 
Factor 4.25  SDS PAGE + 
Coomassie blue stain 
Not mentioned Yin et al., 2011 
Bromelain from 
pineapple 
 Phase A: 0.05M 
sodium phosphate 
pH 9.5+ 0.2M 
Kcl. 
 Phase B: pH 7.0, 
0.4M KCL 
 Reverse micelle 
HSCCC 
 1.5ml/min 
 999rpm 
 
Not mentioned  Proteninase activity 
determined by Casein 
digestion unit.  
 280nm 
SDS PAGE + Coomassie 
blue stain. 
 
 
 
44% Yin et al., 2011 
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Protein/ 
Feedstock 
ATPS CCC conditions Purity Biological activity Reference 
Analytical techniques 
used 
Retention 
biological 
activity (%) 
Lactic acid 
dehydrogenase 
(LDH) from bovine 
heart crude extract 
16% (w/w) PEG 
1000-12.5% (w/w) 
potassium phosphate 
pH 7.3 
 CPC 
 1 ml/min 
 500rpm 
 
Not mentioned  Enzymatic analysis 
using nicotinamide 
adenine dinucleotide 
(NAD). Colorimetric 
assay at 560nm. 
 SDS PAGE + staining 
with Coomassie blue 
Not mentioned Shibusawa et 
al., 1997 
Proteins from 
chicken egg 
16% (w/w) PEG 
1000 12.5% (w/w) 
dibasic potassium 
phosphate 
 CPC 
 1 ml/min 
 500rpm 
Not mentioned  SDS PAGE + staining 
with Coomassie blue 
Not mentioned Shibusawa et 
al., 1998 
Glycoproteins 
Morchella 
esculenta 
12.5% (w/w) PEG 
8000+ 25% (w/w) 
potassium phosphate 
 CPC 
 1 ml/min 
 500rpm 
Not mentioned  HPLC using methyl 
linoleate-sillca-based-
polymer-based column 
Not mentioned Wei et al., 
2001 
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Protein/ 
Feedstock 
ATPS CCC conditions Purity Biological activity Reference 
Analytical techniques 
used 
Retention 
biological 
activity (%) 
Lactic acid 
dehydrogenase 
(LDH) from bovine 
heart crude extract 
PEG 1540 
ammonium sulphate 
+ retainer (10nm) 
Acetic acid 
 pH focussing 
CPC 
 0.5ml/min 
Not mentioned  Enzymatic analysis 
using nicotinamide 
adenine dinucleotide 
(NAD). Colourmetric 
assay at 560nm. 
 SDS PAGE + staining 
with Coomassie blue. 
Not mentioned 
 
 
  
Shibusawa et 
al., 2002 
Single strand DNA 
from Escherichia 
cell lysate 
 
16% (w/w) PEG 
1000 + 17% (w/w) 
ammonium sulphate 
 CPC 
 0.5 ml/min 
 500rpm 
Not mentioned  280nm measurement 
 SDS PAGE with 
Coomassie blue stain 
Not mentioned Shibusawa et 
al., 2003 
Alcohol 
dehydrogenase 
(LDH) from bovine 
liver crude extract 
PEG 1000 (16%)-
potassium phosphate 
pH 7.3 containing 
Procion red as 
affinity dye ligand 
 CPC 
 0.5 ml/min 
 500rpm 
 
Not mentioned  Enzymatic analysis for 
ADH  at 340nm. 
 SDS PAGE with 
Coomassie blue stain 
Not mentioned Shibusawa et 
al., 2004 
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Protein/ 
Feedstock 
ATPS CCC conditions Purity Biological activity Reference 
Analytical techniques 
used 
Retention 
biological 
activity (%) 
Glucosyltransferase 
(GTF) from cell 
lysate of 
streptococcus 
mutans 
4.4% (w/w PEG 
8000, 6% (w/w) 
dextran T500 + 
10mM phosphate 
buffer pH 9.2 
 CPC 
 1 ml/min 
 400rpm 
 
Increased 87%  Bradford assay used to 
determine enzymatic 
activity 
 SDS PAGE with 
Coomassie blue stain. 
79% Yanagida et al., 
2004. 
Glucosyltransferase 
(GTF) from cell 
lysate of 
streptococcus 
mutans 
 
 
 
7.5% PEG 3350-10% 
dextran T40 +10mM 
potassium phosphate 
pH 9. 
 CPC 
 0.5 ml/min 
 400rpm 
 
Not mentioned  Enzymatic assay GTF 
by measurement of 
water insoluble glucan 
(WIG) measured at 
490nm. 
 SDS PAGE with 
Coomassie blue stain. 
95% Shibusawa et 
al., 2006 
Histone deacetylase 
(HDAC) from 
Escherichia cell 
lysate. 
7.0% PEG 3350-10% 
dextran T40 + 10mM 
potassium phosphate 
pH 9. 
 CPC 
 0.25 ml/min 
 400rpm 
 
 
Not mentioned  Analysed by HPLC to 
look at HDAC activity. 
 SDS PAGE with 
Coomassie blue stain. 
Not mentioned Shibusawa et 
al., 2007 
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Protein/ 
Feedstock 
ATPS CCC conditions Purity Biological activity Reference 
Analytical techniques 
used 
Retention 
biological 
activity (%) 
Pea Albumin: 
PA1B 
n-butanol-water-n-
butanl-aqueous 
20mM trifluoracetic 
acid (TFA) 
 CPC 
 5ml/min 
 1200rpm 
95%  Reverse Phase HPLC, 
280nm detection 
Not mentioned Berot et al., 
2007 
Various 
ribonucleases 
16%  (w/w) PEG 
1000-12.6% (w/w) 
potassium phosphate 
pH 6.6 
 CPC 
 0.5 ml/min 
 1000rpm 
 
88%  RNase activity 
determined colour 
metrically. BSA as 
standard pH 4.25 at 37 
degrees. 
Not mentioned Shinomiya et 
al., 2009. 
Table 1.4.4.1: Selected examples of protein purification from varying feed stocks with differing CCC machines. Particular attention is given to analytical 
techniques used and the mention of retention of biological activity.  
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 Table 1.4.4.1 shows a large number of protein separations using 
CCC. Within the literature studied there seems to be neglect in the mention of 
biological activity following a CCC run. Protein purification seems to be attained with 
the assumption of full biological activity. In the few cases where biological recovery 
has been stated, crude absorbance assays or SDS PAGE have been used. When 
biologically active material is purified, there is a need to establish that material is still 
functional. In the case of mAbs, this is of paramount importance as the end products 
are injected into patients. An inactive or denatured product could potentially cause 
adverse immunogenic reactions.  
Several successful protein purifications have been reported by CCC (Keay et 
al., 2011).  Monoclonal antibody purification however has never been demonstrated 
by CCC (Berthod et al., 2009). It is believed that the work in this thesis is the first 
time that ATPS extraction with CCC purification has been combined for mAbs. 
Ultimately, this work investigates the feasibility of CCC as an alternative to PA HPLC 
purification. Usually non chromatographic purification methods lack specificity. By 
the use of CCC with continual mixing and settling, high resolution separation is 
possible. Furthermore of all the protein purifications that have been carried out by both 
ATPS extraction and CCC, there seems to have been a neglect for determination of 
biological activity preservation post purification.  Throughout the project, this aspect 
is addressed and furthermore a solution found in providing retention of biological 
activity with a separation.  
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1.5  Aims and Objectives 
The aims and objectives of this PhD project are listed below: 
1) Development of a multiprobe robotic programme  
To allow the investigation of a range of different aqueous two phase systems 
(ATPS) which are fundamental to achieving a counter current chromatography 
(CCC) separation for biologics. 
2) Development of a Protein A HPLC quantification method  
To allow the partitioning of the monoclonal antibody (mAb) within the varying 
ATPS, produced by robotic programming, to be determined analytically. 
Furthermore developing a method where chromatograms are not affected by the 
presence of the phase system.  
3) Direct comparison of centrifugal partitioning chromatography (CPC) and 
CCC for monoclonal antibody separation. 
To conduct side by side comparison of the CPC and CCC with Protein A purified 
IgG. 
4) Investigation and further optimisation of CCC conditions using crude cell 
culture supernatant (CCS). 
To carry out CCC runs with crude cell culture supernatant, with the objective of 
attaining high resolution separation and full retention of mAb biological activity.  
5) Characterisation of CCC purified samples with a range of Lonza quality 
control assays.  
To analyse the CCC purified samples produced with the optimal CCC 
operating parameters to determine whether they could possible be of industry standard, 
ultimately, allowing comparison to be drawn to the industry gold standard of Protein A 
HPLC mAb purification. 
 
 
 
 
 58 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: Robotic phase 
system selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
2) Robotic solvent system selection 
2.1       Summary  
2.2       Introduction 
2.3       Method and materials 
2.3.1    Creation of solvent system table: obtained from Lukasz Grudzien 
2.3.2    Preparation of solvents for the robot 
2.3.3    Sample used 
2.3.4    Stock solution preparation 
2.3.5    Robot programming 
2.3.6    Initial run with model proteins 
2.3.7    Changes made to robotic handling due to the nature of the ATPSs 
2.4       Results and discussion 
2.4.1    Investigation of differing protein assays 
2.4.2    Development of protein A HPLC analytical method for two phase samples 
2.4.3 Robotic run using crude Cell Culture Supernatant (CCS), and result analysis by 
developed protein A HPLC 
2.5       Conclusions 
 
2.1       Summary 
Counter Current Chromatography (CCC) is a form of liquid chromatography, which 
has been developed to process scale by the Brunel Institute for Bioengineering (BIB) 
team. Key to this technique is phase selection, which tends to be laborious.  
Considerable insight is required into the effects of components on the distribution ratio 
of the molecule of interest. Phase systems can comprise of 2,3,4,5 or more 
components, hence the possibilities are endless. Previously solvent system selection 
was by significant trial and error. The systematic and logical approach offered by a 
liquid handling robot was required. 
The chapter details the creation of a fully automated, robotic selection table of 
a range of Aqueous Two Phase Systems (ATPS). A Perkin Elmer liquid handling 
robot was used to prepare PEG-salt phase systems, perform partitions, and take 
samples for analysis. All phase systems were made from concentrated aqueous stocks. 
Systems included PEG 400, 1000, 3350 and 8000 with sodium, potassium and 
ammonium phosphate, sulphate and citrate salt. Partition coefficients (K) were 
subsequently calculated for each ATPS, by the ratio of mAb partitioning between 
upper to that of the lower phase.   
The aim of this work was to allow both rapid and easy identification of the 
most appropriate system for mAb purification.  This was based on the criteria of good 
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IgG recovery and a partition coefficient in the range of 0.5-2. The 0.5-2 partition 
coefficient range allowed IgG elution within a reasonable time, while also allowing 
sufficient time for the IgG to be resolved from nearby impurities. For all systems 
tested, IgG favoured the PEG upper phase which resulted in a very high K value. A 
lower K range (0.5-2) prevented excessive IgG retention within the coil, avoiding the 
use of significant quantities of mobile phase for elution (Garrard thesis, 2005). As the 
mobile phase was the lower salt phase, avoidance of the use of large amounts resulted 
in fewer disposal issues. The PEG 3350 11.1%/11.1% ammonium sulphate system and 
the PEG 1000 17.5%/17.5% sodium citrate system were seen to be the most 
appropriate. A range of PEG 1000 phosphate systems were also seen to fit this criteria 
of a K in the range of 0.5-2 and a high IgG recovery. However, due to environmental 
disposal issues associated with phosphates, the two systems named previously were 
chosen to be thoroughly investigated.  
In comparison to previous work on the robot with aqueous organic systems 
(Garrrard, 2005), significant changes were made to robotic programming, mainly due 
to the nature of the aqueous two phase systems. The selection process of the most 
appropriate phase systems is detailed in this chapter, whilst subsequent purification in 
a range of CCC machines are investigated in the further chapters.  
2.2  Introduction 
The project objective was for the rapid, scalable purification of mAbs from crude cell 
culture supernatant (CCS) using countercurrent current chromatography (CCC). A 
robotic selection method for aqueous-organic two-phase systems has previously been 
developed and is routinely applied in the Brunel Advanced Bioprocessing Centre 
(ABC). The list of tables required for full robotic selection of all molecules is shown 
in Figure 2.2.1.    
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        Non polar 
Figure 2.2.1: Overview of robot tables. Initial work completed by Dr Ian Garrard focussed on 
aqueous organic systems for the separation of small molecules. This chapter focuses on the 
creation of a polymer phase system selection table, for example, made of an aqueous PEG and 
aqueous salt solutions.  
 
The studies in this chapter were conducted to provide a thorough investigation of a 
vast range of ATPS. Investigation was based on the robotic programming of ATPS 
using an automated liquid handling robot. The objective was to find the most 
appropriate system, to allow IgG separation from impurities, based on their respective 
partition coefficients. Work in this chapter details how this was achieved. 
Furthermore, an appropriate protein assay was developed to quantitate IgG 
partitioning between the phases.  
2.3 Method 
2.3.1 Creation of solvent system table  
Initially, an ATPS table was obtained from Lukasz Grudzien (a PhD student at the 
Institute, investigating CCC as a possible bioreactor for enatiomer separation of an 
amino acid). The table comprised of 112 ATPS made of a wide range of salt and PEG 
concentrations, various salt types and various molecular weights of PEG (Figure 
2.3.1.1). 
 
Medium 
polarity 
aqueous 
organic 
systems 
Salt solutions 
E.g.  Ammonium 
sulphate 
Polymer phase 
systems E.g. 
PEG, salt  
Alternative 
selection table 
E.g. with  
ACN 
Non polar 
selection table: 
Organic organic  
Systems 
pH control 
E.g. Ammonia 
solution or TFA 
Polar 
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PEG 
type 
(Da) 
Salt type Phase 
system 
Conc. 
%(w/w) 
Strength of the stock solution (%) Water 
55 55 35 30 40 40 40 29 29 40 40 
PEG400 PEG1000 PEG3350 PEG8000 K 
citrate 
KPO4 Na 
citrate 
NaPO4 NaSO4 NH4PO4 NH4SO4 
400 K citrate 16 1064 0 0 0 1241 0 0 0 0 0 0 1695 
400 K citrate 18 1197 0 0 0 1396 0 0 0 0 0 0 1407 
400 K citrate 20 1330 0 0 0 1552 0 0 0 0 0 0 1119 
400 K citrate 22 1463 0 0 0 1707 0 0 0 0 0 0 831 
400 KPO4 16 1064 0 0 0 0 1154 0 0 0 0 0 1783 
400 KPO4 18 1197 0 0 0 0 1298 0 0 0 0 0 1506 
400 KPO4 20 1330 0 0 0 0 1442 0 0 0 0 0 1228 
400 KPO4 22 1463 0 0 0 0 1586 0 0 0 0 0 951 
400 Na citrate 16 1064 0 0 0 0 0 1252 0 0 0 0 1684 
400 Na citrate 18 1197 0 0 0 0 0 1408 0 0 0 0 1395 
400 Na citrate 20 1330 0 0 0 0 0 1565 0 0 0 0 1105 
400 Na citrate 22 1463 0 0 0 0 0 1721 0 0 0 0 816 
400 NaPO4 16 1064 0 0 0 0 0 0 1731 0 0 0 1205 
400 NaPO4 18 1197 0 0 0 0 0 0 1947 0 0 0 856 
400 NaPO4 20 1330 0 0 0 0 0 0 2164 0 0 0 507 
400 NaPO4 22 1463 0 0 0 0 0 0 2380 0 0 0 157 
400 NaSO4 16 1064 0 0 0 0 0 0 0 1707 0 0 1230 
400 NaSO4 18 1197 0 0 0 0 0 0 0 1920 0 0 883 
400 NaSO4 20 1330 0 0 0 0 0 0 0 2134 0 0 537 
400 NaSO4 22 1463 0 0 0 0 0 0 0 2347 0 0 191 
400 NH4PO4 20 1330 0 0 0 0 0 0 0 0 1612 0 1059 
400 NH4PO4 22 1463 0 0 0 0 0 0 0 0 1773 0 765 
400 NH4SO4 16 1064 0 0 0 0 0 0 0 0 0 1301 1636 
400 NH4SO4 18 1197 0 0 0 0 0 0 0 0 0 1463 1340 
400 NH4SO4 20 1330 0 0 0 0 0 0 0 0 0 1626 1044 
400 NH4SO4 22 1463 0 0 0 0 0 0 0 0 0 1789 749 
1000 K citrate 14 0 931 0 0 1086 0 0 0 0 0 0 1983 
1000 K citrate 16 0 1064 0 0 1241 0 0 0 0 0 0 1695 
1000 K citrate 18 0 1197 0 0 1396 0 0 0 0 0 0 1407 
1000 K citrate 20 0 1330 0 0 1552 0 0 0 0 0 0 1119 
1000 K citrate 22 0 1463 0 0 1707 0 0 0 0 0 0 831 
1000 KPO4 14 0 931 0 0 0 1009 0 0 0 0 0 2060 
1000 KPO4 16 0 1064 0 0 0 1154 0 0 0 0 0 1783 
1000 KPO4 18 0 1197 0 0 0 1298 0 0 0 0 0 1506 
1000 KPO4 20 0 1330 0 0 0 1442 0 0 0 0 0 1228 
1000 KPO4 22 0 1463 0 0 0 1586 0 0 0 0 0 951 
1000 Na citrate 14 0 931 0 0 0 0 1095 0 0 0 0 1974 
1000 Na citrate 16 0 1064 0 0 0 0 1252 0 0 0 0 1684 
1000 Na citrate 18 0 1197 0 0 0 0 1408 0 0 0 0 1395 
1000 Na citrate 20 0 1330 0 0 0 0 1565 0 0 0 0 1105 
1000 Na citrate 22 0 1463 0 0 0 0 1721 0 0 0 0 816 
1000 NaPO4 14 0 931 0 0 0 0 0 1515 0 0 0 1555 
1000 NaPO4 16 0 1064 0 0 0 0 0 1731 0 0 0 1205 
1000 NaPO4 18 0 1197 0 0 0 0 0 1947 0 0 0 856 
1000 NaPO4 20 0 1330 0 0 0 0 0 2164 0 0 0 507 
1000 NaPO4 22 0 1463 0 0 0 0 0 2380 0 0 0 157 
1000 NaSO4 14 0 931 0 0 0 0 0 0 1493 0 0 1576 
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PEG 
type 
(Da) 
Salt type Phase 
system 
Conc. 
%(w/w) 
Strength of the stock solution (%) Water 
55 55 35 30 40 40 40 29 29 40 40 
PEG400 PEG1000 PEG3350 PEG8000 K 
citrate 
KPO4 Na 
citrate 
NaPO4 NaSO4 NH4PO4 NH4SO4 
1000 NaSO4 18 0 1197 0 0 0 0 0 0 1920 0 0 883 
1000 NaSO4 20 0 1330 0 0 0 0 0 0 2134 0 0 537 
1000 NaSO4 22 0 1463 0 0 0 0 0 0 2347 0 0 191 
1000 NH4PO4 14 0 931 0 0 0 0 0 0 0 1128 0 1941 
1000 NH4PO4 16 0 1064 0 0 0 0 0 0 0 1289 0 1647 
1000 NH4PO4 18 0 1197 0 0 0 0 0 0 0 1450 0 1353 
1000 NH4PO4 20 0 1330 0 0 0 0 0 0 0 1612 0 1059 
1000 NH4PO4 22 0 1463 0 0 0 0 0 0 0 1773 0 765 
1000 NH4SO4 14 0 931 0 0 0 0 0 0 0 0 1138 1931 
1000 NH4SO4 16 0 1064 0 0 0 0 0 0 0 0 1301 1636 
1000 NH4SO4 18 0 1197 0 0 0 0 0 0 0 0 1463 1340 
1000 NH4SO4 20 0 1330 0 0 0 0 0 0 0 0 1626 1044 
1000 NH4SO4 22 0 1463 0 0 0 0 0 0 0 0 1789 749 
3350 K citrate 12 0 0 1294 0 931 0 0 0 0 0 0 1775 
3350 K citrate 14 0 0 1509 0 1086 0 0 0 0 0 0 1404 
3350 K citrate 16 0 0 1725 0 1241 0 0 0 0 0 0 1034 
3350 K citrate 18 0 0 1941 0 1396 0 0 0 0 0 0 663 
3350 KPO4 12 0 0 1294 0 0 865 0 0 0 0 0 1841 
3350 KPO4 18 0 0 1941 0 0 1298 0 0 0 0 0 762 
3350 Na citrate 12 0 0 1294 0 0 0 939 0 0 0 0 1767 
3350 Na citrate 14 0 0 1509 0 0 0 1095 0 0 0 0 1395 
3350 Na citrate 16 0 0 1725 0 0 0 1252 0 0 0 0 1023 
3350 Na citrate 18 0 0 1941 0 0 0 1408 0 0 0 0 651 
3350 NaPO4 12 0 0 1294 0 0 0 0 1298 0 0 0 1408 
3350 NaPO4 14 0 0 1509 0 0 0 0 1515 0 0 0 976 
3350 NaPO4 16 0 0 1725 0 0 0 0 1731 0 0 0 544 
3350 NaPO4 18 0 0 1941 0 0 0 0 1947 0 0 0 112 
3350 NaSO4 12 0 0 1294 0 0 0 0 0 1280 0 0 1426 
3350 NaSO4 14 0 0 1509 0 0 0 0 0 1493 0 0 997 
3350 NaSO4 16 0 0 1725 0 0 0 0 0 1707 0 0 568 
3350 NaSO4 18 0 0 1941 0 0 0 0 0 1920 0 0 139 
3350 NH4PO4 12 0 0 1294 0 0 0 0 0 0 967 0 1739 
3350 NH4PO4 14 0 0 1509 0 0 0 0 0 0 1128 0 1362 
3350 NH4PO4 16 0 0 1725 0 0 0 0 0 0 1289 0 986 
3350 NH4PO4 18 0 0 1941 0 0 0 0 0 0 1450 0 609 
3350 NH4SO4 12 0 0 1294 0 0 0 0 0 0 0 976 1731 
3350 NH4SO4 14 0 0 1509 0 0 0 0 0 0 0 1138 1352 
3350 NH4SO4 16 0 0 1725 0 0 0 0 0 0 0 1301 974 
3350 NH4SO4 18 0 0 1941 0 0 0 0 0 0 0 1463 596 
8000 K citrate 12 0 0 0 1521 931 0 0 0 0 0 0 1548 
8000 K citrate 14 0 0 0 1774 1086 0 0 0 0 0 0 1139 
8000 K citrate 16 0 0 0 2028 1241 0 0 0 0 0 0 731 
8000 KPO4 12 0 0 0 1521 0 865 0 0 0 0 0 1614 
8000 KPO4 14 0 0 0 1774 0 1009 0 0 0 0 0 1216 
8000 KPO4 16 0 0 0 2028 0 1154 0 0 0 0 0 819 
8000 Na citrate 12 0 0 0 1521 0 0 939 0 0 0 0 1540 
8000 Na citrate 14 0 0 0 1774 0 0 1095 0 0 0 0 1130 
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PEG 
type 
(Da) 
Salt type Phase 
system 
Conc. 
%(w/w) 
Strength of the stock solution (%) Water 
55 55 35 30 40 40 40 29 29 40 40 
PEG400 PEG1000 PEG3350 PEG8000 K 
citrate 
KPO4 Na 
citrate 
NaPO4 NaSO4 NH4PO4 NH4SO4 
8000 Na citrate 16 0 0 0 2028 0 0 1252 0 0 0 0 720 
 
8000 
NaPO4 12 0 0 0 1521 0 0 0 1298 0 0 0 1181 
8000 NaPO4 14 0 0 0 1774 0 0 0 1515 0 0 0 711 
8000 NaPO4 16 0 0 0 2028 0 0 0 1731 0 0 0 241 
8000 NaSO4 12 0 0 0 1521 0 0 0 0 1280 0 0 1199 
8000 NaSO4 14 0 0 0 1774 0 0 0 0 1493 0 0 732 
8000 NaSO4 16 0 0 0 2028 0 0 0 0 1707 0 0 265 
8000 NH4PO4 12 0 0 0 1521 0 0 0 0 0 967 0 1512 
8000 NH4PO4 14 0 0 0 1774 0 0 0 0 0 1128 0 1097 
8000 NH4PO4 16 0 0 0 2028 0 0 0 0 0 1289 0 683 
8000 NH4SO4 12 0 0 0 1521 0 0 0 0 0 0 976 1503 
8000 NH4SO4 14 0 0 0 1774 0 0 0 0 0 0 1138 1087 
8000 NH4SO4 16 0 0 0 2028 0 0 0 0 0 0 1301 671 
Figure 2.3.1.1: Initial solvent selection table for partitioning studies using the liquid handling 
robot. The salt type abbreviations used have been fully detailed in the abbreviations list on 
page 10. Volumes dispensed in µl from stock solutions by the robot. The total volume of each 
phase system was 4ml. 
  
2.3.2 Preparation of solvents for the robot 
Due to the nature of PEG and salt, stock solutions were prepared. The liquid handling 
robot functions based on the transfer of a known volume of liquid (Figure 2.3.2.1).  
 
Figure 2.3.2.1: Photo of Perkin Elmer robot, based on the use of 4 probes. On the left hand 
side the robot platform can be seen, which includes the stock containers, tube rack and the tip 
washing system. The programming was conducted with the computer software shown on the 
right-hand side.  
 
 
Stock containers 
 
Tube 
rack 
Tip 
washing 
system  
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2.3.3 Sample used 
For initial trial runs, IgG that had been purified by Protein A preparative 
chromatography (PA purified IgG) was used. This was provided by Lonza, batch 
number cB72.3 IgG4, lot number L17765/39, concentration 11.6mg/ml with storage 
conditions at 4ºC.  
Lysozyme was also used for trial runs, purchased from Sigma Aldrich, catalogue 
number L6876-1G lyophilized powder, protein ≥90 %, ≥40,000 units/mg protein from 
chicken egg white, storage condition -20ºC. 
 
Crude Cell culture supernatant (CCS) was provided by Lonza, and was 0.22µm 
filtered. Batch number IgG4 cB72.3, Lot number L16508/49 
 
2.3.4 Stock solution preparation 
A list of PEG and salts used along with their suppliers are detailed below (Figure 
2.3.4.1): 
Salt/PEG Supplier CAS number 
PEG molecular weight 400 Sigma Aldrich 25322-68-3 
PEG molecular weight 1000 Sigma Aldrich 25322-68-3 
PEG molecular weight 3350 Sigma Aldrich 25322-68-3 
PEG molecular weight 8000 Sigma Aldrich 25322-68-3 
Ammonium sulphate Fisher 7783-20-2 
Potassium sulphate Sigma Aldrich 7778-80-5 
Sodium sulphate Sigma Aldrich 7757-82-6 
di-Ammonium hydrogen orthophosphate Fisher 7783-28-0 
Ammonium di-hydrogen orthophosphate Fisher 7722-76-1 
di-pottassium monohydrogen phosphate Fisher 7758-11-4 
Potassium dihydrogen phosphate Fisher 7778-77-0 
di-sodium monohydrogen phosphate Fisher 7558-79-4 
Sodium dihydrogen phosphate Fisher 13472-35-0 
Potassium citrate Sigma Aldrich 6100-05-6 
Sodium citrate Sigma Aldrich 6132-04-03 
Citric acid Sigma Aldrich 5949-29-1 
Figure 2.3.4.1: PEG/ salt product details. All products purchased were from either Fisher 
Scientific or Sigma Aldrich based on their corresponding CAS numbers. 
 
Only PEG 400 was liquid at room temperature. PEG 1000 was solid and required 
melting prior to use. All salts, PEG 3350 and PEG 8000 were powders.  Polymer 
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phase systems were made up weight/weight (w/w). The density of all stock solutions 
was measured very accurately (4 decimal places) and only anhydrous salts used. 
Measurement of density was performed by Lukasz Grudzien using a density equation 
related to water. The density difference between a glass filled with a PEG or salt 
solution was taken from that containing just water (Grudzien thesis, 2011). Maximum 
stock solution concentrations were limited due to solubility.  PEG and salt stock 
solutions were both prepared in water, introducing a dilution effect when combined. 
The highest possible stock concentrations of PEG and salt were therefore required, 
which were extremely viscous. The salt solutions in particular were challenging to 
work with. They were very viscous, temperature sensitive and in some cases were seen 
to crystallise. Salt precipitation made aspiration and dispensing challenging. The 
concentrations for each stock solution are shown in Figure 2.3.4.2.  
Solute Concentration prepared for the 
robot (w/w) 
PEG 400 & 1000 55 % 
PEG 3350 35 % 
PEG 8000 30 % 
Most of the salts listed 40 % 
Sodium sulphate/phosphate 29 % 
Figure 2.3.4.2: Stock solution concentrations for the liquid handling robot. Solutions prepared 
in water based on maximum limits of solubility. These stocks were prepared and placed on the 
robot deck for subsequent dispensing using the robotic program.  
 
2.3.5 Robot programming 
Phase systems (4ml) were prepared from concentrated aqueous stocks of PEGs and 
salts using the Perkin Elmer multiprobe liquid handling robot. Sample was 
incorporated into the phase system as part of the make-up of the phases. Mixing was 
achieved by manual inversion of individual tubes, several times. Phases were then 
permitted to settle at room temperature (20-25°C) until a sharp interface was observed, 
typically 2 hours was required. The volume ratio was calculated by measuring the 
height of both phases.  The robot was used to sample both the top and bottom phases. 
The samples were then dispensed into vials or a 96-well plate for analysis. 
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 Solvent programming proceeded with 112 ATPS. Primarily any 
systems unable to form two phases were eliminated, leaving a total of 92 ATPS. Two 
separate robotic programs were created, allowing make up and transfer of ATPS into 
either HPLC vials or a 96 well micro plate (for easy readability on a plate reader). 
2.3.6 Initial run with model proteins 
Trial runs were carried out with Lysozyme using the ATPS detailed in Figure 2.3.1.1: 
 Supplementary information was obtained: 
 Duplicate sample testing to establish if ATPS production was affected by 
protein addition.  
 Phase formation timing at varying sample load (0.5 and 1mg/ml). 
 Volume ratio of each phase, both with and without Lysozyme addition.  
 
Following the trial runs it was seen that some phases were affected by protein 
addition. The volume ratios were changed such that they no longer formed two phases. 
12 phase systems appeared to have low volume due to the high concentrations of salts 
used (particularly ammonium and sodium phosphate precipitation). 17 systems failed 
to make two phases when the Lysozyme was added. The phase appeared to be 
adversely affected and a single phase resulted. 63 true ATPS were left and the mAb 
run proceeded. The final table of 63 ATPS had three water samples (negative controls) 
and a 5 point dilution of the PA purified IgG added, creating a total of 71 samples. The 
same robotic layout was subsequently used for all the proceeding runs (Figure 2.3.6.1).  
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System 
number 
% Concentration (which is the 
same for both PEG and salt 
respectively) 
System 
number 
% Concentration (which is 
the same for both PEG and 
salt respectively) 
System (w/w%) System (w/w%) 
1 Water 36 PEG 3350 NaPO4 12.4 
2 Water 37 PEG 3350 NaPO4 13.9 
3 Water 38 PEG 3350 NaPO4 15.4 
4 PEG 400 KPO4 17 39 PEG 3350 NaSO4 10.7 
5 PEG 400 KPO4 18.5 40 PEG 3350 NaSO4 12.3 
6 PEG 400 NaPO4 18.3 41 PEG 3350 NaSO4 13.9 
7 PEG 400 NaSO4 16.8 42 PEG 3350 NaSO4 15.3 
8 PEG 400 NaSO4 18.2 43 PEG 3350 NH4PO4 11.1 
9 PEG 400 NH4SO4 19.3 44 PEG 3350 NH4PO4 12.8 
10 PEG 1000 KPO4 14.0 45 PEG 3350 NH4PO4 14.5 
11 PEG 1000 KPO4 15.5 46 PEG 3350 NH4PO4 16.1 
12 PEG 1000 KPO4 17.0 47 PEG 3350 NH4SO4 11.1 
13 PEG 1000 KPO4 18.5 48 PEG 3350 NH4SO4 12.8 
14 PEG 1000 Na citrate 17.5 49 PEG 3350 NH4SO4 14.5 
15 PEG 1000 Na citrate 19.0 50 PEG 3350 NH4SO4 16.1 
16 PEG 1000 NaPO4 15.4 51 PEG 8000 K citrate 12.7 
17 PEG 1000 NaPO4 16.9 52 PEG 8000 KPO4 10.8 
18 PEG 1000 NaPO4 18.3 53 PEG 8000 KPO4 12.5 
19 PEG 1000 NaSO4 13.9 54 PEG 8000 KPO4 14.0 
20 PEG 1000 NaSO4 15.3 55 PEG 8000 Na citrate 11.0 
21 PEG 1000 NaSO4 16.8 56 PEG 8000 Na citrate 12.7 
22 PEG 1000 NaSO4 18.2 57 PEG 8000 NaPO4 10.8 
23 PEG 1000 NH4PO4 14.5 58 PEG 8000 NaPO4 12.4 
24 PEG 1000 NH4PO4 16.1 59 PEG 8000 NaPO4 13.9 
25 PEG 1000 NH4PO4 17.7 60 PEG 8000 NaSO4 10.7 
26 PEG 1000 NH4PO4 19.2 61 PEG 8000 NaSO4 12.3 
27 PEG 1000 NH4SO4 14.5 62 PEG 8000 NaSO4 13.9 
28 PEG 1000 NH4SO4 16.1 63 PEG 8000 NH4PO4 11.1 
29 PEG 1000 NH4SO4 17.7 64 PEG 8000 NH4PO4 12.8 
30 PEG 1000 NH4SO4 19.3 65 PEG 8000 NH4SO4 11.1 
31 PEG 3350 K Citrate 14.3 66 PEG 8000 NH4SO4 12.9 
32 PEG 3350 KPO4 14 67 Protein STD 1mg/ml 
33 PEG 3350 KPO4 15.5 68 Protein STD 0.8mg/ml 
34 PEG 3350 Na citrate 14.3 69 Protein STD 0.6mg/ml 
35 PEG 3350 Na citrate 15.9 70 Protein STD 0.4mg/ml 
  71 Protein STD 0.25mg/ml 
Figure 2.3.6.1:  ATPS robotic programme layout. Consists of water negative controls, 63 
phases system and a five point dilution of the protein A purified IgG standard. The same 
layout template was used for all subsequent runs.  
 
2.3.7 Changes made to robotic handling due to the nature of ATPS 
Programming changes were implemented from aqueous organic programming to 
aqueous two phase systems and are detailed in Figure 2.3.7.1.  
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Figure 2.3.7.1 Detailed comparison of changes made to aqueous organic programming to 
allow transition to aqueous two phase programming.  
 
2.4   Results and discussion 
2.4.1   Investigation into differing protein assays 
Absorbance assays, as stated by Beer‘s Law, allows us to measure proportionally the 
concentration of a protein based on its absorbance of light at a particular wavelength. 
Absorbance is widely used to determine protein concentration due to the linear 
relationship that exists within a certain concentration range. Proteins absorb ultraviolet 
light at a maximum of 280nm allowing a direct measurement. An absorbance peak is 
due to the presence of structural aromatic rings. Alternatively, by the use of coloured 
reagents and a standard of known concentration, measurement of absorbance is 
possible. To determine protein concentration within ATPS and their solubility 
distribution, several absorbance assays were investigated. Investigations were 
Robotic step Aqueous-Organic 
systems 
Aqueous two phase systems (ATPS) 
Probe retraction 
speed 
Normal  Slowed down, hence retraction time 
increased. 
 Ensured less sample was on the tip surface. 
Tip submerge 
level 
1mm depth  Increased further to a depth of 2-3mm. 
 Allowed adequate aspiration, as opposed to 
that seen previously at liquid surface level. 
Liquid level 
sensitivity 
Ultra  Tip sensitivity to liquid reduced to medium. 
 Previously, incorrect aspiration of liquids 
was seen due to residual liquid on the lids of 
stock solution containers. 
Aspirating 
/Dispensing speed 
Normal  Speed reduced to prevent excessive pressure 
build up in the tips, due to viscous nature of 
PEGs and salts used. 
Flushing Per procedure  Increased to per transfer group. 
 Allowed continual tip flushing so that no 
blockage occurred. 
System water Water had 10% 
methanol added to 
prevent any algae 
growth. 
 Methanol was not added to the system water 
to prevent precipitation of salts; pure water 
was used. 
 Methanol was added only when the robot 
was inactive for an extended period of time. 
Phase system 
settling 
15 minutes  1 hour settling period. 
 ATPS took longer to form 2 phases than 
most aqueous organic systems. 
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conducted with and without the addition of Lysozyme, to determine whether the phase 
system alone contributed to the absorbance. The following assays were investigated: 
1)  Bradford assay 
2) 280nm measurement on spectrophotometer 
3) Bicinchoninic acid (BCA) assay  
1) Bradford assay 
The Bradford assay was conducted with measurements at 630nm and 450nm (the 
filters available on the Brunel plate reader) to obtain a ratio. Initially all samples 
(Lysozyme and PA purified IgG) were diluted in water within the range of 0.4-
1.4mg/ml. Absorbance readings are tabulated in Figure 2.4.1.1. 
Wavelength Lysozyme (mg/ml) PA Purified IgG (mg/ml) 
 
0.4 
 
0.6 
 
0.8 
 
1 
 
1.2 
 
1.4 
 
0.4 
 
0.6 
 
0.8 
 
1 
 
1.2 
 
1.4 
630nm 0.48 0.49 0.49 0.48 0.48 0.5 0.57 0.50 0.49 0.49 0.48 0.50 
0.49 0.49 0.49 0.48 0.48 0.49 0.49 0.50 0.49 0.50 0.48 0.50 
0.51 0.51 0.48 0.48 0.48 0.50 0.47 0.50 0.50 0.46 0.49 0.50 
Average 0.49 0.50 0.49 0.48 0.48 0.49 0.51 0.50 0.49 0.48 0.49 0.50 
450nm 0.91 0.92 0.93 0.92 0.91 0.94 1.09 0.90 0.88 0.91 0.90 0.90 
0.91 0.93 0.91 0.91 0.91 0.93 0.91 0.90 0.92 0.95 0.92 0.90 
0.90 0.93 0.90 0.90 0.91 0.93 0.87 0.90 0.91 0.85 0.92 0.90 
Average 0.90 0.93 0.92 0.91 0.91 0.93 0.95 0.90 0.90 0.90 0.91 0.90 
Ratio 
630nm:450nm 0.54 0.54 0.53 0.53 0.53 0.53 0.53 0.50 0.54 0.54 0.53 0.50 
Figure 2.4.1.1: Results following the Bradford assay using model protein Lysozyme and PA 
purified IgG. Wavelengths were measured using the Brunel plate reader at 630 and 450nm 
respectively. A ratio was obtained as an absorbance value and correlated to protein 
concentration in Figure 2.4.1.2.     
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Figure 2.4.1.2: Bradford assay results, the effect of Lysozyme and purified IgG4 concentration 
on absorbance.  
 
 
As shown in Figure 2.4.1.2, a linear trend was identified. The absorbance ratio was 
constant over the concentration range tested. No change in the colour of the wells were 
seen when the Bradford reagent was added. Saturation of the detector between 0.5-
1.5mg/ml appeared to have happened. A solution would have been a dilution of 
samples to between 0.1-0.5mg/ml.  
2) 280nm measurement on spectrophotometer 
Measurement at 280nm was also investigated on a spectrophotometer. Water 
was used as a blank for all systems with and without protein. The robot was 
programmed to take 0.5ml samples from the upper and lower phase of each system 
respectively. The remaining samples in the tubes were mixed vigorously and 0.5ml 
samples quickly taken; labelled as the phase control. A control was taken to look at 
recovery of the protein (the sum of upper and lower phase absorbance values for a 
particular system should equal that of the control). All phases were broken by the 
addition of 0.5ml of water and subsequently read on the spectrophotometer. 
 
Bradford assay results for Lysozyme and PA purified IgG 
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No 
System (% w/w) 
 
Average 
upper 
phase 
 
Average 
Lower 
phase 
 
Partition 
coefficient 
No 
System (%w/w) 
 
Average 
upper 
phase 
 
Average 
Lower 
phase 
 
Partition 
coefficient 
4 PEG 400 KPO4 17 0.064 -0.084 -0.760 36 PEG 3350 NaPO4 12.4 -0.005 0.134 -0.037 
5 PEG 400 KPO4 18.5 0.071 -0.006 -11.263 37 PEG 3350 NaPO4 13.9 0.010 0.197 0.050 
6 PEG 400 NaPO4 18.3 0.022 0.277 0.078 38 PEG 3350 NaPO4 15.4 0.083 0.219 0.376 
7 PEG 400 NaSO4 16.8 0.017 0.012 1.365 39 PEG 3350 NaSO4 10.7 0.024 0.045 0.539 
8 PEG 400 NaSO4 18.2 0.041 0.008 5.422 40 PEG 3350 NaSO4 12.3 0.022 0.011 2.062 
9 PEG 400 NH4SO4 19.3 0.037 -0.009 -4.111 41 PEG 3350 NaSO4 13.9 0.038 -0.020 -1.883 
10 PEG 1000 KPO4 14.0 0.040 -0.024 -1.630 42 PEG 3350 NaSO4 15.3 0.142 0.003 50.118 
11 PEG 1000 KPO4 15.5 0.018 -0.062 -0.298 43 PEG 3350 NH4PO4 11.1 0.070 0.020 3.446 
12 PEG 1000 KPO4 17.0 0.054 -0.042 -1.276 44 PEG 3350 NH4PO4 12.8 0.075 0.232 0.321 
13 PEG 1000 KPO4 18.5 -0.034 0.000 102.000 45 PEG 3350 NH4PO4 14.5 0.140 0.414 0.339 
14 PEG 1000 Na citrate 17.5 0.023 -0.002 -10.769 46 PEG 3350 NH4PO4 16.1 0.094 0.157 0.597 
15 PEG 1000 Na citrate 19.0 0.021 -0.002 -11.545 47 PEG 3350 NH4SO4 11.1 0.016 0.000 -32.000 
16 PEG 1000 NaPO4 15.4 -0.042 0.154 -0.272 48 PEG 3350 NH4SO4 12.8 0.020 -0.006 -3.500 
17 PEG 1000 NaPO4 16.9 0.001 0.204 0.004 49 PEG 3350 NH4SO4 14.5 0.022 -0.006 -3.686 
18 PEG 1000 NaPO4 18.3 0.060 0.183 0.326 50 PEG 3350 NH4SO4 16.1 0.037 -0.007 -5.091 
19 PEG 1000 NaSO4 13.9 0.012 0.012 0.932 51 PEG 8000 K citrate 12.7 0.037 -0.089 -0.417 
20 PEG 1000 NaSO4 15.3 0.019 0.002 10.364 52 PEG 8000 KPO4 10.8 0.058 -0.225 -0.257 
21 PEG 1000 NaSO4 16.8 0.019 -0.100 -0.190 53 PEG 8000 KPO4 12.5 0.075 -0.073 -1.032 
22 PEG 1000 NaSO4 18.2 0.098 -0.002 -58.800 54 PEG 8000 KPO4 14.0 0.210 -0.020 -10.571 
23 PEG 1000 NH4PO4 14.5 0.092 0.698 0.132 55 PEG 8000 Na citrate 11.0 0.041 0.000 243.000 
24 PEG 1000 NH4PO4 16.1 0.082 0.695 0.119 56 PEG 8000 Na citrate 12.7 0.035 0.011 3.059 
25 PEG 1000 NH4PO4 17.7 0.055 0.240 0.229 57 PEG 8000 NaPO4 10.8 -0.039 0.129 -0.303 
26 PEG 1000 NH4PO4 19.2 0.039 0.255 0.151 58 PEG 8000 NaPO4 12.4 0.125 0.168 0.743 
27 PEG 1000 NH4SO4 14.5 0.021 -0.009 -2.296 59 PEG 8000 NaPO4 13.9 -0.011 0.255 -0.042 
28 PEG 1000 NH4SO4 16.1 0.026 -0.008 -3.489 60 PEG 8000 NaSO4 10.7 0.021 0.010 2.016 
29 PEG 1000 NH4SO4 17.7 0.027 -0.012 -2.203 61 PEG 8000 NaSO4 12.3 0.004 0.006 0.727 
30 PEG 1000 NH4SO4  19.3 0.031 -0.011 -2.877 62 PEG 8000 NaSO4 13.9 0.074 0.007 10.256 
31 PEG 3350 K Citrate 14.3 0.008 -0.002 -4.545 63 PEG 8000 NH4PO4 11.1 0.067 0.180 0.369 
32 PEG 3350 KPO4 14 -0.021 -0.021 0.961 64 PEG 8000 NH4PO4 12.8 0.071 0.277 0.256 
33 PEG 3350 KPO4 15.5 -0.017 0.005 -3.188 65 PEG 8000 NH4SO4 11.1 0.024 0.001 36.500 
34 PEG 3350 Na citrate 14.3 0.025 -0.002 -15.100 66 PEG 8000 NH4SO4 12.9 -0.007 -0.002 4.667 
35 PEG 3350 Na citrate 15.9 0.025 -0.015 -1.620      
Figure 2.4.1.3: Spectrophotometer readings at 280nm of varying phase systems with Lysozyme 
added, average of triplicate absorbance values taken. Partition coefficient was obtained by 
dividing the lower phase reading into the upper phase reading. A background correction for 
each system was made. 
  
It was hypothesised that the phase system alone would contribute to the 
absorbance. Samples were hence prepared without protein to act as a blank. These 
absorbance values were subtracted from respective protein samples (Figure 2.4.1.3).  
Partition coefficients obtained were variable; no pattern could be seen amongst phase 
systems of the same salt type, thus this assay was discounted. It was thought that 
components within the phase system were producing considerable error. Most 
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considerably, the adverse effect of the phase system on linear absorbance, resulted in 
the 280nm absorbance readings being affected.  
3) BCA assay 
The BCA assay was investigated using the following conditions detailed in Figure 
2.4.1.4. 
PA purified 
IgG 
concentration 
per phase 
Volume of 
phase sampled 
Volume of 
water used to 
break phase 
system 
1 mg/ml 50µl 200µl 
 
  
 
 
 
 
 
Figure 2.4.1.4: BCA assay methodology. BCA kit from Thermo Fisher Scientific, 
Northumberland, UK used. The samples were incubated at 37ºC and agitated. The plate was 
then read at 562nm using a plate reader.  
 
Absorbance values for all systems were calculated with a background subtraction. 
Absorbencies obtained for the standard (PA purified IgG diluted to 1mg/ml in the 
phase system) were extremely low. Solubility of the IgG within the phase system due 
to aggregation was thought to be the issue, as low absorbance values were seen. The 
issue of aggregation would also make the results difficult to optimise. Optimisation 
was however required to increase the signal-to-noise ratio. 
 High background absorbency values were seen for blank samples 
due to phase system components. Initial conditions (Figure 2.4.1.5) caused low IgG 
concentrations as repeated dilutions were performed in order to minimise phase 
25µl of the above was mixed with 200µl of 
BCA reagent. Plates incubated at 37ºC on 
thermo shaker for 30 minutes. Plates cooled 
to room temperature and read at 562nm on 
the plate reader. 
BCA assay 
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system presence. Optimisation was investigated with respect to incubation time, 
incubation temperature and sample: BCA reagent ratio.  
 
Figure 2.4.1.5: BCA assay optimisation. Initial conditions suggested by Thermo Fisher 
Scientific, Northumberland, UK were optimised with the aim of increasing signal to noise 
ratio. The three main parameters investigated were incubation time, incubation temperature 
and sample ratio (ratio of sample volume to BCA reagents). 
 
Incubation time was increased from the standard 30 minutes to 2 hours. It was thought 
a longer incubation time would derivatise more protein, producing a larger absorbance 
signal. Incubation temperature was also increased from 37ºC to 60ºC. It was postulated 
that reaction speed would be faster as kinetics are changed by temperature, thereby 
creating a stronger signal. Finally sample ratio was investigated, with respect to the 
amount of sample added to reagent volume (to a maximum of 225µl, to fit into a multi 
well plate). It was hoped that a compromise between high absorbance values of the 
sample and a low background signal could be found.  The above parameters were 
varied. It was discovered that by heating to 60ºC, an increased absorbance to a greater 
extent than 37ºC was possible. Absorbance was increased by >44 fold. As 
recommended by the BCA kit instructions an enhanced protocol can be used with 
heating to 60ºC, allowing higher absorbance values for lower protein concentrations. 
Due to the presence of the phase system in the sample, additional dilution was needed, 
affecting concentration. Higher absorbance values were obtained at 60ºC, however this 
was represented in the standard curve, hence calculated protein concentrations were 
unaffected. Any difference in absorbance was due to different kinetic behavior of the 
colour development at different temperatures. 
Initial BCA conditions: 25µl sample + 200µl BCA reagents, broken 
1:4 in water. Incubation at 37ºC for 30 minutes on thermo shaker.  
 
 
 
Incubation time 
 
 
 30 minutes 
 2 hours 
 
Incubation 
temperature 
 
 37ºC 
 60 ºC 
 
 
Sample: BCA reagent ratio 
 
 
 Maximum volume of 
225µl. 
 Ratio of 1:9 to 3:4 
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   The conditions that produced the most stable 
increase (Figure 2.4.1.7) were 125µl of sample and 100µl of BCA reagent. 
Absorbance values however appeared out of the linear range of the detector. The 
signal produced was no longer proportional to the mAb concentration. Furthermore, 
extremely high absorbance values were seen for the control system which did not 
contain any IgG. In some cases these absorbencies were higher than that of the PA 
purified IgG standard. It was ultimately decided to investigate HPLC analysis rather 
than spectroscopic absorbance. It was thought that other components within the 
sample were interfering with the results, producing inaccuracies and a large standard 
error.  
 
 
Figure 2.4.1.6:  The effect of sample incubation at 60ºC. PA purified IgG sample volume listed 
on the legend (left hand side) was added to BCA sample reagent to a total of 225µl. Heating 
was increased from 30ºC degrees and seen to have a substantial increase on corresponding 
absorbency. Sample volume ratio (to BCA reagents) and heating time was also increased to 2 
hours.  
BCA assay: PA purified IgG standard curves at 60ºC incubation temperature with varying sample reagent ratio 
and incubation time 
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Figure 2.4.1.7: Graph following the investigation into enhancing the absorbance signal. The 
most appropriate conditions shown in terms of linear increase of absorbency with PA purified 
IgG concentration. PA immunodetection column used, Applied Biosystems,POROS, 2.1mmD x 
30mmL. 
 
 
2.4.2   Development of Protein A HPLC analytical method for two phase 
samples 
 
All HPLC analysis was performed using a Waters 2695 Alliance system, with Waters 
2996 photodiode array detector and operated using Waters EmpowerTM software 
(Waters Elstree, Hertfordshire, UK). A POROS Protein A 20µm column, 4.6mm x 
100mm and a volume of 1.7ml was used. 
 At Lonza, for both preparative and analytical protein A HPLC, low 
pH elution is used.  The following buffers are employed for HPLC analysis: 
 
Binding buffer: 150mM sodium chloride 50mM glycine pH 8 (Buffer A) 
Elution buffer: 150mM sodium chloride 50mM glycine pH 2.5 (Buffer B) 
Standard curve of PA purified IgG dilutions using the best combination of 
test parameters to improve absorbency 
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A fast run time of two minutes with an injection volume (water injection solvent) of 
100µl is routinely used at Lonza. The IgG is eluted as a single sharp peak at 0.51 
minutes using the HPLC program detailed in Figure 2.4.2.1. 
Time 
(minutes) 
Flow 
(ml/min) 
Buffer A: 150mM 
sodium chloride, 50 mM 
glycine pH 8 (%) 
Buffer B: 150mM sodium 
chloride, 50 mM glycine pH 
2.5 (%) 
0.00 2.0 100 0 
0.50 2.0 100 0 
0.51 2.0 0 100 
1.26 2.0 0 100 
1.30 2.0 100 0 
Figure 2.4.2.1:  Lonza HPLC analysis program.  Protein A HPLC immunodetection column 
used. A total run time of 2 minutes with buffer A as the binding buffer (150mM sodium 
chloride, 50 mM glycine pH 8) and buffer B as the elution buffer. Elution is by a drop in pH 
(150mM sodium chloride, 50 mM glycine pH 2.5). IgG elution is at 0.51 minute.  
 
All experiments within this section were conducted with a PEG 3350-sodium 
phosphate, (18%/18% w/w) system pH 7.2, with 1mg/ml of PA purified IgG added. 
Phase system within the injection solvent adversely affected the chromatograms. Peak 
widening was seen with the inability of the baseline to settle. Differing lines of 
investigation were conducted to allow HPLC programme optimisation (Figure 
2.4.2.2), with the objective to improve the chromatogram.  
 
Figure 2.4.2.2: Parameters for investigation for HPLC optimisation of phase system samples. 
Investigation based on improving IgG elution chromatograms injected in phase system. 
Injection run time, elution buffer pH, detergent and injection volume were all investigated.   
 
 
 
HPLC Program 
optimisation using 
phase system samples 
 
Injection run time 
 
Elution buffer  
pH 
 
Addition of 
Detergent 
 
Injection volume 
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Injection run time 
An increased HPLC run time was thought to allow all injection solvent (phase system) 
to be washed off the column, hence a clearer elution peak. The following HPLC 
program was developed (Figure 2.4.2.3) which produced clearer and improved 
chromatograms with a sharp IgG peak at 6 minutes (Figure 2.4.2.5). This was an 
improvement to chromatograms previously seen using the Lonza analytical method 
(Figure 2.4.2.4).  
Time 
(minutes) 
% Binding buffer (A 
pH8) 
% Elution buffer (B 
pH 2.5) 
0:00 100 0 
5:50 100 0 
5:51 0 100 
6:26 0 100 
6:30 100 0 
Figure 2.4.2.3:  Developed HPLC program. Increased run time of 6 minutes.  Protein A HPLC 
immunodetection column used. Buffer A was used as the binding buffer (150mM sodium 
chloride, 50 mM glycine pH 8) and buffer B as the elution buffer. Elution by a drop in pH 
(150mM sodium chloride, 50 mM glycine pH 2.5). IgG elution at 6 minutes.  
 
 
Figure 2.4.2.4: Protein A HPLC analysis of IgG in phase system using Lonza 2 minute elution 
program. Elution started at 1 minute. Due however to the phase system, elution was 
compromised. A large amount of peak tailing was seen with the inability of the baseline to 
settle. 
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Figure 2.4.2.5: Protein A HPLC analysis of IgG in phase system using newly optimised 7 
minute run time. Elution occurred at 6 minutes by the use of a low pH elution buffer.  Sharp 
single peak elution is seen and the chromatogram was not adversely affected by the presence 
of the phase system.  
 
 
Elution buffer pH 
To further improve IgG elution peak, hence reduction of peak tailing due to the phase 
system, a range of lower pH elution buffers were investigated. It was hypothesised by 
reducing pH, the IgG would be further repelled from the protein A hence eluted.  The 
routinely used buffer as specified by Lonza is at pH 2.5. Elution buffers at pH 1.5, 2 
and 2.5 were compared. 
Using the pH 1.5 elution buffer, the elution profile of the IgG was hardly 
affected by the phase system (a similar baseline peak width was seen as compared to 
the Lonza analysis method). An improvement was seen, with no IgG peak tailing 
using the pH 1.5 buffer. When compared to the pH 1.5 buffer, the elution profile at pH 
2 was not clear. The background was very high with noisy peaks. The elution buffer at 
pH 1.5 was subsequently used thereafter. 
Detergent 
To further improve chromatograms, addition of small amounts of Triton 100 was 
investigated. The objective was to prevent aggregation of the antibody, allowing even 
clearer IgG elution from the phase system injection solvent.   
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Triton X-100 was added at 0.1 and 1% to the pH 1.5 elution buffer. The elution 
profiles produced were not clear. Extremely noisy peaks were seen even with a small 
addition of the detergent due to the Triton absorbing at 280nm. This line of 
investigation was not taken further. 
Injection volume 
The injection volume was also optimised to ensure maximum sensitivity without 
column overload. Investigations were carried out at 5, 20, 40, 60, 80 and 100µl.  
A 5µl injection volume created low absorbance values with the inability of the 
baseline to settle. At a 100µl volume, complete saturation of the column was seen. 
Absorbance exceeded 1 unit and peak elution was also seen at 0.1 minutes with the 
solvent front (Figure 2.4.2.6). The optimum injection volume was 80µl. The best 
sensitivity along with the sharpest peaks was seen at this volume.  
A range of different phase systems were investigated with analysis by protein 
A HPLC before the full robotic run was started. Low absorbance readings post HPLC 
analysis were seen even for the control samples (water).  The pH change in the 
programme created an elevated background that was accounted for with each run. An 
average background peak area was deducted for each sample. A comparison of 
changes made to the Lonza HPLC program, allowing analysis unaffected by phase 
system in the sample injection solvents, are shown in Figure 2.4.2.7. 
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Figure 2.4.2.6: Protein A HPLC chromatogram showing column oversaturation by a  sample 
injection volume of 100µl. PA purified IgG used, flow rate of 2ml/min and column 
temperature of 20ºC. Absorbance of nearly 2.50AU is reached at a single wavelength of 
280nm with significant amounts also being eluted at 0.153 minutes with the solvent front.  
 
 Lonza 
conditions 
HPLC conditions required to 
permit analysis in ATPS 
Run time (minutes) 2 7 
Elution buffer (pH) 2.5 1.5 
Injection volume (µl) 100 80 
Binding time (minutes) 0.51 5:51 
Elution time (minutes) 1:00 6:00 
Figure 2.4.2.7: Comparison of HPLC conditions required to permit analysis when injection 
solvent is ATPS with the Lonza analytical method.  ‘Binding time’ denotes the time given for 
the IgG to bind to the protein A ligand. Elution time represents when pH is lowered, such that 
the IgG isoelectric point is changed and released from the protein A.  
 
 
2.4.3 Robotic run using crude Cell Culture Supernatant (CCS) and result 
analysis by developed protein A HPLC 
Robotic partitioning was carried out with 63 ATPS (Figure 2.3.6.1). 1mg of CCS was 
incorporated into each phase system. All samples were robotically programmed to be 
dispensed into HPLC vials, 400µl samples were diluted with 600 µl of water to create 
a single phase.A five point control dilution of the Protein A purified IgG control was 
included at the end of the run (0.2-1mg/ml).  
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At the end of the robotic run samples were subject to Protein A HPLC. HPLC analysis 
of each sample was conducted in triplicate with an 80µl injection volume as 
previously defined. The 6.0 minute peak was noted as IgG. The total IgG area was 
calculated by the addition of the corresponding upper and lower 6 minute IgG peak 
areas. The partition coefficient was obtained by dividing the upper phase peak area by 
the lower. To determine any mass balance deviation, average total IgG area in a given 
phase system was defined as a percentage of the HPLC peak area of the PA purified 
IgG control at 1mg/ml. 
The phase systems of interest were regarded as systems with a 
partition coefficient of 0.5-2 and a total peak area similar to that of the 1mg/ml PA 
purified IgG control (significant difference <85%) (Figure 2.4.3.1).  
Phase system/ sample 
(w/w %) 
HPLC 
injection 
number 
Upper peak 
area 
Lower 
peak area 
Total 
area 
Partition 
coefficient 
(K) 
Average 
partition 
coefficient (K) 
Control 1 (1mg/ml) 1 
 
3446103 
 
Control 1 (1mg/ml) 2 3331455 
Control 1 (1mg/ml) 3 3294387 
Control 2 (0.8mg/ml) 1 2581755 
Control 2 (0.8mg/ml) 2 2504428 
Control 2 (0.8mg/ml) 3 2518835 
Control 3 (0.6mg/ml) 1 1927649 
Control 3 (0.6mg/ml) 2 1929415 
Control 3 (0.6mg/ml) 3 1927654 
Control 4 (0.4mg/ml) 1 1471800 
Control 4 (0.4mg/ml) 2 1469445 
Control 4 (0.4mg/ml) 3 1480765 
Control 5 (0.2mg/ml) 1 1352757 
Control 5 (0.2mg/ml) 2 1345519 
Control 5 (0.2mg/ml) 3 1328807 
Water control 1 554829 
Water control 2 537078 
Water control 3 518036 
Water control 4 527770 
Water control 5 532910 
Water control 6 514379 
PEG 400 KPO4 17 
1 
2 
3 
1329083 1576309 2905392 0.84  
                       
0.87 
1313398 1433128 2746526 0.92 
1312245 1550028 2862273 0.85 
PEG 400 KPO4 18.5 
1 2340075 494979 2835054 4.73 
4.51 
2 2214388 496258 2710646 4.46 
3 2151745 495415 2647160 4.34 
PEG 400 NaPO4 18.3 
1 2545357 475224 3020581 5.36 
5.34 
2 2463273 461364 2924637 5.34 
3 2413468 453616 2867084 5.32 
PEG 400 NaSO4 16.8 
1 2975724 403019 3378743 7.38 
7.62 
2 2958981 382935 3341916 7.73 
3 2942245 379006 3321251 7.76 
 83 
Phase system/ sample 
(w/w %) 
HPLC 
injection 
number 
Upper peak 
area 
Lower 
peak area 
Total 
area 
Partition 
coefficient 
(K) 
Average 
partition 
coefficient (K) 
PEG 400 NaSO4 18.2 
1 2514021 438528 2952549 5.73  
 
5.94 
 
 
 
 
2 2523741 425693 2949434 5.93 
3 2515956 407706 2923662 6.17 
 
 PEG 400 NH4SO4 19.3 
1 2717496 326305 3043801 8.33  
 
8.32 
 
 
 
 
 
2 2680809 324416 3005225 8.26 
3 2663140 318377 2981517 8.36 
PEG 1000 KPO4 14.0 
1 1466477 
 
1466477 
1396958 
1396958 
2863435 
 
2863435 
1.05 
 
1.05 1.04 
2 1440016 817 5 2821771 1.04 
3 288 1 1376598 05 69 4
 
PEG 1000 KPO4 17.0 
1 1870032 1356275 3226307 1.38 
1.40 
2 1852033 1322412 3174445 1.40 
3 1897068 1328744 3225812 1.43 
 
PEG 1000 KPO4 18.5 
1 1848081 1924164 3772245 0.96 
0.95 
2 1829684 1933211 3762895 0.95 
3 1826418 1926009 3752427 0.95 
 
PEG 1000 Na citrate 
17.5 
1 1609361 1926009 3535370 0.84 
0.77 
2 1607102 2201470 3808572 0.73 
3 1607928 2194160 3802088 0.73 
 
PEG 1000 Na citrate 
19.0 
1 1933157 1218534 3151691 1.59 
1.62 
2 1929716 1201999 3131715 1.61 
3 1941926 1157569 3099495 1.68 
 
PEG 1000 NaPO4 15.4 
1 1488783 174925 1663708 8.51 
8.22 
2 1490442 192527 1682969 7.74 
3 1484273 176276 1660549 8.42 
 
PEG 1000 NaPO4 16.9 
1 1047002 178788 1225790 5.86 
6.51 
2 1043530 158672 1202202 6.58 
3 1047067 147298 1194365 7.11 
 
PEG 1000 NaPO4 18.3 
1 974532 144737 1119269 6.73 
6.21 
2 974646 159998 1134644 6.09 
3 977118 168556 1145674 5.80 
 
PEG 1000 NaSO4 13.9 
1 1538937 236216 1775153 6.51 
7.79 
2 1534253 194415 1728668 7.89 
3 1528800 170489 1699289 8.97 
 
PEG 1000 NaSO4 15.3 
1 755060 209252 964312 3.61 
3.53 
2 755806 208483 964289 3.63 
3 751283 223312 974595 3.36 
 
PEG 1000 NaSO4 16.8 
1 1158256 158650 1316906 7.30 
8.86 
2 1160466 127161 1287627 9.13 
3 1153490 113622 1267112 10.15 
 
PEG 1000 NaSO4 18.2 
1 1144038 140862 1284900 8.12 
9.09 
2 1138371 114227 1252598 9.97 
3 1157736 126274 1284010 9.17 
 
PEG 1000 NH4PO4 
14.5 
1 1726906 175301 1902207 9.85 
10.67 
2 1710278 158454 1868732 10.79 
3 1703179 149884 1853063 11.36 
 
PEG 1000 NH4PO4 
16.1 
1 1234724 178939 1413663 6.90 
6.82 
2 1233918 187618 1421536 6.58 
3 1237697 176929 1414626 7.00 
 
PEG 1000 NH4PO4 
17.7 
1 
2 
3 
1203824 171217 1375041 7.03  
 
6.35 
6.35 
1200499 190834 1391333 6.29 
1202377 210140 1412517 5.72 
 
PEG 1000 NH4PO4 
19.2 
1 1419123 218649 1637772 6.49 
6.59 
2 1395298 218190 1613488 6.39 
3 1445586 209802 1655388 6.89 
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Phase system/ sample 
(w/w %) 
HPLC 
injection 
number 
Upper peak 
area 
Lower 
peak area 
Total 
area 
Partition 
coefficient 
(K) 
Average 
partition 
coefficient (K) 
 
PEG 1000 NH4SO4 
14.5 
1 784216 207190 991406 3.79 
3.75 
2 784019 215681 999700 3.64 
3 784740 204572 989312 3.84 
 
PEG 1000 NH4SO4 
16.1 
1 1116467 1142113 2258580 0.98 
0.98 
2 1118026 1144690 2262716 0.98 
3 1116142 1141370 2257512 0.98 
 
PEG 1000 NH4SO4 
17.7 
1 1553776 384186 1937962 4.04 
4.09 
2 1512631 374476 1887107 4.04 
3 1500071 358653 1858724 4.18 
 
PEG 1000 NH4SO4 
19.3 
1 1477253 324749 1802002 4.55 
4.78 
2 1682449 338337 2020786 4.97 
3 1695522 352795 2048317 4.81 
 
PEG 3350 K Citrate 
14.3 
1 1929430 345301 2274731 5.59 
6.01 
2 1936831 310408 2247239 6.24 
3 1934225 311938 2246163 6.20 
 
PEG 3350 KPO4 14 
1 736427 379722 1116149 1.94 
1.99 
2 712772 370390 1083162 1.92 
3 711356 339485 1050841 2.10 
 
PEG 3350 KPO4 15.5 
1 641619 264406 906025 2.43 
2.55 
2 671167 263864 935031 2.54 
3 657342 245619 902961 2.68 
 
PEG 3350 Na citrate 
14.3 
1 724018 261962 985980 2.76 
2.75 
2 758546 269087 1027633 2.82 
3 755182 282674 1037856 2.67 
 
PEG 3350 Na citrate 
15.9 
1 636931 309595 946526 2.06 
2.34 
2 684722 286600 971322 2.39 
3 694221 270121 964342 2.57 
 
PEG 3350 NaPO4 12.4 
1 620912 536459 1157371 1.16 
1.09 
2 605767 581535 1187302 1.04 
3 605499 573209 1178708 1.06 
 
PEG 3350 NaPO4 13.9 
1 268935 769992 1038927 0.35 
0.32 
2 243350 772970 1016320 0.31 
3 232301 769062 1001363 0.30 
 
PEG 3350 NaPO4 15.4 
1 962175 1748012 2710187 0.55 
0.55 
2 1000864 1826706 2827570 0.55 
3 927947 1700206 2628153 0.55 
 
PEG 3350 NaSO4 10.7 
1 963286 256408 1219694 3.76 
3.44 
2 947514 297557 1245071 3.18 
3 936476 277662 1214138 3.37 
 
PEG 3350 NaSO4 12.3 
1 254698 346863 601561 0.73 
0.79 
2 241220 302848 544068 0.80 
3 255721 301162 556883 0.85 
 
PEG 3350 NaSO4 13.9 
1 1011557 191738 1203295 5.28  
 
5.62 
5.61 
2 1010666 179271 1189937 5.64 
3 1017495 171726 1189221 5.93 
 
PEG 3350 NaSO4 15.3 
1 492079 223609 715688 2.20 
2.08 
2 491814 243802 735616 2.02 
3 478121 234999 713120 2.03 
 
PEG 3350 NH4PO4 
11.1 
1 589196 151702 740898 3.88 
4.03 
2 568037 145456 713493 3.91 
3 577802 134553 712355 4.29 
 
PEG 3350 NH4PO4 
12.8 
1 275041 1847982 2123023 0.15 
0.14 
2 272998 1848275 2121273 0.15 
3 230092 1848621 2078713 0.12 
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Phase system/ sample 
(w/w %) 
HPLC 
injection 
number 
Upper peak 
area 
Lower 
peak area 
Total 
area 
Partition 
coefficient 
(K) 
Average 
partition 
coefficient (K) 
 
PEG 3350 NH4PO4 
14.5 
1 159823 351251 511074 0.46 
0.50 
2 162891 321017 483908 0.51 
3 176998 320898 497896 0.55 
 
PEG 3350 NH4PO4 
16.1 
1 290261 281342 571603 1.03 
0.95 
2 271149 299914 571063 0.90 
3 273789 301937 575726 0.91 
 
PEG 3350 NH4SO4 
11.1 
1 1229335 183715 1413050 6.69 
6.57 
2 1229599 183944 1413543 6.68 
3 1228534 193616 1422150 6.35 
 
PEG 3350 NH4SO4 
12.8 
1 954722 2201328 3156050 0.43 
0.43 
2 954208 2206526 3160734 0.43 
3 958740 2209608 3168348 0.43 
 
PEG 3350 NH4SO4 
14.5 
1 149402 870626 1020028 0.17 
0.20 
2 159936 774499 934435 0.21 
3 165315 731776 897091 0.23 
 
PEG 3350 NH4SO4 
16.1 
1 141681 247081 388762 0.57 
0.53 
2 139389 275685 415074 0.51 
3 147574 296871 444445 0.50 
 
PEG 8000 K citrate 
12.7 
1 272920 228005 500925 1.20 
1.18 
2 272726 224844 497570 1.21 
3 257017 228992 486009 1.12 
 
PEG 8000 KPO4 10.8 
1 1214236 991919 2206155 1.22 
1.22 
2 1209248 989050 2198298 1.22 
3 1209157 991538 2200695 1.22 
 
PEG 8000 KPO4 12.5 
1 1067565 1123398 2190963 0.95 
0.88 
2 911128 1072995 1984123 0.85 
3 892480 1066749 1959229 0.84 
 
PEG 8000 KPO4 14.0 
1 326952 1059825 1386777 0.31 
0.32 
2 343962 1053821 1397783 0.33 
3 335592 1067407 1402999 0.31 
 
PEG 8000 Na citrate 
11.0 
1 1069996 437405 1507401 2.45 
2.30 
2 1045639 458799 1504438 2.28 
3 1022284 469445 1491729 2.18 
 
PEG 8000 Na citrate 
12.7 
1 355848 2647580 3003428 0.13 
0.13 
2 352749 2695476 3048225 0.13 
3 342991 2541672 2884663 0.13 
 
PEG 8000 NaPO4 10.8 
1 253294 1087239 1340533 0.23  
 
0.21 
0.21 
2 223436 1083486 1306922 0.21 
3 215187 1099552 1314739 0.20 
 
PEG 8000 NaPO4 12.4 
1 266999 1396150 1663149 0.19 
0.18 
2 253552 1393063 1646615 0.18 
3 244425 1395310 1639735 0.18 
 
PEG 8000 NaPO4 13.9 
1 511557 827242 1338799 0.62 
0.64 
2 508266 802846 1311112 0.63 
3 512476 769193 1281669 0.67 
 
PEG 8000 NaSO4 10.7 
1 468466 445145 913611 1.05 
1.12 
2 481644 435250 916894 1.11 
3 463279 383588 846867 1.21 
 
PEG 8000 NaSO4 12.3 
1 192877 535978 728855 0.36 
0.36 
2 189715 520222 709937 0.36 
3 176499 513608 690107 0.34 
 
PEG 8000 NaSO4 13.9 
1 263589 393018 656607 0.67 
0.66 
2 271104 414389 685493 0.65 
3 279631 420245 699876 0.67 
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Phase system/ sample 
(w/w %) 
HPLC 
injection 
number 
Upper peak 
area 
Lower 
peak area 
Total 
area 
Partition 
coefficient 
(K) 
Average 
partition 
coefficient (K) 
 
PEG 8000 NH4PO4 
11.1 
1 416888 269084 685972 1.55 
1.61 
2 407126 244473 651599 1.67 
3 381193 234594 615787 1.62 
 
PEG 8000 NH4PO4 
12.8 
1 879445 743005 1622450 1.18 
1.15 
2 848626 743079 1591705 1.14 
3 828363 742265 1570628 1.12 
 
PEG 8000 NH4SO4 
11.1 
1 869232 416010 1285242 2.09 
2.00 
2 864620 429932 1294552 2.01 
3 863153 452660 1315813 1.91 
 
PEG 8000 NH4SO4 
12.9 
1 228629 2011564 2240193 0.11 
0.10 
2 202794 2012816 2215610 0.10 
3 182892 2009599 2192491 0.09 
 
Control 1 (1mg/ml) 
1   3072638   
2   3143123   
3   3083849   
Control 2 (0.8mg/ml) 
1   2603168   
2   2597480   
3   2602995   
Control 3 (0.6mg/ml) 
1   1951974   
2   1944271   
3   1941796   
Control 4 (0.4mg/ml) 
1   1404742   
2   1402860   
3   1404882   
Control 5 (0.2mg/ml) 
1   760037   
2   757628   
3   755713   
Figure 2.4.3.1: Full robotic run results with HPLC analysis using crude CCS. HPLC 
analysis using optimised 7 minute HPLC program. All peak areas were measured in µV.sec. 
All systems highlighted in red were deemed most appropriate, based on the criteria of having 
a partition coefficient in the range of 0.5-2 and also an IgG HPLC peak area recovery of 
>85% compared to that of the PA purified IgG control. 
 
PEG 
Partition coefficient (K) HPLC peak area 
Average 
Standard 
deviation 
Standard 
error Average 
Standard 
deviation 
Standard 
error 
400 5.43 2.65 1.08 2967636 209924.03 85701.12 
1000 4.88 2.94 0.59 1998744 798150.43 159630.09 
3350 1.68 1.74 0.36 1165149 812039.31 165756.83 
8000 0.74 0.69 0.16 1518003 622601.83 146748.66 
Figure 2.4.3.2: Average partition coefficient and HPLC peak area of all systems tested based 
on PEG molecular weight. All systems were grouped based on PEG molecular weight (not salt 
type).  
 
Data was collated based on the PEG molecular weight used (Figure 2.4.2.3). It 
appeared that as PEG molecular weight increased the resulting IgG partition 
coefficient decreased (Figure 2.4.3.3). The HPLC peak area of the IgG however 
seemed to decrease (Figure 2.4.3.4). It therefore appeared that at higher PEG 
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molecular weight, IgG solubility was decreasing and aggregation was occurring. A 
higher recovery of total peak area was seen with lower molecular weight PEGs, more 
specifically PEG 1000 and 400.  
 
Figure 2.4.3.3:  The effect of PEG molecular weight on resulting partition coefficient. Results 
collated from triplicate run following protein A HPLC analysis in Figure 2.4.3.1.  
 
 
Figure 2.4.3.4: Effect of PEG molecular weight on resulting HPLC peak area. Results 
collated from triplicate run following protein A HPLC analysis in Figure 2.4.3.1.  
 
The phase systems of interest are shown in Figure 2.4.3.5. These were deemed most 
appropriate based on a partition coefficient of 0.5-2 and a high total peak area >85% 
recovery in comparison to the PA purified IgG control. The PEG 3350 11.1%/11.1% 
ammonium sulphate system was still included despite just being out of the 
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specification, with a partition coefficient at 0.43, as it was extremely close to the 
specification of 0.5≤K≤2 and showed 100% HPLC peak area recovery. Only the 8 
systems detailed in Figure 2.4.3.5 fulfilled both these criteria. 
Phase system/ sample 
(% w/w) 
HPLC 
injection 
number 
Partition 
coefficient 
(K) 
Average K % IgG 
recovery in 
comparison to 
PA purified 
IgG control 
Average 
recovery 
PEG 400 KPO4 17.0 
1 0.84 
0.87±0.041 
93.73 
91.55±2.650 2 0.92 88.60 
3 0.85 92.34 
PEG 1000 KPO4 14.0 
1 1.05 
1.04±0.006 
92.37 
91.30±0.964 2 1.04 91.03 
3 1.04 90.50 
PEG 1000 KPO4 15.5 
1 1.38 
1.40±0.025 
104.08 
103.52±0.961 2 1.40 102.41 
3 1.43 104.06 
PEG 1000 KPO4 17.0 
1 0.96 
0.95±0.008 
121.69 
121.38±0.320 2 0.95 121.39 
3 0.95 121.05 
PEG 1000 KPO4 18.5 
1 0.84 
0.77±0.060 
114.05 
119.85±5.029 2 0.73 122.86 
3 0.73 122.65 
PEG 3350 NaPO4 13.9 
1 0.55 
0.55±0.002 
87.43 
87.81±3.233 2 0.55 91.22 
3 0.55 84.78 
PEG 3350 NH4SO4 11.1 
1 0.43 
0.43±0.001 
101.81 
101.99±0.200 2 0.43 101.96 
3 0.43 102.21 
PEG 1000 Na citrate 17.5 
1 1.63 
1.62±0.018 
101.67 
100.90±0.850 2 1.62 101.03 
3 1.60 99.99 
Figure 2.4.3.5: Highlighted phase systems of interest following robotic run. Based on the 
criteria of a partition coefficient in the range of 0.5-2 and an IgG HPLC peak area recovery of 
>85% when compared to that of the PA purified IgG control.   
 
Highlighted in red in Figure 2.4.3.5, are two phosphate systems. Their very high 
recovery was associated with experimental error and possible adverse phosphate 
interaction with absorbance at these high concentrations. Furthermore, of the eight 
phase systems considered as most the appropriate, 6 of these contained phosphate. Due 
to environmental disposal issues with this salt (Azevedo, 2007) the remaining 2 
systems i.e. the PEG 3350 11.1%/11.1% ammonium sulphate system and the PEG 
1000 17.5%/17.5% sodium citrate system were, initially investigated. 
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2.6 Conclusions  
The robotic solvent selection for aqueous organic two phase systems has been very 
successful and is routinely applied for the separation of small molecules in the 
Advanced Bioprocessing Centre (ABC). For polymer phase systems however, there 
seems to be a greater degree of variables. 
There were many challenges with the use of robotic liquid handling for the 
selection of polymer systems.  Firstly the sheer number of ATPS produced a large 
selection table of 63 phase systems. Previously this table was reduced from 112 
systems due to precipitation and aggregation issues. In some cases, the mAb affected 
the system‘s ability to form two phases.  
 The nature of the PEG, salt and the bio molecules used meant 
temperature and pH complications were seen. Limitations on the concentrations that 
can be prepared by the robot, programming issues and a slow operation time make this 
technique unlikely to be adopted by industry. An alternative method is required that is 
both quick and highly efficient, allowing bio molecules to be tested within phase 
systems. However, this investigation of a vast range of systems provided some very 
valuable data. It allowed trends to be seen, in relation to particular salts and PEG.  
Ultimately robotic programming allowed the identification of the PEG 1000 
17.5%/17.5% sodium citrate and PEG 3350 11.1%/11.1% ammonium sulphate 
systems. These systems have been used for separation in the following chapters. 
Furthermore, this selection process, if completed manually, would have taken 
significantly longer.  
Further work to improve the robotic selection of ATPS requires consideration 
of other factors such as polymer type. Only PEG has been explored in this work. 
Dextran and other polymers with varying hydrophobicity e.g. polypropylene glycol 
and hydroxypropyl dextran could be investigated. Finally, there are also affinity 
molecules, such as Protein A to be added, resulting in a robotic table that has the 
potential to be even larger. Further factors that need to be considered are pH 
adjustment and temperature control. These factors can greatly affect phase systems 
near the critical point.  
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CHAPTER 3: Separation of 
monoclonal antibody cell culture 
supernatant (CCS) using 
Centrifugal partitioning 
chromatography (CPC) 
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3) Separation of monoclonal antibody from cell culture supernatant (CCS) using 
Centrifugal partitioning chromatography (CPC). 
3.1       Summary 
3.2       Introduction 
3.3       Method and materials 
3.3.1    Preparation of phase system 
3.3.2    Sample preparation 
3.3.3 CCC operation 
3.4       Results and discussion 
3.4.1  mAb separation from crude Cell Culture Supernatant (CCS) using CPC: CPC   
run 3-1 
3.4.2    SDS PAGE results 
                  3.4.3    Investigation of the formation Protein A non binding IgG 
3.4.4    Study into species interconversion 
3.4.5    Sample loading capacity: CPC run 3-2 
3.4.6    Stationary phase retention and stripping 
3.4.7    Experimental predictability  
3.4.7    Precipitation issues associated with the ammonium sulphate system 
3.4.8    Comparison of work with the Aires Barros group (Lisbon, Portugal): PEG 
1000 14%/14% potassium phosphate system. 
           3.4.9 PEG 1000 17.5%/17.5% sodium citrate system vs. PEG 3350 11.1%/11.1% 
ammonium sulphate system   
3.4.10  CPC run with the PEG 1000 17.5%/17.5% sodium citrate system 
3.5       Conclusion  
 
 
3.1   Summary 
 
The experiments in this chapter explore mAb separation by centrifugal partitioning 
chromatography (CPC). Previous work by Guan et al (2008) showed the importance 
of column design, hence mode of column mixing, allowing both high stationary phase 
retention and adequate mass transfer between the phases.  CPC studies in this chapter 
have shown experimental predictability and separation from impurities. A loss, 
however, has been demonstrated with the ability of IgG to bind to Protein A. IgG that 
was purified was unable to bind Protein A (PA) and was given the term ―Protein A 
non binding IgG‖. Furthermore, attempts at reversing the production of this non 
functional form by temperature, pH and sonication were not successful.  The PEG 
3350 11.1%/11.1% ammonium sulphate system previously highlighted from the 
robotic run in chapter 2 was seen to cause a precipitation effect on the IgG. This effect 
had not been seen previously, however this became evident following prolonged 
incubation time and CCC processing. It was thought that this effect added to the 
reduction of biological activity found in the IgG once it had been through the CCC 
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instrument. The PEG 1000 17.5%/17.5% sodium citrate, also previously highlighted 
from the robotic run, was deemed more suitable and used thereafter. The experiments 
within this chapter ultimately show the necessity for high resolution separation by 
thorough cascade mixing, affect the resulting IgG functionality.   
3.2  Introduction 
CCC instruments types can be divided into two forms: hydrostatic and hydrodynamic. 
Both utilize a liquid mobile and stationary phase and require rotation, to allow 
stationary phase retention (Sutherland, 2007). The resulting mixing vigour is the main 
difference between these modes. Hydrodynamic mixing utilises gentler wave-like 
mixing as compared to hydrostatic cascade mixing.   
 Hydrodynamic mixing, as seen in all J-type centrifuges, allows 
separation along a continuous length of tubing (Figure 3.2.1). Stationary phase is held 
within the column by centrifugal forces created by continual planetary rotation.  
Mobile phase is pumped into the column, creating zones of mixing and settling. The 
continual length of tubing is wound around a bobbin which rotates in a planetary 
motion i.e. rotating around its own axis whilst  simultaneously rotating around the sun 
gear. These two axes of rotation create the gentler wave like mixing. 
 A hydrostatic mode of mixing is seen with the CPC. Stationary 
phase is trapped by a series of interconnected chambers mounted circumferentially on 
a disk. Rotation is around a single axis (Figure 3.2.1).  Pressure is used to push the 
mobile phase through the chambers. The mixing that ensues is much more vigorous 
when compared to the hydrodynamic mode. The mobile phase penetrates the 
stationary phase by rapid jets or droplets, causing waterfall cascade like mixing.  
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Figure 3.2.1: Hydrostatic and hydrodynamic column designs. Hydrodynamic design is shown 
on the left hand side, seen with J type centrifuges. The hydrostatic design is shown on the right 
hand side as seen with the CPC.  
 
As shown by Guan et al (2008), column design is of paramount importance for the 
separation of biological molecules. Poor protein separation of a model mixture of 
Lysozyme and Myoglobin was previously seen using a J type centrifuge (Bourton et 
al., 2007). Numerous successful high scale separations of small molecules however 
have been seen with aqueous organic systems (Wood et al., 2007; Chen et al., 2007; 
Garrard, 2007). Protein separations using ATPS and hydrodynamic mixing have been 
seen as inefficient (Sutherland et al., 2008; Guan et al., 2008). Adequate mass transfer 
of high molecular weight proteins was considered to be insufficient. The viscous 
nature of the ATPS, due to the high concentrations in each phase, was also to blame.  
Resulting mixing vigour was inadequate (depicted by peak broadening), resolution 
was hence lost and separation from impurities not seen.  
 Earlier work by Bourton (2007) had showed the thorough mixing, as 
achieved by the CPC, was vital. Consequently, having highlighted the possible phase 
systems for separation within this project by robotic selection, these were subject to 
separation by CPC. These studies will be discussed within this chapter. 
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3.3 Method and materials 
3.3.1   Preparation of phase system 
 
Polyethylene glycol of average molecular weight 3350 Daltons and ammonium 
sulphate salts were obtained from Sigma-Aldrich. 4 litres of phase system were 
prepared (Figure 3.3.1.1). 
Component Molecular 
weight 
(g/mol) 
Weight added 
to make 
11.1%/11.1% 
system (g) 
CAS number 
PEG 3350 3350 444 25322-68-5 
Water 18.02 2600  
Ammonium sulphate 132.14 444 7783-20-2 
Figure 3.3.1.1: Phase system preparation: PEG 3350 11.1%/11.1% ammonium sulphate 
system. System prepared weight for weight (w/w %) producing a total volume of 4 litres.  
 
 
The thoroughly mixed phase system was placed in a separating funnel and left to 
equilibrate. Following the formation of a sharp, clean interface (minimum 1hr), upper 
and lower phase were decanted into individual bottles.  
3.3.2   Sample preparation 
 The need for sample conditioning prior to injection on the CPC was found to be of 
great importance. Previously, a dilution of the CCS in lower phase alone (11g lower 
phase in 39ml CCS) was sufficient to cause the two phase system within the CPC to be 
broken. In this sample excess water in the CCS was injected onto the column flooding 
CPC chambers, and creating one phase. As a result all material loaded eluted at the 
K=1 point without separation. 
Thus, all samples for injection were prepared as a two phase system, allowing 
the composition within the machine to be unaffected. To do this, 11% PEG and the 
salt were added directly to the CCS (5.5g salt, 5.5g PEG in 39ml CCS). To ensure the 
antibody did not aggregate or become damaged, PEG was added first to the CCS in a 
slow, step wise manner, whilst the sample was gently mixed using a magnetic stirrer. 
The salt was then sprinkled slowly and the sample left to stir until the solution was 
fully dissolved. The mAb was confirmed as 100% viable at the start of each CPC run 
by protein A HPLC analysis. 
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3.3.3 CCC processing 
The CPC unit used was from Armen instruments (Vannes, France). It was composed 
of two 500ml rotating coils. In this work, only one of the two coils were used. Each 
coil consisted of 1008 chambers, giving a total active volume of 429ml. When the 
volume of the small bore interconnected tubes was accounted for at 71ml, a combined 
volume of 500ml was attained. 
 The CPC was designed with inbuilt pumps; one was used to pump 
upper phase and the other the lower phase respectively. The sample loop was attached 
to the pump, allowing direct injection onto the column, following equilibration. The 
CPC unit was operated in both the ascending and descending mode as described 
further in the chapter.  
 Prior to all runs, the coil was flushed with at least 1000ml of water, 
to remove all air bubbles and residual contaminants. The column was then spun in 
ascending mode and filled with stationary phase, then operated in descending mode or 
vice versa. When equilibration was reached with the elution of mobile phase, injection 
of sample proceeded.  
Example experimental conditions are outlined below (Figure 3.3.3.1). 
CPC - separation 
ATPS…11.1%/ 11.1 %(w/w)…………PEG/Salt, pH…6.40 
PEG…3350……Salt …Ammonium sulphate 
Coil volume……..429ml 
Sample loop……..18.7ml 
Operating mode.…Descending 
Injected mAb: 
1) IgG4 CCS……..… (Batch number L16508/49) 
       Volume…..........39mls diluted with:  
        5.5g…. Ammonium sulphate 
        5.5g….. PEG 
Concentration of the antibody injected into the column……..4mg/ml 
Spin speed…2000rpm, temperature…22.4°C, flow rate…..….5ml/min 
Equilibrated at………5ml/min, extra coil volume……..76ml  
Stationary phase displaced………200ml, pressure…4Bar 
Figure 3.3.3.1: Typical CPC experimental conditions using a PEG 3350 11.1%/11.1% 
ammonium sulphate system. Operated in descending mode using a 18.7ml sample loop at a 
flow rate of 5ml/min.  
 
The sample (mAb made up in a two phase system) was subject to 0.45µm filtration 
(Millipore, Watford, UK) prior to loading onto the sample loop. The PVDF filters 
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were used due to their low protein binding properties (MILLEX-HV PVDF 33mm 
diameter). During the CPC run, fractions were collected every 10 minutes (50ml) and 
subject to protein A HPLC analysis (Figure 3.3.3.2) 
  
Figure 3.3.3.2:  Schematic diagram of CPC processing is collected using a 280nm UV 
detector. A fraction collector was used for further analysis by protein A HPLC.  
 
 
3.4            Results and discussion 
3.4.1       mAb separation from crude Cell Culture Supernatant (CCS) using 
CPC: CPC run 3-1 
A CPC run was performed with the conditions outlined in Figure 3.3.3.1. The results 
following Protein A HPLC analysis are shown in Figure 3.4.1.1. The partition 
coefficient (K) obtained from the robot run was 0.43; elution was therefore as 
theoretically predicted, around 4000 seconds (67 minutes). The crude CCS can be seen 
eluting as several different peaks, as expected due to its heterogeneous nature 
.  
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Figure 3.4.1.1: Graph reconstructed from protein A HPLC chromatograms. CCS separated 
using a PEG 3350 11.1%/11.1% ammonium sulphate system, 500ml coil volume, 5ml/minute 
flow rate, 18.7ml injection volume. CPC run at 20ºC.   
 
Although there is no separation of the IgG in Figure 3.4.1.1 from the impurities, the 
main positive was that the compounds showed some retention in the column, and a 
number of impurities were separated from the product of interest (mAb).   
         A background value was calculated due to the presence of phase system 
contributing to absorbency values in Protein A HPLC analysis; this background was 
subtracted from all fractions. In addition, using a calibration curve created from the 
Protein A purified IgG, the recovery in each fraction was calculated (Figure 3.4.1.2). 
 
 
 
Figure 3.4.1.2:  IgG recovery, calculated following a CPC run for the purification of CCS. A 
PEG 3350 11.1%/11.1% ammonium sulphate system used, 500ml coil volume, 5ml/min flow 
rate, 18.7ml injection volume at 20ºC and analysis by protein A HPLC.  
 
The HPLC analysis chromatogram from the crude CCS injection can be seen in Figure 
3.4.1.3. Any material eluted at 0.1 minutes was termed impurities, as it was unable to 
bind to the protein A column. Material bound to protein A with elution at 6 minutes 
was assumed to be IgG (protein A binding).  
 
 
Total mg of functional IgG recovered from fractions 52.4 
Total mg of functional IgG in control sample 75.2 
% Recovery of functional IgG 69.8 
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ammonium sulphate system using CCS. 
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Figure 3.4.1.3:HPLC analysis of the Crude CCS using a protein A column. Material obtained 
from Lonza at 4mg/ml IgG. Analysis using optimised 8 minute protein A HPLC analysis. 
Elution buffer at pH 2 employed at 6 minutes, 80µl injection volume, and detection at 280nm. 
 
Fraction 7, collected at 70 minutes (Figure 3.4.1.4), contained the highest 
concentration of purified IgG although there was also elution of impurities (0.1 
minutes). The CCS (Figure 3.4.1.3) and the Fraction 7 (Figure 3.4.1.4) chromatograms 
appeared similar. Purity was defined as the ratio of IgG to the sum of the masses of 
IgG and impurities.  
 
 
 
 
 
 
 
 
 
Protein A (PA) 
binding IgG 
Impurities 
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Figure 3.4.1.4: Fraction 7 collected at 70 minutes. Protein A HPLC chromatogram, following 
CPC purification of crude CCS.  Analysis using optimised 8 minute protein A HPLC analysis, 
pH 1.5 elution buffer employed at 6 minutes. 80µl injection volume.   
 
3.4.2          SDS PAGE results 
 SDS is a negatively charged detergent that causes protein 
denaturation on association producing an SDS-protein complex. Under the influence 
of an electric field, proteins migrate towards the positive anode, due to the negative 
charge of the detergent. The resulting size of the SDS-protein complex corresponds 
directly to the protein molecular weight. When the electric field is applied over a 
polyacylamide gel, separation is based on varying rates of migration through the gel 
matrix, corresponding to molecular weight. 
 Both reduced and non-reduced gels can be carried out. Reduced gels 
involve the inclusion of reducing agents e.g Mercaptoethanol in the sample buffer. 
Reducing conditions hydrolyse disulphide bonds present between heavy and light 
chains. A Novex X Surelock minicell from Invitrogen (Paisley, UK) was used with 
pre cast Novex 4-20% tris glycine gradient gels (EC6025BOX). All samples were 
diluted to 2mg/ml using equal volumes of water and reducing buffer. 0.5ml 2-
mercocaptoethanol (Sigma m-7154) was added to 9.5ml of Novex tris glycine SDS 
sample buffer and adjusted to pH8. Samples were then placed in a water bath set at 
70ºC for 2 minutes. 10µl of sample were loaded into each appropriate well.  
Protein A (PA) 
binding IgG 
Impurities 
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 Running buffer was prepared by 1:10 dilution in water (Invitrogen 
LC2675). The gel was run using the Novex X cell Surelock minicell apparatus and a 
power pack of high voltage (Biorad), at 140V, until the dye had run to approximately 
1cm from the slit in the bottom of the gel cassette. The gel was subsequently stained 
with Commassie blue stain for 2 hours, replaced with de-stain and left over night. 
Repeated washing of the gel in deionised water was used to improve the gel 
background and then analysed.  
 
Figure 3.4.2.1 Electrophoresis overview. Schematic of protein separation based on 
molecular weight. Gel loading and gel running conditions allow the preparation of gel for 
staining.  
 
To further observe purification in a qualitative manner, SDS PAGE gel electrophoresis 
was used in a complimentary manner with HPLC analysis. SDS PAGE allows 
purification to be monitored such that any major changes in protein structure can be 
determined. HPLC analysis however is more specific, allowing quantification of 
specific proteins.  Following HPLC analysis Fraction 7 was shown to still be impure 
(as predicted in Figure 3.4.1.2). Several fractions from CPC run 3-1 were investigated 
using SDS PAGE; Fractions 7, 8, 9,10,14,15 and 16. These were comparable with the 
PA purified IgG and the crude CCS starting material.  
                 Initially it was noted (Figure 3.4.1.2) that other contaminants co eluted with 
the IgG.  As shown in Figure 3.4.2.2, all IgG fractions (7-10) appear more similar to 
the PA purified IgG control (lane 2) than would be expected from the HPLC 
chromatogram presented in Figure 3.4.1.4. The PA purified IgG control had 3 bands 
representing heavy chain, light chain and free light chain. The electrophoresis results 
showed just the IgG proteins. It was therefore hypothesised, that previously labelled 
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‗impurities‘ in these fractions, were actually denatured IgG that was unable to bind to 
protein A. This was subsequently termed protein A non-binding IgG (Figure 3.4.2.3).  
 
 
 
                                                                
Figure 3.4.2.2: Reduced SDS PAGE gel. Samples analysed post CPC run,  CCS separated 
using a PEG 3350 11.1%/11.1% ammonium sulphate system, 500ml coil volume, 5ml/min flow 
rate, 18.7ml injection volume . CPC run at 20ºC.   
 
 
 
 
 
 
Lane 
number 
Sample 
1 Molecular weight 
marker (MWM) 
2 Protein A IgG 
(Previously purified 
by Lonza using 
preparative protein 
A HPLC) 
3 CCS 
4 Fraction 7 
5 Fraction 8 
6 Fraction 9 
7 Fraction 10 
8 Fraction 14 
9 Fraction 15 
10 Fraction 16 
 
 
 
200kDa 
16.3 kDa 
97.4 kDa 
66.3 kDa 
55.4 kDa 
36.5 kDa 
31.0 kDa 
21.5 kDa 
14.4 kDa 
6kDa 
Heavy chain 
Light chain 
Free light chain 
1            2         3          4           5             6          7          8          9         10 
                                    Lane number 
  Lane number 
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Figure 3.4.2.3: Hypothesis of creation of protein A non-binding IgG post CPC processing as 
opposed to previously thought impurities.  
 
 
3.4.3          Investigation of the formation of protein A non-binding IgG 
The Protein A HPLC program was developed to tolerate the phase system, and was 
based entirely on two peak elution. The first peak eluted at 0.1 minutes and accounted 
for anything non-binding to protein A. The second peak at 6 minutes was assumed to 
be IgG that bound to protein A. Elution followed a drop in pH to change the protein‘s 
isoelectric point (PI) away from that of the protein A.  
The following observations were noted when CPC Fraction 7 (with the highest 
concentration of IgG) was analysed by protein A HPLC. Fractions were seen by 
protein A HPLC to have elution at both 0.1 minutes and 6 minutes. When these 
fractions were run on a SDS PAGE gel they appeared as just one species, indicating 
purification as no impurities bands were present (Figure 3.4.3.2). They also appeared 
as one species by 280nm trace and as shown by the spectra (Figure 3.4.3.1). They 
resembled that of the PA purified IgG control.  
 
Protein A (PA) 
binding IgG 
Hypothesised 
protein A (PA)  
non binding IgG 
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Figure 3.4.3.1:  Spectra for the 2 peaks in Fraction 7 post CPC. Two spectra obtained 
using the Waters HPLC programme at 200-400nm. Spectra at 0.1 minute (Protein A non-
binding IgG) and at 6 minutes (protein A binding IgG) from Protein A HPLC chromatogram.  
 
 
The 0.1 minute HPLC peak seen in Fraction 7 CPC run 3-1 was previously regarded as 
‗impurities‘, thus was assumed an impure sample. However analysis by SDS PAGE 
and the UV spectra results suggested that these samples were actually predominately 
IgG.  It was hypothesised that non-functional IgG was being produced by the CPC run, 
and this was termed ―PA non-binding IgG‖. The 0.1 minute peak in other samples 
could contain impurities, non-functional IgG, host cell proteins, detergents, media 
components etc.  However, in the case of Fraction 7 from CPC run 3-1, as shown by 
SDS PAGE, only IgG existed.  Protein A non-binding IgG was seen in some Fractions 
(7, 8 and 9 from CPC run 3-1) but in the other fractions, this 0.1 minute peak was 
actually impurities.   
 Consequently, it was suggested that CPC processing or the phase 
system itself was causing an IgG species change. The protein A binding capacity of 
the IgG appeared to have changed, rendering functional IgG non-functional (PA non-
binding IgG). Moreover it was postulated, having identified these two forms, they 
could possibly be inter convertible. IgG incubation in the phase system alone could 
possibly cause aggregation, resulting in the production of two IgG forms. The binding 
and non-binding IgG were detected only by PA HPLC.  
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3.4.4          Study into species interconversion 
A component of CPC processing (phase system or machine) was seen to cause an IgG 
species change. Functionality of some of the IgG was altered creating a protein A 
binding and non-binding form. It was postulated these species were possibly 
interconvertible. Conversion between the PA binding to non-protein A binding was 
investigated by heating to 50ºC, sonciation and pH.  
These studies were conducted with CCS and Fraction 7 from CPC run 3-1 
(Figure 3.4.1.3) which had previously been subject to protein A HPLC analysis and 
SDS PAGE. Aliquots were taken and subject to incubation at 50ºC and sonication for 
250 minutes, samples were taken at 50 minute intervals. With the samples for pH 
adjustment, drops of acid or alkaline (either concentrated NaOH or HCl) were added 
to each aliquot until the required pH was attained. The samples were then diluted 1 in 
4 in water to prevent turbidity and analysed by protein A HPLC.  
 Initially the CCS sample and the Fraction 7 sample were subject to 
incubation at 50ºC, as shown in Figure 3.4.4.1, The graphs show a plot of HPLC peak 
area of the respective PA binding peak (6 minutes) and the PA non binding peak (0.1 
minutes) over time. For both samples the graphs of the data at differing conditions for 
the 0.1 minute and the 6 minute peak appeared to be mirror image of each other. There 
was a possibility of species being interconvertible, however the spread of the data was 
large with fluctuation. With the CCS at 50ºC incubation, the amount of binding to non 
binding PA material remained completely stable (Figure 3.4.4.1). Fraction 7 however 
was not stable due to having a >10 times lower HPLC peak area, this was thought to 
be due to HPLC variation as opposed to a species change. Experiments were carried 
out only one.  
 
 
 
 
Figure 3.4.4.1: CCS and Fraction 7 (post CPC processing) results at 50ºC incubation. 
Incubation over 250 minute, samples taken every fifty minutes and plotted against 
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corresponding HPLC peak area (obtained using protein A HPLC developed analytical 
method).  
 
 
CCS sample and the Fraction 7 sample were subject to sonication over 200 minutes, 
results are shown in Figure 3.4.4.2. The graphs show a plot of HPLC peak area of the 
respective PA binding peak (6 minutes) and the PA non-binding peak (0.1 minutes) 
over time. With both samples a decline in protein A binding IgG was seen, this 
degradation was seen almost immediately in Fraction 7 and also the CCS. (Figure 
3.4.4.2)  
 
 
 
 
Figure 3.4.4.2:  Effect of sonication:  CCS and Fraction 7 (post CPC processing). Sonication 
over 250 minute, samples taken every fifty minutes and plotted against corresponding HPLC 
peak area (obtained using protein A HPLC developed analytical method).  
 
CCS sample and the Fraction 7 sample were also subject to pH change, the respective 
change in HPLC peak area is shown in Figure 3.4.4.3. The graphs show a plot of 
HPLC peak area of the respective PA binding peak (6 minutes) and the PA non-
binding peak (0.1 minutes). With both samples, as the pH increased so did the amount 
of PA binding IgG, to decline in PA non-binding IgG. This increase was more evident 
with Fraction 7, as compared to the CCS sample. An optimum pH in both samples 
allowing the maintenance of higher levels of PA binding IgG was between 8-9. 
 
 
 
 
Figure 3.4.4.3: Effect of pH on CCS and Fraction 7 (post CPC processing), pH changed with 
drops of concentrated NaOH or HCl. Samples subject to protein A HPLC developed analytical 
method and plotted against corresponding HPLC peak area.  
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A criterion of 20% significant difference in HPLC peak area was set, as samples were 
subject to change in the parameters (50ºC incubation, sonciation and pH). When the 
significant difference was calculated, using a >20% change in HPLC peak area, the 
only condition that caused a significant degradation was sonication. It appeared to 
actually further degrade the IgG, rather than, as hoped to return the non-viable form of 
IgG back to its viable form. Temperate had no effect; however increasing pH slightly 
increased the creation of functional IgG but not greatly. These results showed that, 
under these conditions the only possibility of conversion was from the functional 
protein A binding IgG to non binding PA IgG. With the processes tested, there seemed 
to be no possibility of converting back to the functional form. A large spread of data 
and no trends towards protein A binding IgG conversion were seen. 
 3.4.5         Sample loading capacity: CPC run 3-2 
To improve resolution, a second CPC run (Run 3-2) was performed using CCS at 
1mg/ml (previous run was at 4mg/ml) using the same 18.7ml sample loop. The 
reconstructed protein A HPLC chromatogram graph is shown in Figure 3.4.5.1, with 
the IgG elution confirmed at around 57 minutes (Fraction 6).   
 
Figure 3.4.5.1:  Protein A HPLC analysis of CPC runs using crude CCS starting material. 
500ml coil volume, 18.7ml sample loop, operation was in descending mode and a flow rate of 
5ml/min. CCS separated using a PEG 3350 11.1%/11.1% ammonium sulphate system, 500ml 
coil volume, 5ml/min flow rate, 18.7ml injection volume at 20ºC.   
 
The elution time graph was very similar to that seen at 4mg/ml (Figure 3.4.1.2). 
Elution of protein A binding IgG and the remaining non protein A binding IgG was 
with the elution of several impurities.  
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 A reduced SDS PAGE was conducted to assess purity as described 
previously in section 3.4.2 (Figure 3.4.5.2). It was seen that Fraction 6 had a banding 
pattern that resembled that of the protein A control. However, no other bands, which 
would have been expected in fractions containing the impurities, were seen (Lane 7-
10). When rechecking the data it was seen that an error was made in the preparation of 
samples. Samples were prepared identically and not adjusted for their respective 
concentrations.  Despite the differences in concentration due to a calculation error, 
there appeared to be a reduction in impurities in Fraction 7, similar to that of the PA 
purified IgG. Furthermore some impurities had been removed when compared to the 
CCS control in Lane 3. 
 
 
Figure 3.4.5.2: Reduced SDS PAGE gel of the fractions from CPC run 3-2. Samples analysed 
post CPC run.  Gel run at 140 V for 2 hours and stained with Coomassie blue.  
 
3.4.6          Stationary phase retention and stripping 
With all CPC runs, the equilibration method was used. Firstly the coil was filled with 
stationary phase while spinning at 2000rpm in ascending mode. One litre of phase was 
pumped (two column volumes), allowing the column to be completely flushed clean 
with stationary phase. The column spin direction was then changed to descending 
mode and the mobile phase pumped.  Displacement of stationary phase was followed 
Lane 
number 
Sample 
1 MWM 
2 Protein A IgG 
3 CCS control 
4 Fraction 5 
5 Fraction 6 
6 Fraction 7 
7 Fraction 8 
8 Fraction 9 
9 Fraction 10 
10 Fraction 16 
6kDa 
1            2         3          4           5             6          7          8          9         10 
                                    Lane number 
  Lane number 
 
200kDa 
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55.4kDa 
36.5kDa 
31.0kDa 
21.5kDa 
14.4kDa 
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by ‗breakthrough‘ of mobile phase, represented by the attainment of full equilibration. 
Once full equilibration was reached, sample injection proceeded.  
 Following breakthrough, there should ideally be no more displacement 
of the stationary phase, termed stripping. If displacement continues, to the extent that 
all stationary phase is stripped from the column, then only mobile phase is left. All 
material will hence be eluted un-separated at the K=1 point. The continued stable 
retention of stationary phase is important for a separation to occur.   
 To measure stripping, samples post a CPC run (CPC run 3-2) were 
observed. CPC fractions were collected in 50ml graduated tubes. Stripping was 
calculated by observing the percentage of upper stationary phase in graduated 50ml 
collection tubes to lower phase. With the PEG 3350 11.1%/11.1% ammonium sulphate 
system, very little stripping was seen (Figure 3.4.6.1) and by 50 minutes this had 
stopped. 
 
Figure 3.4.6.l:  Stripping data during a CPC run. 200ml of stationary phase was initially lost 
during equilibration. Of the 300ml left at the start of the CPC run, a final 90.2% of stationary 
phase was retained in the coil, which equalled 270ml. CCS starting material used. 500ml coil 
volume, 18.7ml sample loop, 4 bars of pressure. Operation in descending mode and a flow 
rate of 5ml/min. Stripping calculated by observing percentage of upper stationary phase in 
graduated 50ml collection tubes.  
 
3.4.7 Prediction of retention time 
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ammonium sulphate system, 20ml fractions collected every 4 minutes,  
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Prediction of retention time was obtained using the elution time equation applied to 
CCC peak elution. Berthod‘s group (2004) used the following equation: VRI = VM 
+KDIVS.  
This where the following applies: 
VM = Volume of mobile phase 
VS = Volume of stationary phase 
VRI= Retention volume of molecule of interest 
KDI=  Partition coefficient  
Figure 3.4.7.1: Elution time equation used by Berthod’s group (Berthod et al., 2004) where 
retention volume is calculated (VRI). Mobile phase and stationary phase retention are used 
with the partition coefficient of the determinant of interest.  
 
The equation in Figure 3.4.7.2 was used to determine predicted elution time of IgG 
from a CPC run. The volume of mobile phase was calculated by subtracting the 
amount of stationary phase eluted by that of the extra coil volume (Vec).   Total Vec was 
calculated by considering all dead volume (76ml) seen within the CPC, including all 
interconnecting tubing between the chambers and tubing to feed the exterior fraction 
collector. The partition coefficient (K) was 0.43 as obtained from the robot runs 
(Figure 2.4.3.5). Stationary phase volume was calculated by subtracting the coil 
volume of 500ml by the amount of stationary phase eluted prior to breakthrough 
(200ml). The predicted elution time was 65.8 minutes, which was very close to the 
actual IgG elution of 67 minutes seen in Figure 3.4.5.1 and 3.4.1.2.           
 
 
 
 
 
 
 110 
Elution time =       VM + (K * Vs)  +              Vec 
         F                  F 
VM    = Volume of mobile phase = 200-76= 124ml 
K       = Partition coefficient = 0.43  
Vs     = Volume of stationary phase = 500-200=300ml 
F       = Flow rate = 5ml/min 
Vec      = Extra coil volume = 71ml (estimated value,  including 5ml tubing volume) 
Figure 3.4.7.2: Elution equation based on time. Flow rate is additionally used to determine 
elution time of molecule of interest (de Folter et al., 2008).Figures obtained from CPC run 3-
2. 
 
3.4.8 Comparison of work with that of Aires-Barros group (Lisbon, 
Portugal): PEG 1000 14%/14% potassium phosphate system 
Due to the low levels of functional IgG (PA binding) seen post CPC purification, the 
possibility that ammonium sulphate could be having a precipitation effect was 
investigated. Ammonium sulphate precipitation is used as a first step for many protein 
purifications (Ahlstedt, 1973; Arend et al., 1974). Due to the large concentration of 
salt used along with PEG, it was hypothesised that the ammonium sulphate system 
was actually rendering the IgG inactive, or causing IgG precipitation on contact with 
the phase system. Previously during the robotic run (Chapter 2), no IgG aggregation 
was seen with a total peak area of >85%, where many system were rejected. It was 
thought that due to the vigorous mixing with a CPC run as opposed to just bench 
incubation with the robotic run, increased aggregation would result. Furthermore 
during CPC processing the mAb was incubated in the phase system for much longer 
when compared to the robotic run, when the mAb sample was added last following 
phase make up. These were thought to result in the effect ammonium sulphate had on 
the mAb not being seen previously.  
 Comparative studies were carried out with the BIB phase system 
(PEG 3350 11.1%/11.1% ammonium sulphate system) and that of the Aires Barros 
group (PEG 1000, 14%/14% potassium phosphate). The BIB and the Aire-Barros 
group phase system were prepared and CCS was incorapted in the sample make up. 
The phase system was mixed thoroughly and triplicates were taken immediately (0 
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hours), 250µl sample were diluted 1 in 4 in water. These samples were subject to 
protein A HPLC analysis. The two phase systems with the CCS incorporated were 
then incubated for 3 hours on the bench. Following three hours samples were again 
taken in triplicate as described previously and subject to protein A HPLC analysis.  
 As shown in Figure 3.4.8.1, a decrease in viable IgG HPLC peak 
area was seen following three hour incubation in the ammonium sulphate system. This 
highlighted the issue of IgG precipitation with the ammonium sulphate. Instability was 
seen in the ammonium sulphate system, relative to the potassium phosphate system 
used by the Aires-Barros group.  
The potassium phosphate phase system used by the Aires Barros group 
(Azevedo et al., 2009) (PEG 1000, 14% potassium phosphate) has been used for many 
successful separations and resulting published papers. To confirm that the issues seen 
with the loss in IgG functionality were due to CCC processing, a CPC run was carried 
out with this phase system. Loss in IgG functionality had not been noted by this group, 
as they were just using batch extraction (Azevedo et al., 2009). ATPS extraction was 
carried out without the CCC processing.  
 
Figure 3.4.8.1: Comparison of phase system stability. PEG 3350 11.1%/11.1% ammonium 
sulphate system (BIB) compared to that of the Aires-Barros group (PEG 1000, 14%/14% 
potassium phosphate system. Individual phase systems incubated for 3 hours with CCS and 
then samples subject to protein A HPLC analysis.  
 
 
A CPC run was carried out with the PEG 14%/14% potassium phosphate system with 
the same conditions outlined in Figure 3.3.3.1. A control sample was taken pre and 
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post CCC processing and subject to protein A HPLC analysis. To determine the exact 
cause of instability, controls (CCS) were taken in both the phase system and water 
following a 5 hour incubation period. In parallel phase system and water incubation 
samples were prepared. The CCS was prepared in both the PEG 1000 14/14% 
potassium phosphate system and water and subject to bench top incubation for 5 
hours. All samples were mixed thoroughly and diluted 1 in 4 in water before analysis 
by protein A HPLC.  
 The CCS sample was typically composed of 16-20% PA binding IgG. This 
was calculated from the percentage of PA binding IgG (6 minutes), obtained from a 
protein A HPLC chromatogram in comparison to the PA non-binding HPLC peak 
area. Samples were also taken before and after the actual CPC run and the percentage 
of PA binding IgG calculated (results shown in Figure 3.4.8.2). Experiments were 
carried out singly. As shown in Figure 3.4.8.2, CCC processing itself was causing 
instability and a species change. A drop in PA binding IgG from 20.55% to 7.63% was 
reported. Purification was seen by SDS PAGE; however the majority of IgG produced 
was non-functional.  
 
 
 
 
 
 
 
 
Figure 3.4.8.2: Overview of stability of IgG through whole CCC process (phase system 
incubation and CCC processing) using the PEG 1000 14/14% potassium phosphate system. 
All samples subject to protein A HPLC analysis, 6 minute PA binding peak used. Percent of 
PA binding IgG calculated from that of the starting CCS sample. 
 
 The potassium phosphate phase system was not responsible for any 
instability, HPLC peak area in the phase system and water post 5 hours incubation 
were unaffected. The results were highlighted by the use of a phase system used 
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IgG HPLC peak area 2357114 194280 
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IgG HPLC peak area: In phase 2255679 2312576 
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routinely by the Aires-Barros group for aqueous extraction (no CCC processing). 
Many successful separations of IgG from impurities had been demonstrated by this 
group. No losses were seen with aqueous extraction alone, highlighting mixing and/or 
other mechanical aspects of the CCC operation were responsible for loss in IgG 
functionality. A reasonable degree of purification was being achieved, but at the cost 
of damaged and consequently non-functional IgG, which greatly affected yield 
 Despite these results suggesting that CPC processing was resulting in 
the production of inactive IgG, incubation experiments suggested the ammonium 
sulphate system was exacerbating this effect (Figure 3.4.8.1). A decrease in viable IgG 
was seen when incubation was just carried out on the bench for 3 hours. Even without 
CPC processing, precipitation and reduction in viable IgG was seen with the 
ammonium sulphate system. Investigation into how close this phase system was to the 
critical point and its robustness in comparison to another system was required.  
3.4.9 PEG 1000 17.5%/17.5% sodium citrate system vs. PEG 3350 11.1%/11.1% 
ammonium sulphate system 
 
To determine how close the PEG 3350 11.1/11.1% ammonium sulphate system was to 
the critical point a phase diagram was required. If too close to the boundary of a single 
phase the system would be sensitive to a number of parameters, for example 
temperature, pH and any small changes in polymer or salt concentrations. The phase 
diagram was constructed to show the potential working area for this phase system.  
 Stock solutions of PEG and ammonium sulphate were made and the 
turbidometric (Zaslavsky, 2005) titration method used. PEG and ammonium stock 
solutions were made to 28% by dissolving each separate component (20g) in 50g 
water respectively. Drops of each stock solution (PEG and ammonium sulphate 
respectively) were added to one another in a step wise manner until turbidity was seen. 
The weight was noted, and water added to clear the solution. This was repeated over a 
range. The total weight of the test tube and the weight of the diluents added were used 
to calculate the percentage of PEG and salt at particular points.  
 As shown in Figure 3.4.9.1 ammonium sulphate (%w/w) was plotted 
against PEG (%w/w) for the PEG 3350 system. These results were then plotted against 
those using PEG 1000 and 6000 from Boris Zaslavsky‘s aqueous two-phase 
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partitioning book (Aqueous two-phase partitioning, 2005). The phase diagram for PEG 
3350 was seen to fit the trend shown for PEG 1000 and 6000. A high ammonium 
sulphate concentration was needed, lower than that of the PEG to produce a two phase 
system (Figure 3.4.9.1).  
 
 
 
 
 
 
 
Figure 3.4.9.1 Phase diagram: PEG ammonium sulphate system. Phase diagram 
constructed using stock solutions of PEG 3350 and ammonium sulphate. Turdoimetric 
titration method was employed. PEG 1000 and PEG 6000 phase diagrams (carried out at 
25ºC) obtained from Zaslavsky’s book (1995) for comparison. The closeness of PEG 3350 
11.1%/11.1% system to the critical point is highlighted. 
 
As Figure 3.4.9.1 shows, the PEG 3350 11.1%/11.1% system was very close to the 
critical point, hence possibly sensitive to temperature. Due to seasonal fluctuation in 
the laboratory, a constant temperature was hard to maintain. It was thought that the 
mobile phase needed to be maintained at 20ºC or less to prevent the possible 
denaturation of the mAb during CPC processing.   
 Temperature as a variable to phase system composition was then 
investigated using the PEG 3350 11.1%/11.1% ammonium sulphate system. A range 
of temperatures were used. The PEG 1000 17.5%/17.5% sodium citrate system (as 
highlighted in Chapter 2 as appropriate following the robotic run) was compared to the 
PEG 3350 11.1%/11.1% ammonium sulphate system. The two phase systems were 
prepared in graduated measuring cylinders (10g in a 50ml tube) and incubated or 
placed in the fridge (4ºC). After temperature equilibration, the tubes were mixed and 
allowed to phase separate. The volumes of top and bottom phase were measured. The 
tube was then placed at another temperature, thermally equilibrated and then mixed 
Phase diagram: PEG 3350 Ammonium sulphate system at 25ºC compared to 
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and phase volumes measured. A range of temperatures from 4ºC to 67°C were studied. 
The volume ratio was obtained by dividing the upper volume by the lower volume 
(Figure 3.4.9.2). 
Temperature 
(ºC) 
Volume ratio (Upper/lower) 
PEG 1000 17.5%/17.5% 
sodium citrate 
PEG 3350 11.1%/11.1% 
ammonium sulphate 
4 0.80 0.88 
12 0.80 0.77 
20 0.80 0.75 
26 0.80 0.70 
28 0.80 0.70 
35 0.80 0.55 
37 0.80 0.51 
44 0.80 0.47 
48 0.80 0.42 
52 0.54 0.37 
67 0.54 0.30 
Figure 3.4.9.2: Effect of temperature on volume ratio in PEG 1000 17.5%/17.5% sodium 
citrate system and PEG 3350 11.1%/11.1% ammonium sulphate system. 
 
 
Figure 3.4.9.3: Graph to show the effect of temperature on the volume ratio for two different 
PEG-salt two phase systems.  
 
Figure 3.4.9.3 demonstrates increasing temperature plotted against volume ratio for 
the two phase systems. With the PEG 3350 11.1%/11.1% ammonium sulphate system 
a clear linear decrease in volume ratio is seen as temperature increases. By 
comparison, the PEG 17.5%/17.5% sodium citrate system had a stable volume ratio to 
around 50 ºC. The range of phase volume ratios seen with the PEG 3330 11.1%/11.1% 
ammonium sulphate system varied from 0.88 at 4ºC to 0.3 at 67ºC. The typical 
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working range in the lab was from 20°C to 33ºC; the upper temperature range arose 
from heat produced by the machines (CCC). Within this temperature range, a volume 
ratio range from 0.7 to 0.51 with the PEG 3350 11.1%/11.1% ammonium sulphate 
system was seen. The PEG 1000 sodium citrate 17.5%/17.5% system by comparison 
appeared greatly more consistent over the temperature range tested. A change in the 
extremely stable volume ratio can only be seen at temperatures greater than 48ºC.  
 Finally the respective calibration curves of the PEG 11.1%/11.1% 
ammonium sulphate and the PEG 1000 17.5%/17.5% sodium citrate system were 
compared. This to confirm that the PEG 1000 17.5%/17.5% sodium citrate system was 
more suitable.  PEG 1000 17.5%/17.5% sodium citrate and PEG 3350 11.1/11.1% 
ammonium sulphate systems were prepared with CCS incorporated. Calibration curves 
for each phase system were produced using protein A HPLC with a CCS concentration 
from 0-1mg/ml (Figure 3.4.9.4). On preparation of the ammonium sulphate system, 
precipitation of the IgG in the HPLC vial was noticed.  
 
 
 
 
 
 
 
Figure 3.4.9.4:  Calibration curves for PEG 3350 11.1%/11.1% ammonium sulphate system 
and PEG 1000 17.5%/17.5% sodium citrate system. All based on CCS with an injection 
volume of 80µl using protein A HPLC analysis, 8 minute run time injection in phase system.   
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As shown in Figure 3.4.9.4 IgG concentration in the CCS was plotted against 
HPLC peak area. With the PEG 1000 17.5%/17.5% sodium citrate system a typical 
linear calibration curve was seen. With the PEG 3350 11.1%/11.1% ammonium 
sulphate system however an exponential curve was demonstrated. With the PEG 3350 
11.1%/11.1% ammonium sulphate system, a maximum peak area at 1mg/ml of IgG 
was 700,000 µV.sec. With the PEG 1000 17.5%/17.5% sodium citrate system 
however, this was 400,0000 µV.sec (Figure 3.4.9.4). The calibration curve for the 
ammonium sulphate system did not follow a linear trend. An exponential curve was 
seen. It was hypothesised a precipitation effect was seen on the IgG with the use of 
ammonium sulphate. It was thought at a low CCS concentration the ammonium 
sulphate precipitation was reducing IgG solubility and thus the resulting absorbance 
signal was lower (around 100,000 in comparison to 500,000 seen with the sodium 
citrate system). At a higher CCS concentration, aggregation of the insoluble IgG was 
suspected, resulting in the increased exponential absorbance signal seen (Figure 
3.4.9.4).    
 The robustness of the PEG 1000 17.5%/17.5% sodium citrate system was 
demonstrated as opposed to that of the PEG 3350 11.1%/11.1% ammonium sulphate 
system. As the ammonium sulphate system was so close to the critical point, it was 
greatly affected by temperature and prone to aggregation. The PEG 1000 
17.5%/17.5% sodium citrate system was selected for all future separations.  When 
compared to the ammonium sulphate system, it had both a higher pH (7.39 as opposed 
to around 6) therefore reducing the possibility of aggregation (Pan et al., 2009; Wang, 
2005). When the ammonium sulphate phase system was prepared the pH was not 
adjusted. This as adding sulphuric acid to the high salt concentration would have 
resulted in a pH that was challenging to measure. However for the phosphate and 
citrate salt finding the appropriate combination of salts to get a system within the 
physiological range of pH range of 7.5-9 was relatively easier and hence conducted.  
3.4.10          CPC runs with PEG 1000 17.5%/17.5% sodium citrate system 
The phase system was prepared as shown below (Figure 3.4.10.1). 
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Component Mol weight Weight added 
to make 
17.5%/17.5% 
system (g) 
CAS 
PEG 1000 1000 700 25322-68-3 
Water 18.02 2600  
Sodium 
citrate 
Acid 294.1 5.75 5942-29-1 
Base 210.14 694.25 6132-04-3 
Figure 3.4.10.1   Phase system preparation: PEG 1000 17.5%/17.5% sodium citrate system. 
Sodium citrate dihydrate (base) and citric acid monohydrate (acid) added in the weights 
shown above. Both were anhydrous salt, prepared in this particular proportion to obtain a pH 
of >7.4.All components were dissolved in water (g) as noted above to a final volume of 4000g. 
The phase system was left to equilibrate for over two hours and upper and lower phase 
decanted separately.  
 
Initial CPC runs were conducted to investigate if a separation was possible using the 
PEG 1000 17.5/17.5% sodium citrate system. Typical run conditions are outlined 
below (Figure 3.4.10.2).  
CPC - separation 
ATPS…17.5/17.5% w/w…………PEG/Salt, pH…7.41 
PEG…1000……Salt …Sodium citrate 
Coil volume……..429ml 
Sample loop……..18.7 ml 
Operating mode.…Descending 
Injected mAb: 
1) IgG4 CCS……..… (Batch number L16508/49) 
       Volume…..........32.5ml diluted with:  
        8.75g…. Sodium citrate 
        8.75g….. PEG 
Spin speed…2000rpm, temperature…20.4°C, flow rate…..….10ml/min 
Equilibrated at………10ml/min, extra coil volume……..76ml  
Stationary phase displaced………400ml, pressure…4Bar 
Figure 3.4.10.2: Typical CPC run conditions used. 
The CPC was operated in descending mode at a flow rate of both 5 and 10ml/min. The 
stationary phase retention using the CPC at both flow rates was typically low at 20%. 
400ml of stationary phase was displaced leaving 100ml within a 500ml coil volume. 
The PEG and salt phases in turn were used as upper phase, and the results can be seen 
in Figure 3.4.10.4.  Time in minutes for each run is plotted against HPLC peak area. 
Results at both flow rates were similar. Impurities were seen to elute within the run 
time (100 or 200 minutes) as shown by protein A HPLC analysis. The IgG however 
appeared to be retained in the column. The IgG was eluted when the column content 
was blown out with nitrogen gas at 4 bars. 
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Figure 3.4.10.3: CPC run at a 5ml/min. CCS starting material used with the PEG 1000 
17.5%/17.5% sodium citrate system. Samples analysed by protein A HPLC.   
 
 
 
 
Figure 3.4.10.4: CPC data 10ml/min. CCS starting material used with the PEG 1000 
17.5%/17.5% sodium citrate system. Samples were analysed by protein A HPLC. 
 
 
Subsequent HPLC analysis showed the IgG was reasonably pure, with 89.2% 
purity from the 10ml/min run and 98.7% purity from the 5ml/min run. By comparison, 
>99% IgG Purity was seen in the protein A purified IgG control sample. (Figure 
3.4.10.3 and 3.4.10.4). The IgG did not elute at the predicted K=1.62 at a flow rate of 
10ml/min (Figure 3.4.10.4). When a flow rate of 5ml/min was used, a very small 
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amount of IgG eluted at the predicted K=1.62. With both flow rates, the IgG seemed to 
remain in the column and was only eluted when the column content was blown out.   
 Increased flow rate was furthermore investigated (Figure 3.4.10.4) 
with the aim to reduce the residence time of the IgG within the machine.  It was 
considered that a reduction in the number of mixing and settling steps would retain 
IgG activity. CPC runs as described in Figure 3.4.10.2 were conducted where both the 
PEG and salt phases were used alternatively as stationary phase, at a flow rate of 5 and 
10 ml/min. Results can be seen in the bar chart in Figure 3.4.10.5. Flow rate is plotted 
against the recovery of IgG functionality following analysis by protein A HPLC. IgG 
functionality was calculated by dividing the total IgG HPLC peak area in the fractions 
of interest by that of the amount present in the injection sample. At a flow rate of 
10ml/min regardless of whether salt or PEG was used as an upper phase a 
considerably higher retention of activity was seen when compared to those runs 
conducted at 5ml/min.  
 
Flow rate (ml/min) 
Recovery of IgG functionality (%) 
PEG upper Salt upper 
5 44.6 49.83 
10 71.41 70.75 
Figure 3.4.10.5: Effect of flow rate on retention of IgG functionality, using both PEG and salt 
in separate CPC runs as the upper phase. Experiments performed at a flow rate of both 5 and 
10 ml/min. PEG 1000 17.5%/17.5% sodium citrate system, 500ml coil volume with PA 
purified IgG.  
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As shown in Figure 3.4.10.5, despite the use of either PEG or salt as the 
stationary phase, flow rate significantly affected recovery of IgG functionality. A 
higher IgG recovery was seen at 10ml/min (71%) compared to the run at 5ml/min 
(50%). Mass recovery of the IgG post CPC was always >95%, however loss in the 
recovery of active hence viable IgG was seen. Thus, when a recovery of 71% viable 
IgG recovery was seen following a run at 10ml/min, it was assumed the remaining 
29% of IgG was unfunctional. This unfunctional IgG was further assumed to be 
showing up as ‗impurities‘ on the HPLC chromatogram.  
 Despite an increase in the retention of functional IgG at an increased flow rate, 
there was still a loss in the functionality. As it was considered earlier that the 
ammonium sulphate system was having a negative effect on recovery, the PEG 1000 
17.17.5% sodium citrate system was used for these experiments. Losses however were 
still seen. It was thought a mechanical process within the CPC instrument was causing 
an alteration in the ability of some of the IgG to bind to Protein A.  
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3.5 Conclusions 
 
High vigour mixing, previously seen fundamental to high resolution separation in 
ATPS (Bourton et al., 2007), appears to have a detrimental effect on IgG functionality. 
Work in this chapter has concluded that either the phase system itself or some 
mechanical procedure during CPC processing has altered the Protein A binding 
capacity of some of the IgG.  
Protein A HPLC analysis has been optimised, allowing chromatograms to be 
unaffected by the presence of phase system in the injection sample. The HPLC method 
produces 2 peaks, one at 6 minutes, the other at 0.1 minutes. The 0.1 minute peak was 
found to consist of both impurities (if present) and non-functional IgG. Previously this 
peak was regarded as just impurities but, as shown by SDS PAGE, this was not the 
case and non-functional IgG eluted at the same time of 0.1 minutes.  
The phase system and the need for high resolution separation based on 
vigorous cascade mixing has been concluded to not be as benign as previously 
considered (Guan et al., 2008; Sutherland, 2007; Sutherland,2008). Furthermore any 
changes to the non-functional IgG species appeared to be non-reversible. The chemical 
properties of the PEG 3350 11.1%/11.1% ammonium sulphate system have been seen 
to negatively affect the IgG. A precipitation effect, was seen that would possibly 
exacerbate the effect on IgG functionality has been seen. All future runs were 
therefore conducted with the PEG 1000 17.5%/17.5% sodium citrate system.  
 This chapter has shown the trade-off between the need for vigorous 
mixing to allow separation from impurities and the resulting detriment to IgG 
functionality. The possibility of adequate mixing in a system which combines features 
of both hydrostatic and hydrodynamic mixing will be studied next. The toroidal coil 
allows scalability, with no rotating seals, hence is easier to clean.  
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4.1   Summary 
 
Toroidal coil (TC CCC) mAb separation and its resulting effect on IgG functionality 
are investigated within this chapter. The primary aim was to minimise the production 
of non-reversible non-functional IgG. A milder form of cascade hydrostatic mixing 
than described previously in Chapter 3 was investigated. Retention of IgG biological 
activity with the separation from impurities post TC CCC processing was the objective 
of this chapter. 
 Unfortunately a loss in IgG functionality was again seen following 
TC CCC processing. The loss was relatively smaller when compared to that of the 
CPC, however still evident. Such a loss in biological activity cannot gain regulatory 
acceptance or be used to demonstrate the potential of this process for industrial uptake. 
The studies within this chapter look at various experimental parameters and their 
resulting effect on the retention of IgG biological activity. An increased flow rate 
reduced the transit time of the IgG within the machine and significantly increased the 
retention of IgG functionality. A reduction in rotational speed also improved retention 
of activity, but at the detriment to IgG peak width. Peak broadening was seen, it was 
assumed that would ultimately lead to a poor resolution separation.  
 This chapter demonstrates IgG separation from impurities, as 
confirmed by SDS PAGE gel and the removal of host cell proteins as shown by 
 125 
ELISA. However, as highlighted in Chapter 3, following CPC processing a loss in IgG 
functionality was also seen with the TC CCC.  
4.2   Introduction 
Chapter 3 highlighted the clear separation of the mAb from crude CCS, using the CPC 
hydrostatic column; a detrimental effect on IgG functionality was however seen (based 
on the inability of the IgG to bind to the protein A, that is used as an indicator of 
functionality, in the absence of a true bioassay). Initially, precipitation seen with the 
ammonium sulphate system was thought to cause the IgG degradation. However, after 
changing to the sodium citrate system, IgG degradation post CPC was still seen.  It 
was hypothesized that a mechanical process within the CPC process was causing a 
species change. The result was a reduction in the ability of the IgG to bind to PA. An 
alternative CCC machine was sought after that had the benefits of the CPC with high 
resolution separation and good stationary phase retention but did not reduce Protein A 
binding activity. Hypothesized benefits of the hydrodynamic mode were also needed; 
e.g. gentler mixing that was less detrimental to the IgG. However it was anticipated a 
reduced level of mixing would result in the loss of IgG resolution from impurities. 
 The TC-CCC bears similarities to the CPC in that it also uses a 
hydrostatic mixing motion. The CPC uses a uniform, high g-force field created by 
high spinning revolution. Pressure is used to drive material through mixing chambers 
and small bore interconnected tubes (Sutherland, 2011). The wide bore, continuous 
tubing of the TC CCC results in a lower pressure inside the tubing. Additionally, 
unlike the CPC there are no small interconnected chambers and high pressure is not 
applied.  
The toroidal column CCC is composed of multilayer toroidal coils wound 
around a drum. Cascade mixing occurs in its continuous tubing with a variable g force 
field. The coil design allows vigorous mixing, hence good mass transfer and a high 
resolution separation. The stable retention of stationary phase is also seen with 
minimal stripping. Another advantage is the lack of rotating seals, making TC CCC 
less prone to leakage and contamination (Matsuda et al., 1998; Ito, 2005). Moreover 
the TC CCC has more potential for scale up, with no corresponding issues involved in 
the cleaning of small tubing and interconnected chambers. It was predicted the TC 
CCC would allow high stationary phase retention and separation from impurities by 
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high mass transfer across the phase system. As cascade mixing was still employed but 
at a reduced vigor to the CPC, it was postulated that the resulting g force field 
associated with processing would be lower.  
4.3   Method and materials 
 
4.3.1 Preparation of phase system 
The PEG 1000 17.5%/17.5% sodium citrate system was prepared.  The phase system 
was prepared as detailed in Chapter 3 (Section 3.4.9).  
4.3.2   TC CCC operation 
 
The toroidal coil CCC (TC CCC) machine had a column volume of 333ml. Due to the 
way the column is wound (Figure 4.3.2.1) a maximum of 50% stationary retention is 
possible. A lower level of stationary phase retention is seen with the TC CCC as each 
helical turn is entirely occupied by the mobile phase (Zhang et al., 2010). Centrifugal 
forces are used to retain the stationary phase. Mobile phase however, passes 
recurrently through the stationary phase, resulting in stationary phase retention that is 
typically less than 50% of the 333ml column volume (Ito et al., 2009) 
 
Figure 4.3.2.1: Schematic of TC CCC bobbin (Sutherland et al, 2010). TC CCC employs the 
use of tubing that is wound toroidally around the drum.  Cascade mixing is achieved within 
the spinning coil.  
 
Typical TC CCC conditions used are outlined in Figure 4.3.2.2.  
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TC-CCC separation 
ATPS…17.5/17.5% w/w..…PEG/Salt, pH…7.39 
PEG……1000…Salt …Sodium citrate 
Coil volume……333ml 
Sample loop……16.8ml 
Operating mode…Forward 
Column filled at ……30ml/min 
Injected mAb: 
1) CCS……… (Batch number …L156568/47) 
       Volume…........32.5ml diluted with:  
        …..8.75g sodium citrate 
        …..8.75g PEG 
Concentration of the antibody injected into the column……2.2mg/ml 
Spin speed…2000rpm, temperature….20°C, flow rate…..…5ml/min 
Equilibrated at……5ml/min,  
Stationary phase displaced.….240ml 
Figure 4.3.2.2:  Typical TC CCC run conditions, using a PEG 1000 17.5%/17.5% sodium 
citrate system. Operated from centre to periphery using a 16.8ml sample loop at a flow rate of 
5ml/min.  
 
4.4 Results and discussion 
4.4.1  PEG 1000 17.5%/17.5% sodium citrate run on the TC CCC: Run 4-1 
A purification run was completed using CCS on the TC CCC using the conditions 
outlined in Figure 4.3.2.2. Fractions were collected every 5 minutes for 200 minutes 
and subject to Protein A HPLC analysis. Figure 4.4.1.1 shows a reconstructed 
chromatogram following HPLC analysis. Elution time of the IgG and impurities is 
plotted against HPLC peak area.  Again, impurities were regarded as anything that did 
not bind to the Protein A column, these were eluted along with the solvent front at 0.1 
minutes. The IgG eluted as theoretically predicted at K=1.62.  
 
Figure 4.4.1.1: Elution time graph following protein A HPLC analysis of TC CCC run. PEG 
1000 17.5%/17.5% sodium citrate system. Operated from centre to periphery using a 16.8ml 
sample loop at a flow rate of 5ml/min.  
Elution time graph: TC-CCC, flow rate 5ml/min, 1200 rpm, sample loop  
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As shown in Figure 4.4.1.1, elution of the IgG was seen with assumed protein A non-
binding IgG and impurities. Recovery of the IgG functionality however, (calculated 
using the appropriate calibration curve in Figure 3.4.7.1) was seen to only be 58.21% 
(Figure 4.4.1.2). Loss in IgG functionality following the TC CCC processing could 
possibly be explained by   HPLC variation causing large experimental error and/or the 
Protein A binding capacity of the IgG being altered, creating a non-functional form.   
Total mg of viable IgG recovered from 
fractions 
6.81 
Total mg of viable IgG in injection sample 11.70 
% recovery of functional IgG 58.21 
Figure 4.4.1.2: Functional IgG recovery, calculated following a TC CCC run for the 
purification of CCS. A PEG 1000 17.5%/17.5% sodium citrate system was used. 333ml coil 
volume, 5ml/min flow rate, 16.8ml injection volume. Analysis by protein A HPLC.  
 
 
4.4.2          SDS PAGE results: silver stain 
The SDS PAGE protocol as described in Section 3.4.2 was used for fractions from TC 
CCC run 4-1. The gels were initially stained with Coomassie blue (Figure 4.4.2.1). All 
the tested fractions (10-16) appeared to contain the IgG with fewer contaminant bands, 
when compared to the CCS control. As no impurities band were visible with the 
Coomassie blue stain, the more sensitive silver stain was employed.  
 
 
 Figure 4.4.2.1:  SDS PAGE gel with Coomassie blue staining. Reduced SDS PAGE gel. 
Samples analysed post TC CCC run 4-1.  CCS purified using a PEG 1000 17.5%/17.5% 
sodium citrate system, 333ml coil volume, 5ml/min flow rate, 16.8ml injection volume, TC 
CCC run at 20ºC.  10µl sample injected per well.  
 
Lane 
number 
Sample/ 
Fraction time 
1 MWM 
2 Protein A purified IgG 
3 CCS control 
4 Fraction 10 (50 minutes) 
5 Fraction 11 (55 minutes) 
6 Fraction 12 (60 minutes) 
7 Fraction 13 (65 minutes) 
8 Fraction 14 (70 minutes) 
9 Fraction 15 (75 minutes) 
10 Fraction 16 (80 minutes) 
 1          2           3        4        5        6         7            8           9          10 
                                        Lane number 
 
200kDa 
116.3kDa 
97.4kDa 
66.3kDa 
55.4kDa 
36.5kDa 
31.0kDa 
21.5kDa 
14.4kDa 
6kDa 
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A silver staining kit was purchased from Invitrogen and results can be seen in Figure 
4.4.2.2. A marked difference was seen not only in sensitivity but gel quality. 
Interestingly, despite dilution differences, Fractions 12, 13 and 14 have fewer bands 
than the CCS control. However as the CCS is so concentrated, it was thought if this 
sample was diluted many bands apart from those that are very darkly stained would 
disappear. Sliver stain is much more sensitive but not quantitative, hence allowing all 
bands to be detected, however giving no conclusions regarding amount. It appeared as 
shown in Figure 4.4.1.1 very little purification was being achieved.  The species 
change suggested by protein A HPLC does not appear by the SDS PAGE. The 
molecular weights of the fractions post TC CCC purification were not altered. It was 
thought a structural change had occurred or a subtle chemical modification of residues 
at the IgG: Protein A binding interface.  As shown in Figure 4.4.2.1 by SDS PAGE 
gel, it was not a molecular weight change.   
 
 
Figure 4.4.2.2:  SDS PAGE results using silver stain. Reduced SDS PAGE gel. Samples 
analysed post TC CCC run 4-1.  CCS separated using a PEG  1000 17.5%/17.5% sodium 
citrate system, 333ml coil volume, 5ml/minute flow rate, 16.8ml injection volume, TC CCC run 
at 20ºC. 10µl sample injected per well.  
 
 
Purification was shown by SDS PAGE and silver stain (Figure 4.4.2.2). Further 
concentration of samples however was required to validate the SDS PAGE results seen 
at differing dilutions. Without concentration, the SDS PAGE showed no impurities. As 
Lane 
number 
Sample/ 
Fraction time 
1 MWM 
2 Protein A purified IgG 
3 CCS control 
4 Fraction 10 (50 minutes) 
5 Fraction 11 (55 minutes) 
6 Fraction 12 (60 minutes) 
7 Fraction 13 (65 minutes) 
8 Fraction 14 (70 minutes) 
9 Fraction 15 (75 minutes) 
10 Fraction 16 (80 minutes) 
200kDa 
6kDa 
14.4kDa 
21.5kDa 
31.0kDa 
36.5kDa 
55.4 kDa 
66.3 kDa 
97.4 kDa 
116.3 kDa 
   1           2       3      4       5           6         7     8         9      10 
                     Lane number 
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the HPLC 280nm detector (Figure 4.4.1.1) measured non protein components not 
detected by both the Commassie and sliver stain a large impurities peak is seen. It was 
thought that low level impurities could be present in fractions, perhaps below the level 
of detection. 4 pooled samples were prepared from the TC CCC run (Run 4-1) 
fractions: pre IgG elution (fraction 2-10), IgG elution peak (fraction 11-16), post IgG 
elution (fraction 17-40) and stationary phase blow out.  
An Amicon (Watford, UK) stirred cell was used and attached to a pressure 
line. The pressure maintained the flow of the liquid through the membrane, allowing 
concentration. The use of a magnetic stirrer allowed controlled concentration without 
the build-up of molecules on the membrane surface; filter blockage was thus 
prevented. An ultrafiltration membrane (10,000 NMWL and diameter 63.5nm) was 
placed in the bottom of the cell and individual pooled samples loaded and nitrogen 
pressure attached. 
Both the pooled, pre IgG elution fractions and that of the stationary phase were 
subject to a ten-fold concentration. The pooled post IgG elution fractions were 
concentrated five-fold.  Only a five-fold concentration of the pooled post IgG elution 
fraction was conducted due to time constraints. Following the two days of 
concentration, no further concentration was achieved. It was noted during this 
concentration that precipitation of the salts occurred; this would not be desirable 
during manufacturing.  
The SDS PAGE gel following concentration showed all impurities were in the 
pooled samples of both the pre and post IgG elution peak. The IgG elution peak was 
not contaminated with impurities, demonstrating purification had not been 
compromised and that all impurities were accounted for.  
4.4.3      Determination of purity: Host Cell Protein (HCP) ELISA  
Despite the production of two IgG species, purification with the removal of all host 
proteins was demonstrated by ELISA assay.  The host cell protein assay was 
performed at Lonza. A range of fractions were used (Fraction 11, 12, 13, 14, 15, 16) 
from the TC CCC run 4-1 (Figure 4.4.1.1). 
 The basic principle of an ELISA is the detection of binding between 
a specific antigen and an antibody by the use of an enzyme (Ma et al., 2006). The 
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immunoreactivity between the capture and detection antibody is key. The capture 
antibody recognises the target antigen and the detection antibody subsequently 
recognises the bound target (Thompson, 2010). By the use of a blocking buffer any 
non-specific binding is kept to a minimum. Ultimately, the enzyme allows the 
conversion of the substrate into a coloured product, which allows quantification of the 
target antigen, based on the antigen antibody binding affinity. 
 
 
 
Figure 4.4.3.1: Schematic to show the generation of colour that is measured by a HCP ELISA. 
The colour generation is a result of the binding interaction between the antibody and host cell 
proteins present, which by the use of a substrate generates a change in assay solution.   
 
The HCP ELISA used allowed the determination of purity. Moreover it 
highlights all the potential HCPs that could potentially contaminate a product during a 
manufacturing/ purification step have been removed. It is a regulator requirement to 
obtain the lowest level of HCP possible during mAb production (<100ng HCP/mg 
IgG) for human use, following complete purification including polishing steps).  
 To perform the assay, a 96 well plate was coated with pooled sheep 
and donkey IgG anti-Chinese Hamster Ovary (CHO) HCP and left overnight. 
Blocking buffer was applied the following day, to prevent any non-specific binding. 
The blocking buffer was subsequently washed off and a serial dilution of the standard 
was loaded into the initial wells. All fractions were diluted 1:200 in sample buffer and 
placed in appropriate wells. The plate was then incubated at 37ºC for 1.5hrs. 
Substrate Colour generation 
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Biotinylated anti-HCP was added followed by extravidin. Finally the ABTS (2,2'-
Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) substrate was 
added and the plate incubated until a suitable colour development was seen (20-50 
minutes). The plate was read at 490nm on the plate reader.  
The following calculations were used: 
HCP (ng/ml)= Measure HCP in unspike (mg/ml)  x  Sample dilution factor (200) 
HCP (pg/ml)= Measure HCP in unspike (mg/ml)  x  Sample dilution factor (200) 
 Sample protein concentration (mg/ml) From HPLC 
Recovery of HCP spike: 
Recovery (%)= HCP in spiked (ng/ml) – HCP in unspiked (ng) x 100 
   HCP in control sample (ng/ml) 
 
Acceptability of recovery was ±25% of 100%.  
To calculate HCP removal, the sample (unspiked) was subtracted from a spiked 
control. The PA purified IgG was also tested in the phase system as a comparison. 
Results are tabulated in Figure 4.4.3.2, HPLC concentration for each respective 
sample is used to determine HCP concentration that remains in ng/ml. It was seen that 
CCC fractions showed a decrease in HCP when compared to the CCS starting 
material. However, this loss of HCP was not comparable to the removal shown in the 
PA purified IgG sample. Nevertheless there was a tenfold reduction in HCP in the 
fractions from that of the CCS control, demonstrating a degree of purification.  
Sample name 
HPLC value 
(mg/ml) HCP (ng/ml) HCP (ng/ml) 
PA purified IgG  in 
phase system 2.45 <10000.0 <4081.6 
CCS in phase system 0.85 138620.0 163082.3 
Fraction 11 0.45 11218.1 24933.3 
Fraction 12 1.52 27580.0 18144.7 
Fraction 13 3.67 50160.0 13667.6 
Fraction 14 1.81 34380.0 18994.5 
Fraction 15 1.05 24280.0 23123.8 
Fraction 16 0.93 15980.0 17182.8 
Figure 4.4.3.2: HCP ELISA removal results. Conducted at Lonza using fractions post TC 
CCC. PEG 1000 17.5%/17.5% sodium citrate system, 333ml coil volume, 5ml/min flow rate, 
16.8ml injection. TC CCC run at 20ºC. 
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4.4.4 Effect of flow rate, peak width and spin speed 
To determine whether adjusting the experimental parameters could improve the 
retention of IgG functionality, several parameters were investigated. These parameters 
included flow rate, stationary phase retention and rotational speed.  
TC-CCC runs were carried out at varying flow rates to observe the direct effect 
of transit time of the IgG within the machine. Figure 4.4.4.1 shows that the effect of 
flow rate plotted against resulting IgG functionality and stationary phase retention. 
IgG functionality was calculated by Protein A HPLC analysis.  As flow rate increased, 
so did the corresponding IgG recovery considerably. However a slight decrease in 
stationary phase retention as flow rate increased was observed.  All experiments were 
carried out only once.  
 
Figure 4.4.4.1: The effect of flow rate on recovery of IgG functionality. Flow rate investigated 
at 3,5 and 10ml/min using the TC CCC, PEG  1000 17.5%/17.5% sodium citrate system, 
333ml coil volume, 5ml/min flow rate, 16.8ml injection volume, TC CCC run at 20ºC. 
 
Elution profiles were compared at the differing flow rate. As shown in Figure 4.4.4.2 
elution time was plotted against IgG concentration. At a higher flow rate a much 
sharper peak was observed when compared to a lower flow rate at 5ml/min. With the 
flow rate at 3ml/min, the IgG did not elute and was found in the stationary phase pump 
out (after a 400 minute run time). Recovery was extremely poor at 16.33% and was 
thought to be due to excessive time in the machine, causing degradation to the mAb.  
These results appeared to be similar to that of the CPC where a loss in IgG 
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functionality was seen. 
 
Figure 4.4.4.2: Effect of flow rate on viable IgG peak width, Investigated at 5 and 10ml/min 
using TC CCC, PEG  1000 17.5%/17.5% sodium citrate system, 333ml coil volume, 
5ml/minute flow rate, 16.8ml injection volume. T`C CCC run at 20ºC. 
 
The effect of rotational speed was also investigated, with the aim of reducing the ‗g-
force‘ and thus the potential damage to the functionality of the IgG. As seen in Figure 
4.4.4.3, elution times are plotted against IgG concentration at rotational speeds of 900 
and 1200 rpm. At a higher rotational speed of 1200rpm the resulting peak sharpness 
was much greater than that seen at 900 rpm.  
 
Figure 4.4.4.3: Effect of rotational speed of IgG peak broadening. Investigated at 900 and 
1200rpm at a flow rate of 5ml/min on TC CCC using PEG  1000 17.5%/17.5% sodium citrate 
system, 333ml coil volume, 5ml/min flow rate, 16.8ml injection volume. TC CCC run at 20˚C. 
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When the spin speed was decreased to 900rpm at a lower flow rate of 5ml/min as 
opposed to 10ml/min, IgG recovery actually decreased (from 60.54% at 47.56% at 
900rpm). Additionally IgG peak sharpness was lost, resulting in the likelihood of 
elution with impurities being much greater.  
4.4.5  Theoretical predictability: CCC2 modelling programme 
Experimental predictability was investigated using a CCC programme design by Joost 
de Folter (a PhD student working on CCC modelling within the Institute). The 
programme allowed the determination of experimental predictability and 
reproducibility using a theoretical model. As seen in Figure 4.4.5.1 all parameters 
were detailed, most importantly the partition coefficient of the IgG and the volume 
ratio of the phase system.  
 
Figure 4.4.5.1: Parameters entered into the CCC2 programme designed by Joost de Folter, 
2008. Parameters were included to allow the calculation of predicted elution time and peak 
width. System volume was 333ml the coil volume of the CPC, phase volume ratio 0.2:0.8 and a 
flow rate of 5ml/min. D is the partition coefficient of the mAb,  
 
Figure 4.4.5.2 shows the model results based on TC CCC run 4-1 (Figure 4.4.1.1), that 
were replicated for direct comparison with the model prediction. A broad peak elution 
is seen starting at 60 minutes and tailing off around 90 minutes. When directly 
compared to the actual experimental results obtained seen in Figure 4.4.5.3 (TC CCC 
run 4-1), a similar elution time and peak broadness can be seen.  
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Figure 4.4.5.2: Predicted elution peak of IgG using CCC2 programme. Parameters included 
in the program are seen in Figure 4.4.5.1.  
 
 
Figure 4.4.5.3: Actual experimental TC CCC results using PEG 1000 17.5%/17.5% sodium 
citrate system, 333ml coil volume, 5ml/min flow rate, 16.8ml injection volume. TC CCC run at 
20ºC.  
 
4.4.6   Overview 
An overview of TC CCC run results can be seen in Figure 4.4.6.1. Despite stationary 
phase retention being improved by a lower flow rate, improved IgG retention of 
activity was seen at a higher flow rates. The best conditions with regards to retaining 
IgG activity were seen at an increased flow rate of 10ml/min due to a reduced transit 
time of the IgG within the CCC machine. A maximum functional IgG recovery was 
seen of 68.35% (Figure 4.4.4.2). When speed spin was decreased from 1200 to 
900rpm, at a flow rate of 5ml/min, the recovery of IgG activity was virtually the same 
(58.21% and 60.54%). However, at a higher spin speed stationary phase retention was 
improved.  
Elution time graph: TC-CCC, flow rate 5ml/min, 1200 rpm, sample loop  
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Figure 4.4.6.1: Overview of TC CCC results.  All conducted with, PEG 1000 17.5%/17.5% 
sodium citrate system, 333ml coil volume, 16.8ml injection volume. TC CCC runs conducted 
at 20ºC and sample subsequently analysed by protein A HPLC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recovery 
of viable 
IgG (%) 
Rotational 
speed 
(rpm) 
Flow 
rate 
(ml/min) 
Sf retention Comments Figure number 
16.33 1200 3 39.9 Recovery extremely 
poor 
n/a  (mAb 
retained in 
column) 
58.21 1200 5 29.5  4.4.1.1 
68.35 1200 10 27.9 High resolution, sharp 
peak 
4.4.4.2 
60.54 900 5 26.4 Lower spin speed of 
900rpm 
4.4.4.3 
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4.5 Conclusions 
The TC CCC, following on from results obtained in Chapter 3, was used to investigate 
mAb separation from CCS. It was considered that the loss in functionality seen with 
the CPC would be reduced with the TC CCC. There was a need for vigorous 
hydrostatic mixing, to allow sufficient mass transfer of the large weight protein (150 
kDa), however to a reduced degree, to prevent the creation of non functional IgG. It 
was thought that the TC CCC with its continuous wide bore tubing would allow 
gentler mixing when compared to the pressure driven mixing chambers of the CPC 
connected by thin tubing.    
 Runs performed on the TC CCC were comparable to those using the 
CPC in terms of separation from impurities. At lower flow rates however, and with 
most operating conditions, better retention of biological activity was seen with the TC 
CCC. Despite an increase to a maximum of 68.35% IgG recovery, this was still 
insufficient to be adopted for biological purification in industry. 100% bioactivity is 
always the aim.  
 Purification was demonstrated by SDS page and silver stain and HCP ELISA, 
illustrating no change to the molecular weight of the protein had occurred. Future 
investigations into the exact cause of loss to IgG functionality are needed within the 
whole CCC process (phase system and processing).  
  Studies in this chapter have shown high resolution separation using 
the TC CCC is possible. Again however it has been seen, as shown in Chapter 3 with 
the CPC, this level of mixing vigour has a detrimental effect on IgG recovery.  The 
effect, whether presented in terms of phase system or design of the column, needed to 
be addressed. The studies in the next chapter (Chapter 5) were designed to thoroughly 
investigate this.  
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5) Critical look at IgG functionality 
 
5.1 Summary 
5.2 Introduction 
5.3        Method and materials 
5.3.1     Aim of using Biacore from this work 
5.3.2     Biacore theory: Surface Plasmon resonance 
5.3.3 Biacore methodology 
5.4 Results and discussion 
5.4.1 Effect of phase system incubation on IgG functionality 
5.4.2   Comparison of work with that of Lisbon group: PEG 1000 14%/14% potassium  
phosphate system 
5.4.3 Investigation of HPLC column saturation 
5.4.4 Biacore analysis 
5.4.5 Investigation of interfacial tension  
5.4.6 Effect of temperature 
5.4.7 Investigation of shaking vigour at one ‗g‘ using a custom built shaker 
5.5 Conclusions 
 
5.1 Summary 
Both the hydrostatic CCC columns (CPC and TC CCC) with different degrees of 
mixing vigour (as described in Chapters 3 and 4) have been noted to cause IgG 
degradation. Further investigation into the actual cause of loss in IgG functionality 
was conducted. The studies within this chapter were designed to look at a number of 
CCC processing aspects, including the stability of the IgG within the phase system and 
multiple factors associated with mixing in the CCC machine itself.  
 Biacore analysis, based on affinity technology was used to confirm 
results previously seen by Protein A HPLC analysis. Auxiliary proof was obtained that 
purified IgG, following CCC, had a reduction in binding affinity (expressed in 
resonance units) to Protein A. It was generally considered (within pharmaceutical 
companies particularly at Lonza) and within the scope of this project that if IgG was 
able to bind to Protein A, it was still fully functional in vivo. However the results 
within this chapter show this binding association after CCC was reduced. Therefore it 
was hypothesised this IgG could not long bind to the PA due to a structural change and 
hence was non or partially functional. The loss in biological activity was investigated 
by incubation in the phase system (to maximum of 50ºC) and spinning the samples at a 
constant g (de Belval et al., 1998; Wu et al., 2006). Neither of these factors however 
was seen to be detrimental to IgG functionality. 
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By the use of a custom built shaker, some of the relationships between the 
phase system, the shearing effect, mixing vigour and the sample itself (PA purified 
IgG material and CCS) were demonstrated. Loss in IgG functionality was seen to 
involve a combination of factors rather than a single underlying cause. Moreover, the 
effects of other proteins components (e.g. anti-foaming agents, host cell proteins) in 
the CCS, thus increasing total protein concentration were seen to affect the retention of 
IgG functionality. The interface of the phase system was also highlighted as an issue 
in the loss of IgG functionality. Losses were still seen when the IgG was processed in 
a single phase, however not to the same level of degradation as in the phase system. 
The series of experiments within this chapter were designed to understand the 
complexity of mixing within the CCC machines. The causes of loss in functionality 
were highlighted and suitable operating parameters and machine type suggested. 
Ultimately, a balance between separation of the IgG from impurities and the retention 
of biological activity was crucial.   
5.2 Introduction 
Hydrostatic CCC columns have been used in previous chapters for the separation of 
the mAb from cell culture supernatant (CCS). Purification has been achieved by CCC 
in Aqueous Two Phase Systems (ATPS) using the PEG 1000 17.5%/17.5% sodium 
citrate system. Protein A HPLC was used to detect the mAb as it eluted post CCC.  A 
protein A binding peak was detected (6 minutes), and this was confirmed by SDS 
PAGE. Also detected was an IgG peak, confirmed by SDS PAGE, which did not bind 
to protein A (0.1 minutes). Previously this form was regarded as impurities but as 
shown by SDS PAGE was not the case, and some purification had been achieved. It 
was considered, therefore that possibly the ATPS or another factor in CCC processing 
was altering the protein A binding capacity of part of the IgG sample (Asenjo et al., 
2011; Zhi et al., 2005; Shibusawa et al., 2006). Since the ATPS had both a high 
polymer and salt concentration, its effect on the specific protein A-IgG interaction 
needed to be considered. 
  The following observations were noted when individual TC CCC 
fractions were analysed by Protein A HPLC: 
1) Purified fractions as seen by Protein A HPLC had elution peaks at both 0.1 
minutes and 6 minutes.  
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2) When these fractions were run on a SDS PAGE gel they appeared as just one 
species, with the same mobility as the IgG. Thus fractions eluted from CCC 
contained two IgG species; one binding Protein A and one non-binding 
protein A.  The single IgG band demonstrated purification had occurred and 
that other protein bands present in the loaded CCS sample were absent.  
3) The IgG HPLC peak in the CCC fractions and the PA purified IgG control had 
a similar spectra, that was different from that of the CCS 
 In order to determine the exact cause of loss in IgG functionality, the 
studies in this chapter were designed to investigate a number of potentially relevant 
aspects of the CCC technique. Biacore analysis was initially used to confirm the 
species change and is detailed first.  
5.3 Method and materials 
5.3.1 Aim of using Biacore for this work 
The Biacore work was completed as a collaboration with Dr Ian Boulton from the 
Biosciences department of the University. The objective was to use the BiaCore 
instrumentation to measure the interaction between Protein A and the monoclonal 
antibody (mAb), in the presence of the PEG 1000 17.5%/17.5% sodium citrate system. 
5.3.2 Biacore theory: Surface Plasmon resonance 
Biacore is an affinity technology, which is used to determine quantitatively how 
proteins interact.  The technology relies on Surface Plasmon resonance (SPR) and 
measuring the small change in total internal reflection of light produced by binding 
(Thongborisute et al., 2008). 
 The SPR phenomenon allows the measurement of adsorption of a 
particular analyte onto a metal surface (Huang et al., 2007).With the Biacore 
instrumentation a gold layer is attached to the chip sensor surface (Papalia et al., 2006; 
Gopinath et al., 2010). The ligand of interest (in this case Protein A) is immobilised on 
the chip surface. When the analyte is injected through the flow channel, binding 
between the analyte and the ligand is possible (Figure 5.3.2.1). Binding causes an 
accumulation of protein on the chip surface which consequently increases the 
refractive index (Van der Merwe et al., 1996). The change in SPR signal is dependent 
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on the solute concentration at the chip surface, when in contact with the analyte. The 
change in refractive index is thus measured in real time as shown in Figure 5.3.2.1, 
with the production of a sensorgram where resonance units is plotted against time.  
 
 
Figure 5.3.2.1 Surface Plasmon Resonance (SPR) theory.  Protein A was immobilised on 
to the chip surface. The IgG species was flowed over the protein A chip and a sensorgram 
generated. A detector was used to determine quantitatively binding between the IgG species 
and the PA. The analysis was measured in real time, allowing the production of an association 
dissociation curve (Homoll, 2003).  
 
Solutions containing the sample (the two different species of IgG following CCC) 
were flowed over the chip surface. Four channels were used to measure the increase in 
SPR both independently and in real time. The technology allowed the investigation of 
the unique binding interactions and affinity. It was hoped the Biacore instrumentation 
would demonstrate whether or not the two different species IgG species were 
functional.  
5.4      Results and discussion 
 
5.4.1 Effect of phase system incubation on IgG functionality 
It was commonly noted in the literature (Albertsson, 1970; Zaslavsky et al., 2000) that 
due to the high water content and low interfacial tension of aqueous two phase systems 
(ATPS), a mild environment for separation was created. It has been predicted in the 
literature that these phase systems are used due to their negligible effect on biological 
material. However, in the experiments conducted thus far using CCC processing, a 
loss to the IgG biological activity was always seen. The effect of phase system 
incubation on activity was investigated.  
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 Both CCS and PA purified IgG were used. The 7 phase systems of 
interest (from the full robotic run Figure 2.4.3.5) along with a PEG dextran system 
were investigated. The PEG dextran system was included as it has been well 
documented in the literature for being a mild system, which has been used successfully 
for many cell separations (Albertsson, 1958). Furthermore these systems do not 
contain any salts and the resulting interfacial tension is very low (Kumar et al., 2007). 
This particular system (PEG 8000 5% Dextran 500K 7%) was included as it had 
previously been used within the Brunel CCC group and no adverse effect on enzyme 
stability was noted (Grudzien thesis, 2011).  
Phase systems were prepared with the addition of CCS and PA purified IgG 
respectively. Samples were taken pre and post a 5 hour bench top incubation. Samples 
were diluted 1 in 4 and subject to Protein A HPLC analysis. The tested systems, 
resulting HPLC area pre and post incubation and percentage change in mass recovery 
of functional IgG are listed in Figure 5.4.1.1. Experiments were carried out only once. 
Phase systems 
HPLC peak area (µV.sec) 
PA purified IgG CCS 
Incubation time (hr) Mass 
recovery of 
functional 
IgG (%) 
Incubation time (hr) Mass 
recovery of 
functional 
IgG (%) 0 5 0 5 
Control: PA purified IgG in water 7130597 7234222 101.45 2118839 2077332 98.04 
PEG 400 17%/17% KPO4 5325071 5415075 101.69 1612834 1628464 100.97 
PEG 1000 14%/14% KPO4 6372758 6669763 104.66 1600437 1634015 102.10 
PEG 1000 17%/17% KPO4 5194963 5643470 108.63 1517696 1364418 89.90 
PEG 1000 15.5%/15.5% KPO4 5801476 5298336 91.33 1130312 1137342 100.62 
PEG 1000 18.5%/18.5% KPO4 4772497 4152171 87.00 1639800 1596064 97.33 
PEG 3350 11%/11% NH4SO4 4535435 2418408 53.33 1872937 1323365 70.66 
PEG 1000 17.%5/17.5% Na Citrate 5141081 4458171 86.72 1565084 1482723 94.74 
PEG 8000 5% Dextran 500k 7% 6641923 3128767 47.11 1923421 1097162 57.04 
Figure 5.4.1.1: Functional IgG mass recovery data following incubation at 25ºC in various 
phase systems. The potassium phosphate system (KPO4) was prepared with di potassium 
hydrogen phosphate and mono potassium phosphate at a ratio of 3.78:1, to achieve an end pH 
of 8. Recovery of functional IgG post incubation in phase systems was determined by 
measurement of the 6 minute HPLC peak following protein A HPLC analysis.  
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Figure 5.4.1.2: Graphical representation of Figure 5.4.1.1. Functional IgG recovery in a 
number of phase systems using both Protein A purified IgG (top graph) and CCS (bottom 
graph). Recovery determined as change in HPLC peak area, as a percent of initial conditions 
to those post 5 hour incubation.  
 
Figure 5.4.1.1 shows the various phase systems and the % change in HPLC peak area, 
firstly with the PA purified IgG and secondly with the CCS. Generally most systems 
appeared to have a mass recovery of functional IgG that was greater than 85%, as seen 
with both the CCS and PA purified IgG material. Figure 5.4.1.2 is a graphical 
representation of the data in Figure 5.4.1.1, time in hours is plotted against the 
recovery of functional IgG.  As highlighted from Figure 5.4.1.1 all systems apart from 
two (the PEG dextran and PEG ammonium sulphate system) had a straight line 
between the pre and post 5 hour incubation, denoting no significant change (<85% 
HPLC peak area). These results were as opposed to the decreasing IgG recovery seen 
Stability study: CCS in a number of phase 
 systems over a  5 hour incubation period 
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 Time (hours) 
R
ec
o
v
er
y
 o
f 
Ig
G
 (
%
) 
Control: CCS in water 
PEG 400 17%/17% KPO4 
PEG 1000 14%/14% KPO4 
PEG 1000 17%/17% KPO4 
PEG 1000 15.5%/15.5% KPO4 
PEG 1000 18.5%/18.5% KPO4 
PEG 3350 11.1%/11.1% NH4SO4 
  
PEG 1000 17.5%/17.5% Na citrate 
 
PEG 8000 5% Dextran 500k 7% 
Stability study: PA purified IgG in a number of phase 
 systems over a 5 hour incubation period 
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 Time 
(hours) 
Control: PA purified IgG in 
 water 
PEG 400 17%/17% KPO4 
PEG 1000 14%/14% KPO4 
PEG 1000 17%/17% KPO4 
PEG 1000 15.5%/15.5% KPO4 
 
PEG 1000 18.5%/18.5% KPO4 
 
PEG 3350 11.1/%11.1%NH4SO4   
PEG 1000 17.5%/17.5% Na citrate 
 
PEG 8000 5% Dextran 500K 7% 
R
ec
o
v
er
y
 o
f 
Ig
G
 (
%
) 
 146 
with the PEG dextran and PEG ammonium sulphate systems.  Furthermore, it showed 
that the change to the Protein A binding IgG capacity that had previously been seen 
was not primarily due to the phase system. Therefore, some mechanical mechanism in 
the CCC machine was at fault.  
 The phase systems that appeared to affect the IgG stability was the 
PEG 3350 11.1%/11.1% ammonium sulphate system (where previous issues with 
precipitation and aggregation were seen) and the PEG 8000 5% dextran 500k 7% 
system. The result for the PEG dextran systems was contradictory to that seen in the 
literature (Karakatsanis et al., 2007; Mattiasson et al., 1982; Mattiasson et al., 1998). 
PEG-dextran systems had been typically been used as an alternative to PEG/salt 
systems for milder, lower interfacial tension separation of biologics such as cells 
(Walter et al., 1994; Azevedo et al, 2008). It was considered that a detection issue by 
Protein A HPLC had occurred or in the phase system make up. 
 The PEG dextran results were hence retested. A typical 1:4 dilution 
(250µl sample + 750 µl water) had previously been used for all the samples, this was 
increased 10 fold (25 µl sample+ 975 µl water). Additional samples were made at 50µl 
(50µl sample + 950 µl water) and 100µl (100µl sample + 900 µl water).  Samples 
were taken on the hour, for a 5 hour time period and subject to protein A HPLC 
analysis. Experiments were carried out only once. 
  
Figure 5.4.1.3: Investigation of PEG/dextran systems on IgG stability at 25ºC. Dextran was 
from Sigma Aldrich lot number 1387318V. Various concentration of IgG were loaded and 
subject to analysis by the 8 minute protein A HPLC programme. The incubation period was 
over 5 hours.  
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The results of the experiment can be found in Figure 5.4.1.3, HPLC peak area has 
(µV.sec) been plotted against the incubation time, for 4 different concentrations of IgG 
in the PEG dextran system. It can be seen that HPLC peak area declines over time for 
all the concentrations tested.  IgG stability was affected by the PEG dextran system, 
even following a tenfold dilution of the usually loaded sample volume. A sharp 
decline in the HPLC peak area was seen following 1 hour of incubation at 25ºC, a 
further decrease was sustained at a slower rate to 5hours.  
 Further checks were carried out with a new batch of dextran (lot 
number 0001382453) to ensure the loss in activity was genuine. It was thought the 
dextran may have expired and was degraded, causing changes to the IgG or the way in 
which it was detected by Protein A HPLC.  The results are shown in Figure 5.4.1.4 
where results are listed at incubation times (0-4 hours in triplicate) and % change in 
HPLC area. It was seen that as incubation time increased the % change in the HPLC 
peak area appeared to decrease, then increase again. Figure 5.4.1.5 is a graphical 
representation of Figure 5.4.1.4, where incubation time is plotted against average 
HPLC peak area. Again the instability in HPLC peak area data can be seen with a 
decrease followed by the line plateauing off.  It was hypothesised that possibly the 
high concentration combination of PEG and dextran were causing the IgG to 
aggregate. Following a 4 hour incubation period, 80.97% recovery of the original IgG 
peak area was seen. Despite a loss in HPLC peak area being seen (Figure 5.4.1.4) the 
data appeared unstable and was seen to decrease, then increase again after a 4 hour 
incubation period. It was hence suggested, loss in HPLC peak area was due to 
experimental analysis detector error, rather than instability caused by the presence of 
dextran to the IgG.  
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Incubation 
time 
(hours) 
HPLC 
peak area 
Average 
HPLC 
peak area 
STD 
error 
% of the 
original 
peak area 
0 
616479 
663205 23966 100.00 
677319 
695818 
1 
469224 
483819 7530 72.95 
487902 
494330 
2 
373955 
390385 31249 58.86 
450821 
346380 
3 
518514 
494686 13954 74.59 
495353 
470190 
4 
462645 
537028 38197 80.97 
589297 
559143 
Figure 5.4.1.4: Repeat investigation of PEG/dextran systems on IgG stability. Individual 
samples taken in triplicate over a 4 hour period and subject to protein A HPLC analysis. 
Initially samples diluted 10 fold with a new batch of dextran (lot number 0001382453).  
 
 
Figure 5.4.1.5: Graphical representation of Figure 5.1.1.4. Effect of PEG/dextran system on 
IgG HPLC peak area stability over a 4 hour period. Points used are an average of readings 
shown in Figure 5.4.1.4 following protein A HPLC.   
 
5.4.2 Investigation of HPLC column saturation 
The protein A HPLC column only had a 1cm column volume, with a column 
dimension of 0.7x2.5cm and a dynamic binding capacity of at least 30mg. It was 
hypothesised that overloading and column saturation could possibly be an issue, 
resulting in the production of the two IgG species.  
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 PA purified IgG was diluted in 5ml of upper and 5ml of lower phase 
(of the PEG 17.5%/17.5% sodium citrate system). Injection volumes from 5µl up to 
80µl were run using the previously developed protein A HPLC programme.  
 
 
 
 
 
 
 
 
 
Figure 5.4.2.1: Investigation of protein A HPLC column saturation. Various injection volumes 
of PA purified IgG were diluted in equal volumes of the PEG 1000 17.5%/17.5% sodium 
citrate phase system. Results analysed by protein A HPLC, peak area of the 0.1 and 6 minute 
peak plotted. 
 
 Results can be seen in Figure 5.4.2.1 where HPLC peak area is plotted against 
increasing injection volume (µl).  For both the 6 minute and the 0.1 minute peak there 
was a linear increase in HPLC peak area as injection volume increased. These results 
showed that column saturation was not an issue.  
5.4.3 Biacore analysis 
 Biacore analysis was conducted with Fractions 13 and 14 which 
following TC CCC run 4-1 had the highest concentration of IgG. In order to assess the 
two supposed ‗species‘ of IgG, these were collected separately following HPLC 
injection. The peak at 0.1 minutes (non binding IgG) and 6 minutes (PA binding IgG) 
were collected (Figure 5.3.3.1). The fraction itself, which was mixed, therefore 
containing both forms was also tested.  
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Figure 5.4.3.1:  Protein A HPLC chromatogram of the CCS starting material used in the 
Biacore analysis. 8 minute adapted HPLC programme used with 80µl injection volume. The 
0.1 minute and the 6.0 minute fraction were collected separately for Biacore analysis.  
 
 
Initially a chip was coated with protein A. Activation of the chip surface was 
by lysine and a mixture of activation solution. The PA was flowed onto the chip 
surface and immobilised (Figure 5.4.3.2). The refractive index was measured and the 
level of PA attachment determined. To improve PA suspension to the chip surface, a 
pH 8.6 buffer was used. A negative control was primarily used to assess that no 
background binding was seen. This was demonstrated by injection with water, as no 
background readings was seen, no correction for background binding was required.  
Glycine injections were used alternatively between each injection to regenerate the 
column. 10mM glycine of low pH (1.5-2.5) was used, this low pH caused the proteins 
to unfold, and additionally they were positively charged thus repelled from the ligand. 
Importantly, glycine allowed regeneration whilst keeping the ligand active (Drescher 
et al., 2009).  All the other samples were tested undiluted.  
The Biacore instrumentation measured a change in total internal reflection, 
denoted by resonance units (R).  Results were analysed in terms of the change in 
resonance units between association and dissociation. A higher dissociation value i.e. 
maximum resonance unit as compared to the initial association value was indicative of 
greater binding. Ultimately the greatest difference between dissociation and 
association was required to show specific binding. 
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Results following Biacore analysis can be seen in Figure 5.4.3.3 for Fraction 
13 and Figure 5.4.3.4 for Fraction 14. These association dissociation graphs show the 
change in resonance units against time. It was noted the CCC fractions containing the 
IgG did not have the classical association dissociation curve, typically seen in the 
literature (Gopinath et al., 2010). A typical association dissociation curve is shown in 
Figure 5.4.3.2, where there is a steady baseline, followed by sample injection and 
association between the analyte of interest and the ligand, a steady state is then 
reached and the analyte is dissociated from the ligand. With the CCC samples the 
shapes of the curves were very much random and hence the difference between 
association and the dissociation resonance values were used to calculate association.  
 
Figure 5.4.3.2: Typical association/dissociation curve following Biacore analysis. Changes in 
refractive index, thus resonance units are shown at injection, association, sample end and 
finally dissociation (Gopinath et al., 2010). Binding affinity is calculated by change in 
baseline association curve from that of baseline dissociation curve.  
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Control 180R           Fraction 13, 6 minute, 2266R 
 
   Fraction 13, 0.1 minute, 0R            Fraction 13, Mixed, 269R 
        
Figure 5.4.3.3: Individual Biacore association/dissociation curves for Fraction 13. Individual 
fractions obtained by using the HPLC in a preparative mode with the protein A HPLC 
programme. Samples used include CCS (containing both PA binding and non PA binding 
IgG), 6 minute sample (PA binding IgG), 0.1 minute sample (PA non binding IgG) and a 
mixed sample CCS (containing both PA binding and non PA binding IgG).  The resulting 
resonance units (R) were obtained by subtracting the respective dissociation resonance value 
from that of the initial association curve baseline.  
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Fraction 14, 6.0 minute, 1758R                Fraction 14, 0.5 minute, 0R 
    
    
   
Fraction 14, mixed, 192R 
  
 
Figure 5.4.3.4: Individual Biacore association/dissociation curves for Fraction 14. Individual 
fractions obtained by using the HPLC in a preparative mode with the protein A HPLC 
programme. Samples used include CCS (containing both PA binding and non-binding IgG), 6 
minute sample (PA binding IgG), 0.1 minute sample (PA non-binding IgG) and a mixed 
sample CCS (containing both PA binding and non-binding IgG.  The resulting resonance units 
(R) were obtained by subtracting the respective dissociation resonance value from that of the 
initial association curve baseline.  
 
 
The interpretation of the results in Figure 5.4.3.3 and 5.4.3.4 can be seen in Figure 
5.4.3.5. Results from the tested fractions are tabulated in terms of degree of binding 
(R) and respective interpretation about the binding association that exists between the 
IgG and the PA ligand. It was seen that in both fractions the association between the 
PA and IgG in the 6 minute (PA binding IgG) peak was high. This degree of binding 
was > 10 fold that of the CCS control, the sample containing just the 0.1 minute peak 
(PA non-binding IgG) and the CCC ‗mixed‘ sample (with both the 0.1 and 6 minute 
peak).  
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Sample Description Degree of 
binding (R) 
Observations 
Control: CCS 
diluted in water 
CCS mixed sample containing 
both PA binding and non-
binding peak 
180  Weak Association 
Fraction 13: 0.1 
minute 
Fraction 13 PA non-binding 
peak 
0 No association 
Fraction 13: 6.0 
minute 
Fraction 13 PA binding peak 2266 Association 
Fraction 13: Mixed Fraction 13 containing both PA 
binding and non-binding peak 
269 Weak association 
Fraction 14: 0.1 
minute 
Fraction 14 PA non-binding 
peak 
0 No association. 
Fraction 14: 6.0 
minute 
Fraction 14 PA binding peak 1758 Association. 
Fraction 14: Mixed Fraction 14 containing both PA 
binding and non-binding peak 
192 Weak association. 
Figure 5.4.3.5: Results following Biacore analysis. Fraction 13 and 14 used from TC CCC run 
4-1 as they had the highest concentration of purified IgG. Samples were prepared by using the 
HPLC in a preparative mode and collecting the 0.1 minute peak and the 6 minute peak of TC 
CCC fractions separately. The initial TC CCC fraction was also included and contained both 
the 0.1 minute and the 6 minute peak, termed ‘mixed’. Samples were subject to Biacore 
analysis and compared to that of the CCS control.  
 
 
The Biacore results confirmed the previous hypothesis: after CCC processing in the 
phase system, there was an increase in the proportion of the IgG that did not bind to 
PA. These samples had no resonance units (0.1 min samples), indicative of no binding. 
When the 6 minutes HPLC peak for both Fractions 13 and 14 were subject to Biacore 
analysis, there was significant binding of >1758R. This was as expected as the 6 
minute peak from the TC CCC run 4-1 fractions was previously shown to be the 
purified binding form. When the 0.1 minute (non-binding) and 6 minute (binding) 
forms were tested combined the resonance units decreased to around 200, similar to 
the CCS starting control. This highlighted the binding capacity of the IgG had been 
altered, and therefore resulting functional IgG yield was greatly affected. A species 
change was thus evident due to the CCC processing.  
5.4.4 Investigation of shaking vigour using a bench top centrifuge. 
The implication of g force damage on IgG alone was investigated. Samples (PA 
purified IgG) were spun in a bench top centrifuge in varying solutions (upper, lower, 
mixed phase and water) for 200 minutes.  
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Four tubes were prepared (tubes from Eppendorf, Cambridge, UK) and PA 
purified IgG added to each. Samples were taken in triplicate pre and post 
centrifugation. The results can be seen in Figure 5.4.7.1 where percent change in IgG 
HPLC peak area is listed in varying medium. It was seen in the medium tested that 
following shaking at 200rpm for 200 minutes HPLC peak area of the PA binding IgG 
peak was unaffected (< 10% change in HPLC area). The constant ‗g force‘ alone 
created by samples spun using a bench top centrifuge was not responsible for the 
degradation. It was concluded that degradation was due to the mechanism of mixing of 
the two phases within the CCC machines.  
Upper Lower Mixed Water
3113873 3053085 3106122 3083437
3226236 3027522 2969299 2904844
3252350 3167076 2974464 3062486
STD error 42481 42897 44772 56365
3208517 3005143 2956845 3073054
3267784 2704655 3152545 3199816
3211865 2986457 3142173 2872096
STD error 19222 97198 63575 95409
Change in HPLC peak area (%) 1.00 6.00 2.20 1.00
2000 rpm/200 minutes
HPLC peak area
Pre centrifuge
Post centrifuge
 
Figure 5.4.4.1: Effect of g force in a bench top centrifuge on IgG stability. IgG incubated in 
varying buffers and spun in a bench top centrifuge at 2000rpm for 200 minutes (typical CCC 
run time). Samples then analysed by protein A HPLC. The change in HPLC area pre and post 
centrifugation was calculated.    
 
 
5.4.5 Investigation of shaking vigour at one ‘g’ using a custom built 
shaker 
 
To further emulate the forces occurring within the CCC machines in terms of 
mechanism of mixing, shearing and interfacial tension, a shaker was built. The shaker 
allowed experiments to be conducted without the impact of additional parameters such 
as flow rate and stationary phase retention.  
      Mr Tony Bunce, an engineer at Brunel University, designed the shaker based on 
the design specification of a two sample clamp position that would allow extremely 
vigorous shaking. Complete phase system mixing (resulting in one phase) was seen 
during run times. A photo of the shaker can be seen in Figure 5.4.5.1. The shaker itself 
was connected to a laboratory regulated power supply, which allowed the mixing 
vigour of samples in the clamp to be controlled.  
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Figure 5.4.5.1: Photo of custom built shaker. The two clamp positions allowed the sample of 
interest to be tested alongside that of a control. Mixing vigour could also be controlled 
separately by the use of a laboratory regulated power supply.  
 
The direct effect of mixing vigour on IgG degradation in the phase system was 
investigated. A control sample of water was used. Samples were prepared as shown in 
Figure 5.4.4.2 and no air gap was left at the top of the vials. Samples were taken at 30 
minutes then 1, 2 and 3 hours. 50µl samples were taken to minimise any air bubble 
production in the shaker vials. These were then broken with 950µl of water and 
analysed by protein A HPLC. Experiments were carried put only once but repeated at 
a shaking vigour of 5, 7.5 and 10 Volts (V) with corresponding vibrations per minute 
listed in Figure 5.4.4.3. 
 
 
Sample 
PA purified IgG in 
phase system (ml) 
PA purified IgG in 
water (ml) 
Upper phase 11  
Lower phase 11  
Water  22 
PA purified IgG 1 1 
Figure 5.4.5.2:  Sample preparation for shaker investigation. Samples were always prepared 
in parallel; one in the PEG 17.5%/17.5% sodium citrate system and the other in water as a 
control.  
 
Shaking vigour (V) Vibrations per 
minute 
 
5 175 
7.5 245 
10 315 
Figure 5.4.5.3:  Vibrations per minute for the individual shaker vigour, measured in volts (V). 
 
 
 The results are tabulated in Figure 5.4.5.4 and show the effect of increasing shaker 
speed over time on PA purified IgG (HPLC peak area) in both water and the phase 
system. With the PA purified IgG in the phase system, as shaking speed increased the 
Sample 
clamp Direction of agitation 
Laboratory 
regulated power 
supply 
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percentage change in HPLC peak area decreased. The percentage retention of 
bioactivity went from 94.1% at 5V to 78.4% at 10V.  However with the PA purified 
IgG in water, bioactivity remained relatively unchanged at > 98%. Figure 5.4.5.5 is a 
diagrammatic representation of the results in Figure 5.4.5.4. PA binding IgG HPLC 
area is plotted against time at various shaker speeds. With the IgG in the phase system 
a clear decrease in HPLC peak can be seen at all vigours tested, which consequently 
further increased with vigour. This was as opposed to the PA purified IgG incubated in 
water, the graph remained stable over the incubation time and various shaker speeds. 
Furthermore in Figure 5.4.4.6 (data obtained from Figure 5.4.5.4) percent recovery of 
PA binding IgG following shaking at various vigour in water and phase system is 
plotted. IgG in water was stable over increasing shaker speed. However in the phase 
system a decrease in functional IgG recovery was again evident, with increased 
degradation as shaker speed was increased.  
 
PA purified IgG in phase system (HPLC peak area) Control: PA purified IgG in water (HPLC peak area) 
Time (hr) 
Shaker speed 
Time (hr) 
Shaker speed 
5 7.5 10 5 7.5 10 
0 85302 84350 85888 0 86266 84221 84569 
0.50 83599 82331 78310 0.5 89050 82240 82352 
1 83381 80021 68969 1 88567 81285 86723 
2 82331 75263 70997 2 88789 81004 84407 
3 80304 71420 67348 3 86528 82687 86082 
% retention of 
bioactivity 94.1 84.7 78.4 
% retention of 
bioactivity 100.3 98.2 101.8 
Figure 5.4.5.4:  IgG shaker results in both water and PEG 1000 17.5%/17.5% sodium citrate 
phase. Samples shaken at differing mixing vigour over three hours. Samples were taken 
following shaking and subject to PA HPLC analysis. % change in HPLC peak area as a 
percentage of initial starting IgG peak area was calculated, following three hours.  
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Figure 5.4.5.5: Diagrammatic representation of Figure 5.4.5.4. Graphs comparing IgG 
stability in phase system and water over three hours. Following respective shaking runs, 
samples were subject to protein A HPLC analysis. 
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Figure 5.4.5.6:  Diagrammatic representation of Figure 5.4.5.4. IgG expressed in terms of 
biological recovery at different shaking vigour in water and the phase system. 8 minute 
protein A HPLC analysis program used. PA IgG binding peak following three hour incubation 
shown.   
 
The IgG within the water control system remained constant and unaffected by both 
shaking vigour and respective time. A loss in PA IgG binding peak area however in 
the phase system was seen at all the shaking vigour tested (5, 7.5 and 10V). Loss in 
activity was further dependent on increased incubation time and resulting shaker 
speed. The longer the run time, the greater the damage seen. Previously this had been 
highlighted with the CCC runs, resulting in higher flow rates being used in CCC runs 
to reduce IgG transit time in the machines (Section 4.4.4). The interface of the phase 
system or mechanical effects of shearing of the two phases on the IgG were clearly 
thought to accelerate degradation.  
           CCS, when run on a CCC machine, had lower IgG recovery when compared to 
the PA purified IgG. It was hypothesised that additional components within the CCS 
e.g. anti-foaming agents or surfactants were exacerbating the detrimental effect of 
CCC. This was investigated using both IgG samples (CCS and PA purified IgG) and 
various solutions of the PEG 1000 17.5%/17.5% sodium citrate system (upper, lower, 
mixed phase and water). Firstly the two different IgG samples were made up in the 
phase system (PEG 1000 17.5%/17.5% sodium citrate) and incorporated at a 1ml 
volume, hence had different IgG and total protein concentrations. Then also at a 
2mg/ml IgG concentration in the CCS and PA material. These samples therefore had 
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the same IgG concentration but differing total protein concentration. Secondly the 
CCS and PA purified IgG was made up in just lower phase, then just upper phase (of 
the PEG 1000 17.5%/17.5% sodium citrate system) and water. All the prepared 
samples were placed on the shaker for 3 hours at a shaking vigour of 7.5V.  
             The results are shown in Figure 5.4.5.7, CCS and PA purified IgG results are 
listed in varying volume, concentration and medium in respect to their effect on IgG 
recovery. For all the conditions tested stability with the PA purified IgG was always 
higher to that of the CCS. Figure 5.4.5.8 is a diagrammatic representation of Figure 
5.4.5.7 where IgG recovery of bioactivity was plotted against incubation in various 
solutions. It showed that incubation in all buffers even in a single phase (upper or 
lower) or water also had a negative effect on recovery. This was seen in both samples 
but degradation was to a greater degree with the CCS. However when both samples 
(CCS and PA purified IgG) were at a similar concentration (2mg/ml), the IgG 
recovery was higher for the PA material, but not considerably. 
HPLC peak 
area 
1 ml volume 2mg/ml Lower  phase Upper phase Water 
CCS 
PA 
purified 
IgG CCS 
PA 
purified 
IgG CCS 
PA 
purified 
IgG CCS 
PA purified 
IgG CCS 
PA 
purified 
IgG 
Pre 
40087 86997 26797 26631 16109 16494 17148 18315 17583 16552 
49958 83126 28586 29675 18748 17197 16897 18175 16544 15869 
46047 90461 27260 20912 20151 15977 15496 17212 16756 17251 
Average 45364 86861 27548 25739 18336 16556 16514 17901 16961 16557 
Standard error 2870 2119 536 2569 1185 354 514 347 317 399 
Post 
33014 79237 22741 23075 13019 12691 13622 15008 14245 15231 
32287 83335 19587 20095 14411 16172 10507 15033 14736 14995 
34997 78388 26583 24448 13688 12093 12758 15630 14323 15213 
Average 33433 80320 22970 22539 13706 13652 12296 15224 14435 15146 
Standard error 810 1527 2023 1285 402 1272 928 203 152 76 
%  change in 
recovery 73.7 92.47 83.38 87.57 74.75 82.46 74.46 85.05 85.11 91.48 
% Standard 
error  2.71 0.49 5.61 3.41 2.48 5.80 3.20 0.51 0.68 1.71 
Figure 5.4.5.7:  Stability of IgG in various buffer mediums and phase system pre and post 
shaking at 7.5V. CCS and protein A purified IgG used. Each sample was taken in triplicate. 
Following shaking experiments samples were subject to Protein A HPLC analysis. The 6 
minute IgG peak was used; change in recovery was calculated by change in peak area 
following shaking at 7.5V for three hours.  
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Figure 5.4.5.8: Diagrammatic representation of Figure 5.4.5.7. Expression in terms of 
different IgG recovery in various buffering medium and phase system. Samples were subject to 
protein A HPLC analysis. The 6 minute IgG peak was used; change in recovery was 
determined by calculating change in HPLC peak area following shaking at 7.5V for three 
hours.  
 
The hypothesis of total protein concentration further exacerbating degradation was 
supported. This as additional components would add to shearing and possibly 
aggregation when shaken at such vigours. When the 1ml sample volumes were used, 
CCS recovery was 73.70% as compared to 92.47% when PA purified IgG was used. 
When CCS was diluted to a specific IgG concentration that didn‘t account for total 
protein concentration, a very considerable effect on acceleration of degradation was 
seen. This was due to the presence of additional proteins and components within the 
CCS. Degradation was not due to the interface alone. It appeared a single phase and 
water were also having a contributory negative effect when shaken at such vigour. The 
possibility of IgG degradation in the single phases and water was thought to be due to 
the amplitude and frequency of the mixing occurring. IgG shearing at the interface of 
the two phase systems was also suggested.  
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5.5                       Conclusions 
A critical investigation of IgG functionality was conducted. Previously it was observed 
that hydrostatic CCC (CPC and TC CCC) was responsible for the degradation of 
Protein A binding capacity of the IgG. It was hypothesised and experimentally 
supported in this chapter that this degradation was not due to incubation in the phase 
system, despite the previous concerns about high salt and polymer concentrations in 
phase systems. The only phase system exceptions were the PEG 3350 11.1%/11.1% 
ammonium sulphate, seen to cause a precipitation effect to the IgG, and a PEG dextran 
system which affected the HPLC analysis.  
 Degradation was also quantitatively confirmed by Biacore affinity technology. 
IgG post CCC was shown to have an extremely poor affinity to the PA. Purification 
was demonstrated, but the IgG left was rendered unfunctional. 
 The loss in IgG functionality was shown to be caused by some 
mechanism of mixing within the CCC machine. The effect however was that of a 
complex one dependent on a number of inter-connected factors. Shearing of the two 
phases, interfacial tension and the CCS sample content itself with a number of other 
components e.g. anti-foaming agents and surfactants, have all been implicated.  A 
reduction in these combined effects was required to retain IgG functionality during 
CCC processing. It was thought by gentler wave like mixing, as offered by that of the 
hydrodynamic Mini CCC, a separation would be possible without the loss in IgG 
functionality.  
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6.1  Summary  
 
In the previous chapters, the need for gentle mixing was highlighted due to the 
detrimental effect mixing vigour had on IgG functionality. The studies within this 
chapter explore the use of the Mini CCC centrifuge, with its milder, wave like mixing. 
Flow rate was seen to be critical to the retention of IgG activity. A faster flow rate, 
hence shorter CCC run time, was needed to reduce the corresponding number of 
mixing and settling steps the IgG was exposed to. The resulting damage to the IgG 
was consequently reduced. Rotational speed was also seen to be key. At an increased 
flow rate of 1ml/min and a rotational speed of 1200rpm, a recovery of 81.97% viable 
IgG, was achieved when using PA purified IgG. This was the first time such high 
recovery of the functional IgG (>80%) had been seen using any CCC instrument. 
When this run was repeated with CCS however, the resolution of the IgG from the 
impurities was poor. The IgG was seen to elute over 60 minutes, which inevitably 
meant it co-eluted with the impurities. Resolution of the IgG was improved by 
increasing rotational speed; this conversely negatively affected viable IgG recovery. 
 IgG degradation within the CCC machine was seen even when 
processed in a single phase. Greater detriment to recovery was seen with the salt phase 
as opposed to that of the PEG phase. This IgG degradation effect, even in single phase, 
was observed to be exacerbated when both phases were together.  
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 The chapter finally looks at degradation with model proteins, also 
confirming the damage to more robust, smaller molecules.  An in-depth look at the 
literature also suggested biological recovery post CCC was frequently just assumed, 
and even those that did investigate it suffered losses.   
6.2     Introduction 
 
The harsh mechanical effect seen with cascade mixing using both the CPC and TC-
CCC caused an irreversible loss in the Protein A binding capacity of the antibody. An 
alternative milder form of mixing was sought.  
 The Mini CCC utilises hydrodynamic, wave like mixing, which is 
less vigorous when compared to the hydrostatic instrument, used in the CPC and TC 
CCC. Hydrodynamic CCC occurs along a continuous length of tubing which is wound 
around a drum. The coil planet centrifuge has two axis of rotation (planetary and solar) 
allowing the creation of mixing and settling zones. Where mixing occurs closest to the 
centre of the planetary coil, g force is lowest. At the farthest side of the planetary coil 
the force field is highest and settling occurs (Sutherland, 2007). 
  
    
Figure 6.2.1: On the left is a photo of the prototype Mini CCC used for all experiments in this 
chapter. It had a 45.1ml column volume and 2.7mm bore size. On the right-hand side is a 
diagram showing functioning in the hydrodynamic mode CCC. Mixing and settling occurs 
along the continuous length of tubing.  
 
It was postulated that by using this different mechanism of mixing as opposed to the 
previously used cascade mixing, the retention of biological activity would be possible. 
The mechanism of mixing was thought to be gentler on solutes, presumably due to the 
lower shear forces being present. It was hoped that IgG damage could therefore be 
reduced with sufficient separation of IgG from impurities, without resolution being 
compromised.  
Axis of 
rotation 
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6.3 Method and materials 
6.3.1 Sample preparation 
Initially to investigate degradation, PA purified IgG was used. Latter runs were 
conducted with CCS as the loading sample, allowing investigation of the separation of 
the IgG from the impurities.  
6.3.2 CCC processing 
The Mini prototype (Brunel Mini CCC) was used. The tubing was composed of wide 
bore polytetrafluoroethylene (PTFE) and the specification is detailed in Figure 6.3.2.1. 
The typical Mini CCC run conditions are listed in Figure 6.3.2.2. 
Bore size (mm) 2.7 
Column volume (ml) 45.1 
Column length (m) 7.9 
Rotor radius (mm) 5 
 value 0.53-0.73 
Figure 6.3.2.1: Overview of Mini CCC machine parameters including beta (β) value; the ratio 
of the tube coil radius over the rotor radius. 
 
 
Mini CCC separation 
ATPS…17.5/17.5% w/w..…PEG/Salt, pH…7.41 
PEG……1000…Salt …Sodium citrate 
Coil volume……45.1ml 
Sample loop……1.72ml 
Operating mode…Run flowed from head to tail 
Stationary phase…..Lower phase 
Column filled at ……5ml/min 
Injected mAb: 
1) CCS……… (Batch number …L156568/47) 
       Amount…........6.4 mls diluted with:  
        …..0.44g sodium citrate 
        …..0.44g PEG 
Spin speed…1200 rpm, temperature….20°C, flow rate…..…0.5ml/min 
Equilibrated at……0.5ml/min,  
Stationary phase displaced….22ml % stationary phase retained………..51.2% 
 
Figure 6.3.2.2: The typically used Mini CCC operating parameters.  
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6.4 Results and discussion 
6.4.1   Effect of rotational speed on IgG functionality 
Rotational speed was investigated with the hypothesis that reduction of g-force by 
lowering rotational speed would allow increased IgG recovery. A Mini CCC run was 
carried out with Protein A purified IgG and a PEG 1000 17.5%/17.5% sodium citrate 
system. A 1.72ml injection volume was used with a flow rate of 0.5ml/min (flowing 
from head to tail). Repeat runs were carried out at a rotational speed of 800, 1000 and 
1200 rpm. Samples were subsequently analysed by Protein A HPLC and recovery of 
functional IgG was obtained by totalling functional IgG in fractions as a percentage of 
the amount in the starting injection. Experiments were carried out only once. 
 The results are shown in Figure 6.4.1.1, increasing rotational speed 
is listed against resulting recovery of functional IgG. It can be seen as rotational speed 
increases the recovery of functional IgG decrease. Furthermore the graph in Figure 
6.4.1.2 shows the relationship between recovery of viable IgG, stationary phase 
retention and IgG total elution time at various rotational speeds. It can be seen as 
rotational speed is increased, stationary phase retention is also increased however 
viable IgG recovery decreases. However the time taken for the IgG to elute from the 
column is extended as rotational speed increases.  
Rotational speed  (rpm) 
 
800 1000 1200 
Recovery of functional IgG (%) 
 
60.77 46.35 41.05 
Figure 6.4.1.1: Effect of rotational speed on recovery of viable IgG (PA binding IgG). All 
experiments carried out with protein A purified IgG, flow rate of 0.5ml/min. Samples analysed  
by protein A HPLC, 8 minute injection time and 80µl injection volume.  
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Figure 6.4.1.2: Effect of rotational speed on recovery of viable IgG. All experiments carried 
out with protein A purified IgG, flow rate of 0.5ml/min.  
 
The observations were as predicted. As rotational speed increased, IgG recovery 
decreased (Figure 6.4.1.2). A higher rotational speed however allowed greater mixing, 
which achieved the peak sharpness needed for a successful separation. The detrimental 
effect of increased rotational speed on resulting IgG recovery was seen. As rotational 
speed increased, higher stationary phase retention was attained, thus increasing the 
total time taken for IgG to elute from the coil. Consequently, the IgG was retained in 
the coil for longer at a high rpm, resulting in the corresponding loss in recovery of 
viable IgG.  
 
6.4.2     Investigation of CCC transit time on IgG functionality 
As seen in Chapter 4 (Section 4.4.6), an increased flow rate resulted in shorter run 
times and allowed a significant improvement in retention of IgG activity. A higher 
flow rate was investigated on the Mini CCC.  A typical run at 0.5ml/min was 200 
minutes long; the flow rate was doubled to 1ml/min.  The same run condition as 
detailed in Section 6.4.1 were used with an increased flow rate (1ml/min) and a 
rotational speed of 1200rpm. Retention of viable IgG was again calculated following 
Protein A HPLC analysis. An IgG recovery of 81.97% was seen at 1ml/min as 
opposed to the previously demonstrated 41.05% at 0.5ml/min. A substantial 
improvement was made and no previous results with this level of IgG recovery had 
been achieved on any other CCC machine. 
The effect of rotational speed and total elution time on recovery of viable  
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6.4.3 Investigation into sample loading capacity 
The sample loading capacity was investigated; previously a 1.72ml (3.82% coil 
volume) sample loop was used on a 45.1ml column. Sample load was increased to a 
4.95ml sample loop (10.98% coil volume).  
Operating conditions as detailed in Figure 6.3.2.2 were used for both runs at 
different sample sizes. The results are shown in Figure 6.4.3.1 where as sample size is 
increased from 1.72ml to 4.95ml recovery of functional IgG remains very similar at > 
80%. The higher recovery of 84.37% functional IgG showed great promise for 
throughput as column saturation had not been reached at 10.98% of the coil volume 
(Figure 6.4.3.1). This as the recovery of functional IgG appeared to be unaffected by 
the increased load, as opposed to resulting in further IgG degradation.  
Sample size (ml) Recovery of 
functional IgG (%) 
 
 
1.72 81.97 
 
4.95 84.37 
Figure 6.4.3.1: Effect of sample size on the recovery of viable IgG (PA purified IgG). 
Experiments carried out with protein A purified IgG and an increased flow rate of 1ml/min. 
Samples analysed by protein A HPLC, 8 minute injection time and 80µl injection volume.  
 
 
The reconstructed elution time profile for both sample volumes followed the same 
distinct pattern but at different concentrations, showing reproducibility (Figure 
6.4.3.2).   
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Figure 6.4.3.2: Reconstructed CCC chromatogram. Protein A HPLC used to make 
reconstructions.  IgG concentration calculated using calibration curve and plotted against 
time of elution. Similar elution patterns are seen at 2 concentrations, showing reproducibility.  
 
 
6.4.4 Mini CCC separation using CCS  
Significantly higher IgG recovery was seen with the Mini CCC in comparison to 
previously used hydrostatic columns. Results were attained with an increased flow rate 
of 1ml/min. Previous runs were conducted with the PA purified IgG to look 
specifically at IgG functionality. Further investigations were with crude CCS, to 
observe the separation from impurities and any resulting effect on functionality. The 
results seen in Figure 6.4.4.1 show HPLC peak area plotted against elution time 
(minutes). The IgG can be seen to be eluted over 55 minutes (25-80 minutes). The 
elution of the IgG is also with that of the impurities, which can be seen to co elute at a 
higher HPLC peak area.  Furthermore the elution profile of the IgG when in the 
impure CCS (Figure 6.4.4.1) is very similar to that in the pure material (Figure 
6.4.3.2), with the elution peak starting and ending at the same times. Although a high 
recovery of 77.12% IgG functionality (calculated following protein A HPLC analysis) 
was demonstrated, resolution and final purification were completely compromised. 
The IgG eluted over a very large/wide peak (around 60 minutes) which would 
inevitably include the impurities.  
Investigation of sample loading capacity: Mini CCC 2.7mm bore, 1ml/min,  
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Figure 6.4.4.1: Reconstructed CCC chromatogram. Protein A HPLC used to make 
reconstructions.  Carried out with CCS (crude sample), CCC run at a flow rate of 1ml/min. 
Samples analysed by protein A HPLC, 8 minute injection time and 80µl injection volume. IgG 
HPLC peak area (6 minute peak) and impurities (0.1 minute peak) plotted against time of 
elution from the CCC coil.   
 
 When the separation shown in Figure 6.4.1.1 was compared with the 
TC CCC results in Figure 4.4.5.3, it could be seen that resolution had been completely 
lost. The sharp peak elution of the IgG by the TC CCC is not seen, with the impurities 
also eluting over an extended period. When the separation in Figure 6.4.4.1 is 
compared with other Mini CCC results however, similar IgG elution within the same 
time scale is seen (Figure 6.4.3.2). Again, as detailed in Chapter 5 (section 5.4.4.7) 
IgG recoveries from CCC processing using PA purified IgG had higher recoveries 
than CCS, despite the same experimental conditions being used.    
IgG recovery at the expense of purification was seen as shown in Figure 
6.4.4.1.  It was predicted that higher resolution could be attained by an increased 
rotational speed (1200rpm was previously used). An increased rotational speed was 
needed that would allow adequate mixing but be gentle enough to minimise any 
damage to the IgG. Mini CCC runs were carried out with crude CCS and a PEG 1000 
17.5%/17.5% sodium citrate system. A 1.72ml injection volume was used with a flow 
rate of 1ml/min (flowing from head to tail).  Runs were carried out at a rotational 
speed of 1500 and 1800 rpm and samples analysed by protein A HPLC. A very similar 
stationary phase retention of around 30% was seen with both runs.  
Elution profile: Mini CCC 2.7mm bore using CCS, 1ml/min, 1.72ml  
sample loop, 1200 rpm 
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Results are tabulated in Figure 6.4.4.2 and show the relationship between 
rotational speed, stationary phase retention, IgG elution peak time and viable IgG 
recovery. When CCS was loaded in similar concentration (around 0.80 mg of IgG) as 
rotational speed increased so did corresponding stationary phase retention and IgG 
elution time. Viable IgG recovery however decreased as rotational speed increased 
over the speeds tested. Moreover as shown in Figure 6.4.4.3 (a diagrammatic 
representation of Figure 6.4.4.2), recovery of functional IgG is plotted against 
increasing rotational speed. The very clear trend of loss in functional IgG can be seen 
as rotational speed is increased. The CCC chromatograms reconstructed from protein 
A HPLC analysis at 1500 and 1800rpm are shown in Figure 6.4.4.4. The results 
showed HPLC peak area plotted against time in minutes. The IgG at both speeds 
(1500 and 1800rpm) eluted from 30 to 65 minutes. Also co elution with impurities was 
seen. At a rotational speed of 1500rpm a higher HPLC peak area was seen for the 
impurities as compared to a rotational speed of 1800rpm.  
Rotational 
speed (rpm) 
Amount of IgG 
loaded (mg) 
Stationary 
phase 
retention (%) 
Elution time of 
IgG peak 
(minute) 
Viable IgG 
Recovery (%) 
1200 0.84 29.5 35 77.12 
1500 0.79 31.8 40 56.88 
1800 0.79 36.4 45 44.24 
Figure 6.4.4.2:  Effect of rotational speed on recovery of viable IgG on the Mini CCC, at an 
increased flow rate of 1m/min using CCS (crude.) PEG 1000 17.5%/17.5% sodium citrate 
system used and 4.95ml sample load. Samples analysed by protein A HPLC, 8 minute injection 
time and 80µl injection volume.  
 
Figure 6.4.4.3:  Diagrammatic representation of Figure 6.4.4.2. Effect of rotational speed on 
recovery of viable IgG on the Mini CCC, at an increased flow rate of 1ml/min using CCS 
(crude). The detrimental effect of increased rotational speed on the resulting IgG recovery can 
be seen. The PEG 1000 17.5%/17.5% sodium citrate system used and 4.95ml sample load  
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Figure 6.4.4.4: Reconstructed CCC chromatogram. Protein A HPLC used to make 
reconstructions. Carried out on the Mini CCC, at varying rotational speed, with CCS (crude 
sample), flow rate of 1ml/min. Samples analysed by protein A HPLC, 8 minute injection time 
and 80µl injection volume. IgG HPLC peak area (6 minute peak) and impurities (0.1 minute 
peak) plotted against time of elution.  
 
 
Figure 6.4.4.2 and 6.4.4.3 confirmed that, as rotational speed increased even at a 
higher flow rate, a decrease in functional IgG recovery was seen. Surprisingly, even at 
higher rotational speeds (1500 and 1800pm) IgG peak sharpness was still lost (Figure 
6.4.4.4). It was thought at such an extreme spin speed, emulsification could possibly 
be occurring inside the machine. Emulsification would result in the broadening of the 
IgG peak, such that the distinction between the stationary phase and mobile phase was 
lost. The transition therefore between the two would be blurred and peak broadening 
would mean that the separation from impurities was not achieved (Figure 6.4.4.4). 
 The results showed, even with the Mini CCC at a higher rotational 
speeds, which typically results in higher stationary phase retention hence improves 
resolution, a high resolution separation could not be demonstrated. Rotational speed 
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Elution profile: Mini CCC 2.7mm bore using CCS, 1ml/min, 1.72ml  
sample loop, 1500 rpm 
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was detrimental to the IgG functionality even at a higher flow rate. Under the 
conditions employed, an acceptable balance between recovery of IgG activity and the 
separation from other contaminants was not achieved.  
 
6.4.5 Investigation of model proteins 
Following on from the effect CCC had on the monoclonal antibody functionality, a 
review was prompted of previous work using model proteins. Dr Emma Bourton has 
previously investigated the separation of model proteins Lysozyme and Myoglobin 
with CCC using a PEG 1000 12.5%/12.5% dipottassium phosphate system. (PhD 
thesis 2008). Altered Myoglobin was seen post CCC known as Apomyoglobin. This 
was Myoglobin that had lost its haem group. The Myoglobin sample itself initially 
contained 63.4% of this Apomyoglobin form. It was thought when drawing on 
conclusions from previous work with the IgG that CCC processing would further 
accelerate the formation of this non-functional Myoglobin.  
 To observe the recovery of these model proteins and the effect of 
CCC processing on the retention of their functionality, a Mini CCC run was 
conducted.  The HPLC analysis program previously designed by Dr Bouton was used 
for the quantification of Lysozyme, Myoglobin and Apomyoglobin. A C18 column 
with an extra-large pore size (20nm) (Figure 6.4.6.1.) was used and the calibration 
curve for each respective protein component was created as seen in Figure 6.4.5.2. 
Following the CCC separation of model proteins, samples were subject to HPLC 
analysis, the HPLC method is described in Figure 6.4.5.1.  
Column details YMC, ODS-AQ, particle size 5µm, pore size 
20nm, length 150mm and internal diameter 
4.6mm 
 
Injection volume 10µl 
Run time 15 minutes 
Flow rate 1 ml/min 
Column temperature 40ºC ± 5ºC 
Gradient 30% Acetonitrile to 55% Acetonitrile over 10 
minutes 
Solvent A: 0.05% TFA + ultrapure water 
Solvent B: 0.05% TFA + acetonitrile 
Held at final conditions for 1 minute.  
Detector wavelength range 210-600nm. 
Figure 6.4.5.1: HPLC analysis method used, as designed by Dr Bourton for the separation of 
model proteins Lysozyme and Myoglobin.  
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Figure 6.4.5.2: HPLC calibration curve for Lysozyme, Myoglobin and Apomyoglobin. C18 
column with extra large pore size used. Respective concentrations of proteins plotted against 
HPLC peak area.  
 
A Mini CCC run was conducted with the run conditions outlined in Figure 6.4.5.3. 
Mini-CCC separation 
ATPS…12.5%/12.5% PEG/Salt 
PEG……1000       Salt …Dipotassium phosphate  
Coil volume……45.1 ml 
Sample loop……...1.72ml 
Operating mode…run flowing from head to tail 
 Column filled at …5ml/min 
Stationary phase…..Lower phase 
Injected sample: 
1) Lysozyme and Myoglobin 
       Amount…..0.03mg of both mixed with 3ml upper phase + 3ml lower phase:  
        …..…3g sodium citrate 
        …..…3g PEG 
 Spin speed…1800rpm, temperature….20°C, flow rate…..0.5ml/min 
Equilibrated at……0.5ml/min,  
Stationary phase displaced.…..28ml 
Figure 6.4.5.3: Typical Mini CCC conditions used in previous work by Dr Bourton when 
preparing the PEG 1000 12.5%/12.5% dipotassium phosphate system for the separation of 
model proteins Lysozyme and Myoglobin.  
 
Results can be seen in Figure 6.4.5.4 where the amount of protein is plotted against 
elution time (minutes). The separate elution of Lysozyme and Myoglobin is seen. 
Furthermore, the co-elution of Myoglobin with the Apomyoglobin is evident. In 
Figure 6.4.5.5 the amount of Myoglobin and Apomyoglobin is plotted against time in 
minutes. It shows that following CCC a clear increase in Apomyoglobin can be seen to 
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a decrease in the Myoglobin. The Apomyoglobin rose from 0.70 to 0.90mg from the 
start of the CCC run, at the expense of a decrease in functional Myoglobin from 0.42 
to 0.12mg. 
  
Figure 6.4.5.4: Elution time graph following HPLC analysis (using conditions as described in 
Figure 6.4.5.1) C18 column with extra large pores used (20nm), model protein mixture of 
Lysozyme, Myoglobin and non functional Myoglobin named Apomyoglobin prepared and 
loaded as a single injection. Respective concentrations of proteins plotted against elution 
times.  
 
 
Figure 6.4.5.5: The effect of Mini CCC processing on the production of Apomyoglobin from 
the decline of functional Myoglobin. Results following a 200 minute Mini CCC separation 
using a flow rate of 0.5ml/min and a PEG 1000 12.5%/12.5% di potassium phosphate system.  
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In addition to the Mini CCC run with the model proteins, incubation studies were also 
performed. The mixture of model proteins was incubated in water and the potassium 
phosphate phase system for three hours on the bench at 25ºC. The overview results 
table is shown in Figure 6.4.5.6. It showed that water and the phase systems alone 
were not detrimental to the Lysozyme, Myoglobin and Apomyoglobin stability, all 
proteins had a recovery of ≥92%. The total recovery of Apomyoglobin and Myoglobin 
pre and post CCC were almost identical (94.64%), showing mass balance. After the 
CCC runs however, the ratio between them changed. Apomyoglobin increased by 
133.78% whilst Myoglobin fell to 27.48% of the original starting amount.  The 
damaging effect CCC was having on functionality was highlighted in this study and 
furthermore in small robust model proteins (Thielges et al., 2011; Jory et al., 2008). 
The IgG was a larger, more fragile protein and would therefore be more prone to 
damage. The measurement of Apomyoglobin production against loss in functional 
Myoglobin allowed direct comparisons to be made.  
Total mg Apo Lysozyme Myoglobin 
Recovery of Apomyoglobin 
and Myoglobin (%) 
 
Water control start 0.56 0.48 0.27 
98.8 Water control 
Water control end 0.55 0.46 0.27 
Recovery (%) 99.58 95.52 101.23 
Control phase start 0.41 0.42 0.24 
98.46 Phase system control 
Control phase end 0.40 0.39 0.24 
Recovery (%) 97.83 92.83 97.26 
CCC Start 0.70 0.73 0.42 
94.64 CCC 
CCC end 0.94 0.64 0.12 
Recovery (%) 133.78 87.18 27.48 
Figure 6.4.5.6: Overview of production and decline of Apomyoglobin, Lysozyme and 
Myoglobin following water incubation, phase system incubation and CCC processing. 
Recovery of Apomyoglobin and Myoglobin calculated by determining any % change in 
Apomyoglobin and Myoglobin at the start to end of each condition. Recovery of each protein 
for various conditions was determined by calculation of the amount of individual proteins at 
the end of incubation in comparison to that at the start. Concentrations of proteins were 
calculated using individual HPLC calibration curves (Figure 6.4.6.2). 
 
6.4.6 Conclusions drawn from the literature 
 
A critical review of protein separation by CCC was carried out to see if other groups 
had experienced similar issues with a lack of retention of activity post CCC. As 
documented in section 4.4 a thorough literature review was conducted from 1960 to 
present. Papers were collected from Scopus, science direct and pubmed and over 100 
papers studies. From the review of papers carried out, there seemed to be a frequent 
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neglect in the mention of recovery of activity. Purification was reached with no 
mention of recovery. Most papers used either enzyme assays, 280nm absorbance or 
protein assays for quantification. Only two papers found within the search mentioned 
recovery of biological activity using the multi-layer J-type CCC and they too both 
suffered losses.  
Paper 1: Performance of an aqueous two phase based countercurrent chromatographic 
system for horseradish peroxidase purification. Magri et al, 2003, Argentina 
This group used a multilayer CCC (1.6mm diameter), at 1000rpm, with a 4 hour run 
time. A system of 10% w/w PEG 1540 14.8% w/w di-phosphate was used with 
2mol/kg of sodium chloride added. A recovery of 45% activity with a purification 
factor of 6 was noted. Peroxidase activity was measured according to an enzymatic 
assay were guaiacol was used as the substrate. They attributed the loss of activity to 
overloaded stationary phase, other species, and thermal inactivation.  Previously this 
group had mentioned recoveries as low as 15%. 
 
Paper 2: Purification of glucosyltransferase from cell-lysate of streptococcus mutants 
by counter-current chromatography using aqueous polymer two phase system. Journal 
chromatography B (2004). Ito et al . 
The researchers used a 4.4% (w/w) PEG 8000, 6% (w/w) dextran T500 pH 9.2 and a 
flow rate of 1ml/min. The Streptococcus mutant was retained in the dextran rich lower 
stationery phase. Samples were analysed for enzymatic activity and by SDS PAGE. 
Purity was seen to have increased 87 times. Recovery of 79% bioactivity was stated as 
‗good‘ by this research group. 
6.4.7 Overview of results 
As documented in previous chapters varying results were obtained with the use of the 
CPC, TC-CCC and multilayer CCC (Mini). Results are presented in Figure 6.4.8.1 in 
terms of resolution, separation and resulting retention of IgG recovery with differing 
machines. 
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Figure 6.4.7.1: Overview of experimental runs on various CCC machines. Results tabulated in 
terms of machine type, functional IgG recovery, sample used, rotational speed, flow rate and 
resulting stationary phase retention.  
 
Machine Sample Rotational 
speed 
(rpm) 
Flow rate 
(ml/min) 
Sf 
Retention 
(%) 
Functional 
IgG 
Recovery 
(%) 
Comments Section 
of 
thesis 
CPC CCS 2000 5 20 44.60 
 When rotational 
speed was high, 
recovery was 
low. 
 An increased 
flow rate greatly 
improved 
functional IgG 
recovery. 
3.4.10 
CPC CCS 2000 10 14.2 71.41 
3.4.10 
TC-CCC 
PA 
Purified 
IgG 
900 5 26.4 60.54 
 Resolution 
highest at a high 
flow rate. 
 Best separation 
results were 
seen at 
maximum spin 
speed and a high 
flow rate; 
however 
functional IgG 
recovery was 
adversely 
affected. 
4.4.4. 
TC-CCC 
PA 
Purified 
IgG 
1200 10 27.9 68.35 
4.4.4 
TC-CCC 
PA 
Purified 
IgG 
1200 3 39.9 16.33 
4.4.4 
TC-CCC CCS 1200 5 29.5 58.21 
4.4.1 
Mini 
CCC 
PA 
Purified 
IgG 
800 0.5 27.4 60.77 
 With increased 
rotational speed 
(800-1200rpm) 
at a flow rate of 
0.5ml/min, IgG 
recovery 
decreased. 
6.4.1 
Mini 
CCC 
PA 
Purified 
IgG 
1000 0.5 31.8 46.35 
6.4.1 
Mini 
CCC 
PA 
Purified 
IgG 
1200 0.5 38.6 41.05 
6.4.1 
Mini 
CCC 
PA 
Purified 
IgG 
1200 1 29.5 81.97 
 Recovery at 
1200rpm is 
greatly 
improved by 
increasing flow 
rate to 1 ml/min. 
 As rotational 
speed increased 
(1200-1800rpm) 
at 1ml/min, 
functional IgG 
recovery 
decreased. 
However, 
separation was 
much improved 
at expense of 
recovery. 
 
6.4.2 
Mini 
CCC 
CCS 1200 1 29.5 77.12 
6.4.4 
Mini 
CCC 
CCS 1500 1 31.8 56.88 
6.4.4 
Mini 
CCC 
CCS 1800 1 36.4 44.24 
6.4.4 
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The results showing the effect of flow rate on functional IgG recovery, in varying 
machines is shown in Figure 6.4.7.2. In both the CPC and the Mini CCC, doubling of 
the flow rate allowed a very significant increase in the retention of IgG activity. In the 
CPC using crude CCS retention of activity went from 44.60 to 71.34%. Whilst also 
with the Mini CCC an increase in IgG functionality from 44.72% to 77.12% was seen. 
In the TC CCC however this increase was not as significant going from 60.54 to 
68.35%.  
 
Figure 6.4.7.2: The effect of flow rate on functional IgG recovery in various CCC machines. 
Recoveries calculated following sample analysis by protein A HPLC, 8 minute injection time 
and 80µl injection volume. The IgG recovery was plotted against flow rate used.   
 
A lower retention of functional IgG activity (around 70% as shown in Figure 6.4.8.3), 
even at increased flow rate was seen with the hydrostatic machines when compared to 
the Mini CCC. The CPC allowed high speed spin and pressure driven, successful IgG 
separation. Functional IgG recovery however was badly affected at 44.60% at 5ml/min 
and 71.40% at 10ml/min. With the TC CCC, separation was also seen but at the 
expense of IgG functionality. Again high flow rate and speed spin was needed, giving 
a functional IgG recovery of 58.21% at 5ml/min and 68.35% at 10ml/min. It was 
suggested that an increased flow rate with the CPC, resulted in such a difference in 
initial recoveries when compared to the TC CCC, as the IgG was less exposed to high 
The effect of flow rate in varying CCC machines on the retention of 
IgG functionality
0
10
20
30
40
50
60
70
80
90
100
CPC: CCS TC CCC: PA
purified IgG
Mini CCC: PA
purfied IgG
Mini CCC: CCS
F
u
n
ct
io
n
a
l 
Ig
G
 r
ec
o
v
er
y
 (
%
)
Flow rate (x1)
Flow rate (x2)
 181 
g forces associated with using this hydrostatic machine. As doubling the flow rate, 
halved CCC run times and respective mixing and settling steps.  
 With the Mini CCC, as flow rate was doubled with a rotational speed 
of 1200 rpm using PA purified IgG, the functional IgG recovery rose from 41.05% to 
81.97%. With a trial run using the CCS at this doubled flow rate, IgG recovery was 
comparable with the PA purified IgG at 77.12%, showing a higher IgG recovery than 
had been seen with any other CCC machine. The multilayer CCC (Mini) using a 
hydrodynamic design allowed greater retention of biological activity than had been 
seen in any hydrostatic machine. Conversely this mechanism of mixing was not 
adequate to allow the separation of IgG from impurities, IgG elution was over an 
extended time period, thus resolution was lost.  
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6.5 Conclusions 
The studies in this chapter showed that hydrodynamic, wave like mixing, as offered by 
the Mini CCC allowed the significant retention of biological activity up to 81.97%. 
Retention of activity however, was only possible at extremely low rotational speeds 
thus IgG resolution was affected, with broad IgG elution peaks. At these lower 
rotational speeds, resulting stationary phase retention is lower hence separation is 
affected. The Mini CCC allowed for relatively increased retention of IgG activity but 
separation from impurities was not achieved.  
 The retention of activity is critical with biological molecules. When 
reviewing the literature there appeared, in the vast majority of cases, no mention of 
recovery. For those groups who did analytically determine recovery, it was with crude 
absorbance assay and losses were still encountered.  
 Despite an IgG activity of 81.97% being retained with the use of the 
Mini CCC, no separation was possible. Moreover despite this being an improvement 
to the TC CCC and the CPC, it is still not industrial acceptable, as particularly 
expressed by the purification scientists at Lonza.  
 A compromise between hydrostatic and hydrodynamic mixing was 
needed. A mode was required where mixing was gentle enough to retain the IgG 
biological activity. However this needed also to be sufficient to allow mass transfer 
and adequate stationary phase retention, such that separation from impurities could be 
achieved. Previously CCC machines were designed based on high throughput, high g 
separation of small molecules, which are robust. Work in this project thus far has 
shown this level of mixing is not suitable for large, fragile biologics. An alternative 
mode of CCC is detailed and discussed in the next chapter.  
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7)     Successful monoclonal antibody separation: Solution as provided by the     
non synchronous CCC 
7.1       Summary 
7.2       Introduction 
7.3       Method and materials 
7.4       Results and discussion 
7.4.1    Investigation of differing Pr ratios using PA purified IgG: effect on recovery 
7.4.2    Investigation of differing Pr ratios using CCS 
7.4.3    Investigation of sample loading capacity using CCS  
7.4.4    Increased fraction collection: effect on purity 
7.4.5    Throughput: Studies into sample loading capacity 
7.4.6 Effect of mass balance, purity and IgG recovery on throughput. 
7.4.7 Investigation of associated g force with non synchronous processing 
7.5 Conclusions 
 
7.1 Summary 
 
The need for a change in CCC design for protein separation has been highlighted in 
previous chapters. Loss in IgG functionality was seen with hydrostatic machines and 
also hydrodynamic CCC machine, using a gentler wave like mixing. The studies in 
this chapter investigate a non-synchronous CCC machine operated in a hydrodynamic 
mode. The benefit of this non synchronous (non-synch) CCC machine is that the rotor 
to bobbin speed ratio (Pr ratio) can be altered.  Independent control of mixing and 
settling is thus possible. Reduction of the Pr ratio from a normal 1, in J type 
centrifuges (Mini) to 0.33 was investigated; giving reduced mixing and increased 
settling time.  The retention of IgG biological activity with a sharp, high resolution 
separation of the IgG from impurities was seen. This chapter details how this was 
achieved with optimisation of loading capacity and the maintenance of purity (>85%). 
The low level g force associated with these machines was also investigated and 
compared to other CCC machines, using the g force program created by Dr Van den 
Heuvel (Van den Heuvel et al., 2011).  
 The resulting verdict from the studies in this chapter showed promise 
for the non-synchronous CCC instrument in monoclonal antibody separation from 
fermentation cell culture supernatant.   
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7.2 Introduction 
The vigour of mixing or the shear created by the two phases appeared detrimental to 
IgG functionality in all the CCC machines tested thus far (CPC, TC CCC and Mini 
CCC). There was a need for gentler mixing with increased settling time. Mixing 
needed to be just sufficient such that the stationary phase could be retained inside the 
column and allow mass transfer. 
 The loss to IgG activity was experienced in both hydrostatic and 
hydrodynamic mode (as shown in Figure 7.2.1 depicted by the red colour). There was 
the situation of either: 
1) Higher recovery of biological activity but the loss of IgG resolution, resulting in no 
separation from impurities e.g. in the Mini multilayer CCC. 
Or 
2) Separation of IgG from the impurities but loss of IgG biological activity e.g. as seen 
in the CPC and toroidal coil CCC 
A compromise between the two modes was needed. It was thought that the non 
synchronous CCC could provide a solution.  
 
 
 
 
 
 
 
 
 
 
Figure 7.2.1: A diagram to show the varying modes of CCC operation; hydrostatic and 
hydrodynamic and the respective machines they encompass. The red colouring is used to 
illustrate the machines that have been investigated and have been found unsuitable. The green 
colour is used for the non synchronous CCC machine, representing a possible solution.  
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The non-synchronous CCC, when first introduced, was investigated using biologics 
(Shinomiya et al., 2003). Its non-synchronous nature allowed the combination of the 
rotor rotation (about its own axis and the sun gear) and revolution of the bobbin 
around the coil holder (Kobayashi et al., 2005). The non-synchronous machine uses a 
hydrodynamic mode which is governed by the selected planetary drive ratio (Pr ratio). 
The planetary drive ratio (Pr ratio) is defined as the speed of the bobbin over the speed 
of the rotor (ratio of bobbin to rotor speed) (Wood, 2010). Hence the with the non-
synchronous CCC machines the bobbin and rotor speed can be controlled separately, 
ultimately allowing independent control of mixing and settling.  
 As highlighted by Ito, normal J type centrifuges have a 1:1 ratio (Ito, 
2000). The bobbin rotates once for every rotor rotation, hence termed synchronous. 
Non synchronous CCC has recently been developed with the use of non-twist ‗flying 
leads‘, permitting the machine design without the use of rotary seals. A 1:1 ratio, as 
seen in previous chapters, has some constraints when attaining separations using 
ATPS. ATPS require greater settling time with reduced bobbin to rotor speed. The 
small density differences between the phases and resulting interfacial tension means 
mixing vigour is not as critical as previously thought (Ito et al., 1983). The adjustable 
coil rotation offered by the non-synchronous CCC, allows the theoretical separation 
and also the retention of stationary phase. A low bobbin rotation rate, increases phase 
system settling time which is needed by ATPS under a strong centrifugal force field 
(Shinomiya et al., 2003).  
 
Figure 7.2.2: Diagram to show non twist flying leads. The use of flying leads in synchronous 
CCC has allowed the connection of the bobbin to that of the rotor, without the use of rotary 
seals. Previously this 1:1 ratio was needed to prevent the flying leads from twisting. Non twist 
flying leads have now been developed which allows the CCC machine to be operated in a non 
synchronous mode.  
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A normal J-type centrifuge has a Pr ratio of 1 (Figure 7.2.3). As the Pr ratio decreases 
e.g. 0.33 or 0.67 the bobbin rotates once for increased rotor rotations. More settling 
and gentler mixing is thus achieved when compared to that of the J-type centrifuge.  It 
was considered that, by fixing the rotor speed at 800 rpm and investigating a Pr ratio 
of 0.33 and 0.67, IgG recoveries would be sustained. Previously high vigour mixing 
was seen to be detrimental to the IgG. By a reduction in mixing time but an increase 
settling time, greater mass transfer was predicted, allowing high resolution separation 
of mAb from the impurities.  
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Figure 7.2.3: Diagrammatic representation using the g force program  (Van den Heuvel et al., 
2011) at various Pr ratios. Pr of 1 (top) seen in J type synchronous centrifuges. The bobbin 
rotates once for one rotor rotation. Pr ratio of 0.67(middle) seen using a non-synchronous 
centrifuge. The bobbin rotates twice for three revolutions of rotor rotation. Pr ratio of 
0.33(bottom,) seen using non synchronous centrifuge. The bobbin rotates once for three 
revolutions of rotor rotation. Maximum, minimum and mean g forces for each Pr ratio are 
noted. Below this, also on the right hand side, tangential g-force is shown. Within this work 
the g force range is predominately used.  
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7.3   Method and materials 
 
The non-synchronous coil planet centrifuge was used for separations, initially with 
PA purified IgG and subsequently when the crude CCS. Rotor and bobbin parts 
were supplied by Dynamic Extractions, Slough, UK. The column volume was 
475mL.  
 The machine (Figure 7.3.1) used a spider, which allowed the speed 
of the rotor to be changed relative to that of the bobbin. The spider allowed motion 
to continue and ensured the flying leads were not twisted during operation, thus no 
rotator seals were required. With a J type centrifuge, bobbin and rotor speed are 
identical. They have a Pr ratio of 1 and no spider is used.  The spider allows a range 
of Pr ratios to be investigated from the normal J type centrifuge (Pr=1) through to 
Pr=0 (a toroidal coil centrifuge) and -1 (I type centrifuge).  
  
 
Figure 7.3.1: A photo of the interior of the non synchronous CCC machine. Typically the rotor 
speed would be kept constant at 800rpm. The spider speed control is changed to attain the 
appropriate Pr ratio for the run.   
 
7.4  Results and discussion 
 
7.4.1 Investigation of differing Pr ratios using PA purified IgG: effect on 
the recovery of biological activity 
 
To determine optimum operating parameters in terms of the retention of IgG 
functionality in the non-synchronous CCC, protein A purified IgG was initially used. 
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The operating conditions as detailed in Figure 7.4.1.1 were used, where material was 
flowed from periphery to centre, the upper phase being PEG.  
Non synchronous CCC separation 
ATPS…17.5%/17.5% w/w..…PEG/Salt, pH…7.43 
PEG……1000…Salt …Sodium citrate 
Coil volume……475ml 
Sample loop……16.8ml 
Operating mode…Forward 
Column filled at ……50ml/min 
Injected mAb: 
1) CCS……… (Batch number …L156568/47) 
       Volume…........32.5ml diluted with:  
        …..8.75g sodium citrate 
        …..8.75g PEG 
Spin speed…800rpm, temperature….20°C, flow rate…..…10ml/min 
Equilibrated at……10ml/min,  
Stationary phase displaced.….425ml      % stationary phase displace ....10.5% 
Figure 7.4.1.1: Typical non synchronous CCC operation parameters. 
 
IgG however did not elute, it remained in the column  Water was used to flush the 
column contents out, 10x 50ml fractions were taken and analysed by protein A HPLC. 
The IgG was seen to be in the stationary phase pump out. 
 In order to allow the IgG to be eluted within a column volume the 
direction of flow and flow rate were changed. Material was pumped from centre to 
periphery at a flow rate of 10ml/min and the upper phase was changed to salt. 
Stationary phase retention was around 20%, but the elution of the IgG within the coil 
volume was seen. Triplicate non synchronous CCC runs were conducted at a Pr ratio 
of 0.33 and 0.67. 
 Results are shown in Figure 7.3.1.2 where the IgG concentration 
recovered from the fractions is compared to that of the starting control, at a Pr ratio of 
0.33 and 0.67. For both Pr ratios a recovery of around 80% functional IgG was seen. 
Furthermore reproducibility between the runs was seen.  
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Pr=0.33 
Run 
IgG concentration (mg) 
Functional IgG recovery 
(%) Mean st dev st error Fractions Control 
1 2.00 2.52 79.37 
79.35 0.91 0.30 
2 1.99 2.48 80.24 
3 2.00 2.55 78.43 
Pr=0.67 
Run 
IgG concentration (mg) 
Functional IgG recovery 
(%) Mean st dev st error Fractions Control 
1 1.93 2.48 77.53 
79.99 3.48 1.16 
2 2.14 2.55 83.98 
3 2.00 2.55 78.47 
Figure 7.4.1.2: Tabulation of triplicate non synchronous runs at a Pr ratio of 0.33 and 0.67. 
The ‘fractions’ column in the table refers to total functional IgG in all fractions collected for 
each individual run. This is as compared to IgG in the starting ‘control’. Carried out with PA 
purified IgG. Fractions were analysed by protein A HPLC, 80µl injection and 8 minute run 
time.  
 
 
7.4.2 Investigation of differing Pr ratios using CCS 
IgG recovery of nearly 80% was attained with both Pr ratios using protein A purified 
IgG. Investigations with crude CCS followed, to observe if separation from impurities 
was possible. Previous experimental conditions as outlined above were used. 
Concerning the analysis of the fractions, a HPLC calibration curve (Figure 7.4.2.1) as 
previously used (Figure 3.4.7.1) for other CCC runs was applied to obtain the IgG 
concentrations.  
 
Figure 7.4.2.1: Calibration curve used to calculate the concentration of IgG in CCS sample. 
Calibration curve prepared by samples diluted in the PEG 1000 17.5%/17.5% sodium citrate 
system and then subject to protein A HPLC, 80µl injection and 8 minute run time.  
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Initial runs using conditions outlined in Figure 7.3.1.1 were employed. Material was 
pumped from centre to periphery at a flow rate of 10ml/min and salt was used as the 
upper phase. Results are shown in Figure 7.4.2.2 and detail the recovery of viable IgG 
at a similar concentration, at a Pr ratio of 0.33 and 0.67. At a Pr ratio of 0.33 the 
retention of viable IgG was seen at 73.07%. At a Pr ratio of 0.67, viable IgG recovery 
fell to 60.39%. 
IgG concentration in CCS 
loaded (mg/ml) 
Pr ratio Viable IgG recovery (%) 
0.67 0.33 73.07 
0.66 0.67 60.39 
Figure 7.4.2.2: Overview of resulting functional IgG recovery using differing Pr ratios and 
crude CCS. Samples subject to non-synchronous CCC and protein A HPLC was used to 
determine IgG recovery, 80µl injection and 8 minute run time. Viable IgG recovery was 
calculated by comparing initial IgG concentration to that remaining after the CCC run.  
 
Again, a lower recovery was seen following the non-synchronous CCC processing 
with the crude CCS material, as opposed to PA purified IgG (Chapter 5.7.4 and 6.4.4). 
The possibility of column overloading was thought to be the cause. As seen 
previously, the CCS contained a whole host of additional proteins, anti-foaming 
agents, cell culture components etc which exacerbated the IgG degradation (Figure 
6.3.2.2). When the CCS samples was loaded to the same concentration of the PA 
purified IgG, total protein concentration was many times greater and therefore needed 
to be taken into consideration.  
With relatively more mixing to settling at a Pr ratio of 0.67 when compared to 
a Pr ratio of 0.33, increased damage to the IgG functionality was seen (Figure 7.4.2.2). 
Even at this mixing vigour compared to a Pr ratio of 1 used for all other CCC 
machines, loss of functional IgG recovery was seen.  
The CCC reconstructed chromatogram following protein A HPLC analysis can 
be seen in Figure 7.4.2.3. HPLC peak area is plotted against elution time in minutes, at 
both a Pr ratio of 0.33 and 0.67. At a Pr ratio of 0.33 the IgG elutes as a single sharp 
peak at 55 minutes. At a Pr ratio of 0.67 the IgG had a broader peak eluting over 20 
minutes between 30 to 50 minutes.  
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Figure 7.4.2.3: Elution time graph at a Pr ratio of 0.33(top) and 0.67 (bottom). Reconstructed 
protein A HPLC chromatograms following non-synchronous CCC runs. Carried out with CCS 
(crude sample), flow rate of 10ml/min. Samples analysed by protein A HPLC, 8 minute 
injection time and 80µl injection volume. IgG HPLC peak area (6 minute peak) and impurities 
(0.1 minute peak) plotted against time of elution. IgG elutes just before the impurities at 
Pr=0.67 but just after the impurities at a Pr=0.33. 
 
At a Pr ratio of 0.67 as opposed to 0.33, a broader IgG elution peak was seen. 
It suggested that these systems did not require a great extent of mixing due to the low 
interfacial tension of the phase system, but sufficient settling time was critical. With a 
lower Pr ratio of 0.33 adequate settling time was given, allowing mass transfer of the 
high molecular weight IgG between the phases. All proceeding runs were 
subsequently conducted at a Pr of 0.33. 
 
Elution time graph: non synchronous CCC Pr=0.33, CCS, flow rate 10ml/min, 16.8ml  
sample loop, 11.23mg of IgG loaded, 50 ml 
fractions collected every 5 minutes. 
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Elution time graph: non synchronous CCC Pr=0.67, CCS flow rate 10ml/min, 16.8ml 
 sample loop, 11.09mg of IgG loaded, 50ml 
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7.4.3 Investigation of sample loading capacity using crude CCS  
When 11.23mg of the IgG was injected onto the non-synchronous CCC at a Pr of 0.33, 
a recovery of 73.07% viable IgG was seen. As previously mentioned it was thought 
the total protein concentration in the CCS load was having a detrimental effect. The 
IgG load was hence lowered and the effect on functionality investigated.  
 A CCC run was conducted using the conditions outlined in Figure 
7.3.1.1. Material was pumped from centre to periphery at a flow rate of 10ml/min and 
salt was used as the upper phase. 1.34mg of IgG was loaded onto the non-synchronous 
CCC at a Pr ratio of 0.33. Following the CCC run, the column contents were flushed 
out with 500ml of water. 10 x50ml fractions were taken termed ‗pump out 1-10‘. 
These were then subject to Protein A HPLC analysis with the other samples. These 
additional samples were taken to ensure that all IgG had been accounted for and that 
no IgG had been trapped in the column.  
 The results table can be seen in Figure 7.4.3.1 where the 
concentration of IgG in fractions is noted. The table lists HPLC peak area, 
concentration of IgG in mg (obtained using the calibration curve in Figure 7.4.2.1) and 
mg per fraction (obtained by multiplying the IgG concentration by the sample 
volume). The HPLC peak area of the impurities (from the 0.1 minute peak following 
Protein A HPLC analysis) is also noted and background correction noted.  The IgG 
was seen to elute in Fractions 11 and 12 between 60-65 minutes. A total recovery of 
93.28% functional IgG was seen. Figure 7.4.3.2 is a representation of the data in 
Figure 7.4.3.1 which shows a reconstructed CCC chromatogram following protein A 
HPLC analysis. HPLC peak area is plotted against time in minutes. The relatively 
smaller IgG peak can be seen to be co eluting with that of the larger impurities peak 
(overlap between 55-60 minutes).  
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Fraction 
Time 
(minutes) 
PA binding IgG 
 Volume of 
sample 
(ml) 
Impurities 
Corrected impurities 
peak area 
Peak area 
conc./ 
mg/ml 
Mg per 
fraction 
Control: 
load 
 353219 
0.08 1.34 
16.8 2792620 2617769 
Control: 
load 
 307722 
16.8 2552060 2377209 
Control: 
load 
 325336 
16.8 2682043 2507192 
1 5 6037   50 193020 18169 
2 10 6371   50 176975 2124 
3 15 5688   50 186487 11636 
4 20 9400   50 202138 27287 
5 25 7212   50 192317 17466 
6 30 6019   50 217365 42514 
7 35 4154   50 186520 11669 
8 40 6097   50 137818 0 
9 45 7675   50 547850 372999 
10 50 3422   50 531068 356217 
11 55 11593 0.005 0.25 50 254689 79838 
12 60 94106 0.02 1.00 50 198640 0 
13 65 6736   50 181493 6642 
14 70 7400   50 171644 0 
15 75 5803   50 197527 22676 
16 80 6170   50 174573 0 
17 85 6089   50 187167 12316 
18 90 6689   50 163963 0 
19 95 7254   50 182121 7270 
20 100 3322   50 172576 0 
Pump out 1 6082   50 183334 
 
Pump out 2 4991   50 192877 
Pump out 3 6339   50 202171 
Pump out 4 6017   50 183688 
Pump out 5 9574   50 159774 
Pump out 6 7038   50 152630 
Pump out 7 6582   50 199688 
Pump out 8 5387   50 183268 
Pump out 9 5891   50 162319 
Pump out 10 6578   50 89944 
Total mg in fraction 1.25 
Total mg in control 
1.34 
% recovery of functional IgG 93.28 
Figure 7.4.3.1: IgG (6 minute peak) and impurities (0.1 minute peak) HPLC peak area and 
respective concentration following protein A HPLC analysis. 50ml pump out fractions were 
taken to a total of 500ml to ensure that all possible IgG had been accounted for. These results 
were following a non synchronous run using a Pr of 0.33 using crude CCS at a flow rate of 10 
ml/min. 
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Figure 7.4.3.2: Elution time graph. Reconstructed protein A HPLC chromatogram following a 
non-synchronous CCC run at a Pr ratio of 0.33. Carried out with CCS (crude sample), flow 
rate of 10ml/min. Samples analysed by protein A HPLC, 8 minute injection time and 80µl 
injection volume. IgG HPLC peak area (6 minute peak) and impurities (0.1 minute peak) 
plotted against time of elution.  
 
Despite the overlap of IgG and impurities (Figure 7.4.3.2) these results were 
promising. The HPLC program detected anything that absorbed at 280nm. Absorbance 
could thus not necessarily be proteins and could for example include medium 
components and foaming agents. These results showed the best retention of IgG 
biological activity seen thus far, with any CCC instrument.  
7.4.4 Increased fraction collection: effect on purity 
Previously fractions were collected every 5 minutes, with a corresponding volume of 
50ml, it was thought this fraction size was too large and needed to be reduced. It was 
considered that by increasing collection to every minute during the period of overlap 
(Figure 7.4.3.2) separate elution would be possible.  
 A CCC run was conducted using the conditions outlined in Figure 
7.3.1.1. Material was pumped from centre to periphery at a flow rate of 10ml/min and 
salt was used as the upper phase. Fractions were taken every 5 minutes up to 50 
minutes, then from 50-65 minutes fractions were collected every minute. The CCS 
was diluted 6 times (to 0.09mg/ml) and used as the injection load. Following the CCC 
run samples were subject to Protein A HPLC analysis.  
Elution time graph: Non synch Pr=0.33, flow rate=10 ml/min, diluted  
CCS sample flowing from centre to periphery, upper phase salt 
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 The results are shown in Figure 7.4.4.1 where HPLC peak area is 
plotted against time in minutes. The IgG and impurities can be seen to elute separately. 
Furthermore the IgG elutes as a sharp peak, whilst the impurities peak is larger and 
broader and can be explained by its heterogeneous nature.  
  
Figure 7.4.4.1: Elution time graph with increased fraction collection between 50-65 minutes 
as compared to Figure 7.4.3.2. Non synchronous CCC run at a Pr ratio 0.33. Carried out with 
CCS (crude sample), flow rate of 10ml/min. Samples analysed by protein A HPLC, 8 minute 
injection time and 80µl injection volume. IgG HPLC peak area (6 minute peak) and impurities 
(0.1 minute peak) plotted against time of elution.  
 
A clear separate elution of the IgG from impurities with recovery of 89.29% of viable 
IgG was seen (Figure 7.4.4.1).  When Figure 7.4.4.1 was compared with Figure 
7.4.3.2, the results looked reasonably similar showing a degree of reproducibility. The 
same experimental conditions were used but with increased fraction collection.  
7.4.5 Throughput: Studies into sample loading capacity 
Previous results in Section 7.4.4 indicated both separation and the retention of IgG 
activity. Throughput however needed to be improved by increasing the sample load. A 
constraint was seen with loading capacity due to the need for CCS preparation in the 
phase system, such to not affect the running of the CCC machine. As detailed in 
Section 3.3.2, if the injected sample was not prepared appropriately as part of a two 
phase system prior to injection onto the CCC, this could perturb the two phase system 
Elution time graph: Non synch Pr=0.33, flow rate=10ml/min, diluted CCS sample,  
flowing from centre to periphery, upper phase salt  
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within the machine. The result could mean the two phase system being broken, 
creating a single phase where all material is eluted at the K=1 point, unseparated.  
Experiments were conducted with increased CCS load to observe both 
separation and the resulting effect on IgG recovery. The experimental outline as 
shown in Figure 7.3.1.1 was followed for all runs in this section, but adjustments in 
sample preparation were made based on the starting IgG concentration required.   
Non synchronous CCC run 1 
 A sample loading of 10.81mg of IgG was used and a non-
synchronous CCC separation conducted. Results can be seen in Figure 7.4.5.1, where 
HPLC peak area is plotted against elution time in minutes. The IgG was clearly seen to 
elute separately from that of the impurities.  A recovery of >100% viable IgG was 
demonstrated by protein A HPLC.  
 
Figure 7.4.5.1: Elution time graph with increased fraction collection between 50-65 minutes 
and 10.81mg sample load. Non synchronous CCC run at a Pr of 0.33. Carried out with CCS 
(crude sample), flow rate of 10ml/min. Samples analysed by protein A HPLC, 8 minute 
injection time and 80µl injection volume. IgG HPLC peak area (6 minute peak) and impurities 
(0.1 minute peak) plotted against time of elution. 
 
Non synchronous CCC run 2 
All runs previously mentioned were conducted with a 16.8ml sample loop. To further 
increase sample load a 29.8ml sample loop was used and 20.56mg of IgG injected. 
Elution time graph: Non synch Pr=0.33, flow rate=10ml/min, 10.81mg IgG loaded,  
 flowing from centre to periphery, upper phase salt 
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Results following protein A HPLC analysis are shown in Figure 7.4.5.2. The table lists 
HPLC peak area, concentration of IgG in mg (obtained using the calibration curve in 
Figure 7.4.2.1) and mg per fraction (obtained by multiplying the IgG concentration by 
the sample volume). The HPLC peak area of the impurities (from the 0.1 minute peak 
following protein A HPLC analysis) is also noted and background correction noted.  
IgG purity is further calculated by determining the percentage of PA binding IgG 
HPLC area to that of the impurities. The IgG appeared to elute over 7 minutes; 
however the greatest amount was at 55 and 56 minutes. The purity in the other 
fractions was lower due to low concentrations of IgG. When all the fractions were 
taken into consideration a 96.72% recovery of functional IgG was demonstrated. The 
results in Figure 7.4.5.3 are a diagrammatic representation of Figure 7.4.5.2, where 
HPLC peak area is plotted against elution time. Some co elution of the impurities was 
seen at the beginning of the IgG elution peak, however the majority of impurities had 
eluted at 50 minutes.  
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Fraction 
Time 
(minutes) 
PA binding IgG Volume of 
sample 
(ml) 
Impurities 
Corrected 
impurities 
peak area 
IgG 
purity 
(%) 
HPLC  peak 
area 
conc/ 
mg/ml 
Mg per 
fraction 
Control: 
load 
 2456033 
0.68 20.26 
29.8 13788669 13229547 15.66 
Control: 
load 
 2420758 
29.8 15152485 14593363 14.23 
Control: 
load 
 2496434 
29.8 15531071 14971949 14.29 
1 5 0 0.00 0.00 50 799255 240133 
 
2 10 0 0.00 0.00 50 800389 241267 
3 15 0 0.00 0.00 50 466755 0 
4 20 0 0.00 0.00 50 598995 39873 
5 25 0 0.00 0.00 50 355831 0 
6 30 0 0.00 0.00 50 377364 0 
7 35 0 0.00 0.00 50 424401 0 
8 40 0 0.00 0.00 50 543596 0 
9 45 0 0.00 0.00 50 4151064 3591942 
10 50 0 0.00 0.00 50 5196734 4637612 
 
51 64185 0.01 0.10 10 2007388 1448266 4.24 
52 352865 0.09 0.90 10 1246024 686902 33.94 
53 374361 0.10 1.00 10 1473160 914038 29.06 
54 403523 0.10 1.10 10 772603 213481 65.40 
55 2695153 0.75 7.50 10 1285837 726715 78.76 
56 3036294 0.84 8.40 10 784369 225247 93.09 
57 238681 0.06 0.60 10 1148293 589171 28.83 
58 0 0 0 10 725609 166487 
 
59 0 0 0 10 691321 132199 
60 0 0 0 10 608949 49827 
61 0 0 0 10 648330 89208 
62 0 0 0 10 602019 42897 
63 0 0 0 10 523744 0 
64 0 0 0 10 550598 0 
65 0 0 0 10 484991 0 
14 70 0 0 0 50 460411 0 
15 75 0 0 0 50 486534 0 
16 80 0 0 0 50 524129 0 
17 85 0 0 0 50 509214 0 
Total mg in fraction 19.60 
Total mg in control 
20.26 
% recovery of functional IgG 96.72 
Figure 7.4.5.2: Results following a non-synchronous CCC run using a Pr of 0.33, crude CCS 
and a flow rate of 10 ml/min (Figure 7.4.5.1). IgG (6 minute peak) and impurities (0.1 minute 
peak) at increased sample load of 20.56mg. HPLC peak area and respective concentration 
following protein A HPLC analysis are shown.  
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Figure 7.4.5.3: Elution time graph with increased fraction collection between 50-65 minutes 
and 20.56mg sample load. Non synchronous CCC run at a Pr of 0.33. Carried out with CCS 
(crude sample), flow rate of 10ml/min. Samples analysed by protein A HPLC, 8 minute 
injection time and 80µl injection volume. IgG HPLC peak area (6 minute peak) and impurities 
(0.1 minute peak) plotted against time of elution. 
 
Purification of non-synchronous CCC run 2 fractions was observed by an SDS PAGE 
gel and silver stain. The method as described in Section 3.42 was used for the running 
of the SDS PAGE gel and sliver staining was carried out as described in Section 4.4.2. 
The use of silver stain ensured not only the separation of IgG from impurities but that 
all impurity where accounted for.  
 The results are shown in Figure 7.4.5.4, a molecular weight marker 
is used for indication, along with control samples of PA purified IgG and crude CCS 
which are compared to the eluted impurities and purified fractions following non 
synchronous CCC. Firstly the eluted impurities as shown in Fraction 9 and 10 had a 
very similar banding to that of the CCS. Furthermore the purified IgG fractions (54-
56) had much fewer bands than compared to the crude starting CCS material. The 
CCC purified fractions resemble that of the PA purified control, all unwanted protein 
bands from the CCS appear to have been removed and are captured in the eluted 
impurities fractions.  
 
 
Elution time graph: Non synch Pr=0.33, flow rate=10ml/min, CCS  
20.26mg, 29.8ml sample loop, flowing from centre to periphery,  
upper phase salt 
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Figure 7.4.5.4: Reduced SDS PAGE gel, samples from Figure 7.4.5.3 used. Gel run at 150V 
using a pre cast tris-glycine gradient gel. 10µl sample injected into each respective well along 
with the molecular weight marker, PA purified IgG control and crude starting CCS sample. 
Gel then subject to silver stain.  
 
Purification by the non-synchronous CCC which was comparable to that of the protein 
A control was shown by SDS PAGE in Figure 7.4.5.4. When the purity of time point 
Fractions 55 and 56 (Figure 7.4.5.2) are just considered an IgG purity of 85.93% can 
be attained following Protein A HPLC analysis. The majority of impurities were 
accounted for and the gel highlighted the removal of bands, (hence proteins) following 
non synchronous CCC purification. 
7.4.6 Effect of mass balance, purity and viable IgG recovery on 
throughput. 
The results in Figure 7.4.6.1 show the effect of increasing sample load on mass 
recovery, biological activity recovery and purity. IgG amount in mgs in the CCS 
starting material is initially listed, this was calculated using protein A HPLC analysis 
and the calibration curve in Figure 7.4.2.1. Mass recovery was calculated by summing 
all fractions used that contributed to purity, as a percentage of that initially loaded in 
the CCS. Biological activity was calculated by determining the percentage of 
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functional PA binding IgG post a CCC run in comparison to that of the starting 
control. Purity was calculated as a percentage of the PA binding IgG HPLC peak area 
to that of the peak area of the corresponding impurities within the fractions.  
 
 
 
Figure 7.4.6.1: The effect of increasing sample load on mass recovery, biological recovery 
and corresponding purity. Increased CCS starting concentrations. Samples subject to protein 
A HPLC analysis. Recovery calculated by the change in IgG amount at the start of the run to 
that at the end of CCC processing.  
 
In order to improve the purity only fractions of 10% of the starting amount were 
considered. Figure 7.4.6.1 showed biological recovery was always high (>88%). 
Purity however seemed to decrease slightly as concentration increased. The results 
showed that even when sample load was pushed to 20.26mg (10 fold that of the 
starting concentration), purity and biological recovery was not greatly affected, 
showing promise for future runs.  
 
IgG in 
CCS 
(mg) 
% 
Mass 
recovery 
Biological 
activity 
recovery Purity 
1.34 74.60 89.29 98.48 
1.51 86.09 86.64 93.87 
4.53 88.37 88.37 99.13 
10.81 90.66 104.53 92.38 
11.32 80.39 93.61 89.91 
20.26 78.48 96.72 85.93 
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7.4.7 Investigation of associated g force with non-synchronous CCC 
processing 
A variable and high g-force was previously implicated in contributing to the IgG 
degradation. High g-force however was needed to allow the stationary phase retention 
required for resolution. As seen in chapter 5, a continual g force, when material was 
spun down in a bench top centrifuge, was not detrimental. The varying g force created 
within the CCC machines, along with the sheer created by the two phases, was 
investigated using the g force program (as introduced in Figure 7.2.3). With the use of 
the Pr ratio, beta values and radius, as listed in Figure 7.4.7.1, g force ranges were 
calculated. 
 
 
 
 
Figure 7.4.7.1:  Overview of Pr ratios used for differing CCC machine types and respective 
beta values with radius. Figures were used to calculate g-force ranges using Dr Van den 
Heuvel’s program.  
 
Using the above figures and corresponding rotational speed, the g force program was 
used to determine the minimum, maximum and mean predicted g force (Figure 
7.4.7.2). Highlighted in red were the best conditions for each machine in terms of 
retention of the biological activity of the IgG. The g force program had the ability to 
calculate both tangential and radial g force, for this work radial g force was observed.  
 
 
 
 
 
 
Machine Pr ratio Beta values 
(mm) 
Radius 
(mm) 
CPC 0 1 70 
TC CCC 1 0.85 110 
Mini CCC 1 0.85 50 
Non synch 0.33 or 0.67 0.85 110 
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Figure 7.4.7.2: Varying machine types and modes of CCC operation. Figures grouped by 
machine type, Pr ratio, IgG recovery, sample type, rotational speed and respective g-force 
range (minimum, maximum and mean) using Dr Van Den Heuvel’s g force program 
 
The g force created by the non-synchronous CCC at both Pr ratios (0.33 and 0.67) was 
much lower when compared to the multilayer CCC (Mini), TC-CCC and CPC (Figure 
7.4.7.2). From an engineering stance, as rotational speed increased, so did the 
associated g force. In the Mini CCC and the TC-CCC the higher the g force, the 
greater the difference ( g) between maximum (gmax) and minimum (gmin) values. 
When using the highest rotational speed as an example, a g= 362.3 for the Mini CCC 
and g =354.2 for the TC CCC was seen. With the non-synchronous CCC however, 
this g =< 157.  
 When CCC machines are ordered in terms of increasing g force a 
very clear pattern can be seen. Results are shown in Figure 7.4.7.3, the hydrodynamic 
machines with the lowest g force (non-synchronous and Mini CCC) are plotted first 
then the hydrostatic (CPC and TC CCC) machines. It can be seen that as g force 
increases, recovery of functional IgG decreases. G force appears detrimental to IgG 
functionality. Consequently a pattern was seen in terms of the machines that provided 
Pr ratio Machine Recovery 
of viable 
IgG 
(%) 
Concentration 
IgG loaded  
(mg) 
Sample Rotational 
speed (rpm) 
Minimum 
'g' 
Maximum 
'g' 
Mean 
predicted 
'g' 
 
0 CPC 56.00 
 
18.06 PA Purified IgG 2000 577.00 577.00 577.00 
0 CPC 71.41 18.22 PA Purified IgG 2000 577.00 577.00 577.00 
0.33 Non synch 79.35 18.15 PA Purified IgG 800 39.00 196.50 117.70 
0.67 Non synch 79.99 18.01 PA Purified IgG 800 106.90 264.30 185.60 
0.33 Non synch 89.29 1.34 CCS 800 39.00 196.50 117.70 
0.33 Non synch 86.64 1.51 CCS 800 39.00 196.50 117.70 
0.33 Non synch 88.37 4.53 CCS 800 39.00 196.50 117.70 
0.33 Non synch >100 10.81 CCS 800 39.00 196.50 117.70 
0.33 Non synch 96.72 20.26 CCS 800 39.00 196.50 117.70 
1 Mini 60.77 2.18 PA Purified IgG 800 84.40 156.00 120.20 
1 Mini 46.35 2.22 PA Purified IgG 1000 131.90 243.80 187.90 
1 Mini 41.05 2.13 PA Purified IgG 1200 190.00 351.00 270.50 
1 Mini 81.97 1.46 PA Purified IgG 1200 190.00 351.00 270.50 
1 Mini 44.72 0.82 CCS 1200 190.00 351.00 270.50 
1 Mini 77.12 0.84 CCS 1200 190.00 351.00 270.50 
1 Mini 56.88 0.79 CCS 1500 296.90 548.50 422.70 
1 Mini 44.24 0.79 CCS 1800 427.50 789.80 608.70 
1 Mini 57.49 0.35 PA Purified IgG 1800 427.50 789.80 608.70 
1 TC-CCC 60.54 13.95 PA Purified IgG 900 237.30 436.60 336.90 
1 TC-CCC 68.35 14.15 PA Purified IgG 1200 421.90 776.10 599.00 
1 TC-CCC 16.33 11.15 PA Purified IgG 1200 421.90 776.10 599.00 
1 TC-CCC 58.21 14.09 CCS 1200 421.90 776.10 599.00 
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the greatest IgG recovery. A trend appeared which highlighted the most detrimental 
machines to IgG functionality to be equally the CPC and TC-CCC. This was followed 
by the Mini CCC and then the non-synchronous CCC, which provided the best 
recoveries with the lowest g force.  
 Even when the non-synchronous CCC was used at a Pr of 0.67, the g 
force fields created were similar to that of the Mini CCC. Similar recovery was seen 
with 79.99% of IgG activity retention with the non-synchronous CCC at a Pr of 0.67 
and 81.97% IgG recovery with the Mini CCC. It further highlighted the ability of the 
non-synchronous CCC to provide a low g force separation, not detrimental to IgG 
recovery with a Pr ratio of 0.33.  
 
                           Hydrodynamic         Hydrostatic  
Figure 7.4.7.3: Representation of the effect of varying machine types on viable IgG recovery 
and corresponding mean g force value. g force mean calculated using the g force program. 
Recovery was calculated using protein A HPLC, where change in IgG concentration post 
CCC to initial starting concentration was calculated as a percentage. 
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7.5 Conclusions 
A thorough investigation of the non-synchronous CCC has been conducted. The novel 
machine allows the independent control of mixing and settling, which was exploited to 
allow increased rotor to bobbin rotations (Pr ratio).  With a J type Mini CCC the Pr 
ratio is always 1, with non-synchronous CCC this Pr ratio can be changed. 
Investigations were carried at by reducing the Pr ratio to 0.67 and 0.33, to allow 
increased settling time with decreased mixing. 
In previous chapters, mixing at a Pr ratio of 1 on the Mini CCC with wave like 
mixing was sufficient to cause loss to IgG functionality. With the non-synchronous 
CCC, investigations at a Pr ratio of 0.33 and 0.67 with crude material showed clear 
high resolution separation of IgG from impurities. It was seen however, even at 
reduced Pr ratio of 0.67, this was still sufficient to cause IgG damage when compared 
to a ratio of 0.33. Additionally, at this Pr 0.67 ratio, IgG resolution was decreased due 
to reduced settling times. 
One of the most critical parameters noted in the study of this mAb separation 
using CCC has been settling time. Vigorous mixing which was previously highlighted 
(both in the literature and by the Brunel CCC group) as key has been seen as 
secondary to settling. Low interfacial tension and density differences between the 
phases meant vigorous mixing was not critical.  However, adequate settling time, 
where IgG could experience mass transfer, was vital. Even at a Pr ratio of 0.67, this 
level of settling for the amount of mixing offered was not sufficient.  
By optimisation of the sample fraction collection in a non-synchronous CCC 
run at a Pr ratio of 0.33, clear separate elution of the IgG from impurities was seen and 
furthermore confirmed by SDS PAGE and silver stain. Loading capacity was pushed 
to 20.26mg of IgG with a 29.6ml sample loop and a separation was demonstrated.   
 With the use of the g force program, the clear relationship of 
increased g force ranges created by various machines (both hydrostatic and 
hydrodynamic) and degradation to IgG functionality were seen. A significantly lower 
g force was created with the non-synchronous CCC machine, especially at a Pr ratio of 
0.33. As mentioned in other chapters, degradation was not resultant on a single 
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parameter. However g force created within the machine itself was clearly a major 
factor. 
 Work within this chapter has showed the separation of IgG from 
impurities with the retention of biological activity by the non-synchronous CCC at a 
Pr of 0.33. Clearly sample loading and throughput could be improved, as the sample 
must be prepared in a two phase system. The work that is detailed in the next chapter 
investigates non-synchronous CCC fractions undergoing rigorous quality control 
testing at Lonza. A direct comparison of this technology in terms of purification with 
Protein A HPLC can hence be drawn. These results will be indicative of whether this 
technology could possibly, with optimisation, be an economical alternative to Protein 
A HPLC purification.   
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8.1 Summary 
 
A CCC operational mode with a non-synchronous machine at a Pr ratio of 0.33 has 
been found. At a Pr ratio of 0.33, rotor rotations are increased relative to those of 
bobbin rotations, allowing greater phase settling time with reduced mixing. A 
correspondingly lower g force range results, that was sufficient to allow high 
resolution separation but retain IgG functionality. This was the first time such results 
had been achieved with any CCC instrument used and these fundamental studies 
showed promise for the separation of biologics.  
 Following the work on the non-synchronous CCC, an investigation 
to characterise the purified proteins at Lonza was carried out by their purification 
scientists. A range of QC assays were conducted that demonstrated not only the 
removal of product contaminates such as free DNA and host cell proteins but also 
highlighted any evidence of structural changes. It was seen that the removal of 
impurities by the non-synchronous CCC processing is possible, but a significant 
amount of optimisation work is essential. Due to the mixing and setting that occurs as 
part of the CCC technique, compounded also by the high concentration of PEG and 
salt used, aggregation of the IgG was not surprising. Isoelectric focussing results 
showed that some structural changes had occurred post non synchronous CCC that 
were not evident with the PA purified IgG control.  
 The fundamental work that has been carried out within this project 
has given a positive indication. With significant process optimisation, the non-
synchronous CCC may possibly be adopted in the future as an industrially used 
purification protocol. The consideration of other purification steps that can be aligned 
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with CCC must be investigated. The removal of all product related contaminates 
should be observed following three separate purification steps, as opposed to just one 
protocol.  The production of aggregates or any structural changes however that have 
been implicated following QC testing by CCC processing, requires considerable 
further investigation.  
8.2 Introduction 
 
As detailed in Chapter 7, the best CCC instrument for mAb separation was found to be 
the non-synchronous machine. Furthermore, a rotor to bobbin rotational speed ratio of 
0.33 was identified as the most appropriate. At this Pr ratio both the retention of mAb 
biological activity and also high resolution separation from impurities was possible. 
As shown with the work in other chapters (judged using PA binding as an indicator), 
this was the only machine tested thus far that was able to fulfil the criteria of 
separation and retention of biological activity.  
Non synchronous CCC sample were investigated with a range of quality 
control assays. These assays were conducted at Lonza by their purification scientist. 
Non synchronous runs were carried out in triplicate and the preparation of samples and 
reproducibility is documented. The studies within this chapter described the reasoning 
for why particular assays were conducted and what the results showed. Ultimately this 
chapter will debate whether optimisation of the fundamental CCC conditions found 
within this work would be sufficient to interest future industrial use of this technology.  
   
8.3 Method and materials 
 
8.3.1       Investigation of sample up clean using PD-10 size exclusion columns 
  
 
All quality control assays were performed at Lonza by their purification scientists. To 
allow these assays to be conducted without interference from the presence of the 
phase system, most specifically the PEG mobile phase, sample clean-up was required. 
A form of buffer exchange was necessary to exchange the IgG from the PEG phase to 
a low salt formulation buffer used at Lonza (10mM sodium phosphate/40mM sodium 
chloride pH 7.0). Initially this was investigated with the non-synchronous CCC 
samples. PD-10 columns were purchased from GE healthcare, which were designed 
for the clean-up of biological molecules of >5kDa. As the PEG was 1kDa this column 
was thought to retain the IgG within the pores, allowing other impurities and 
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contaminants to flow straight through the column (termed flowthrough). The elution 
of the IgG from the column was by the use of an elution buffer.  
 PA purified IgG was made up in both water and upper phase 
respectively and applied to a fresh PD-10 column (2ml of PA purified IgG and 18ml 
of water or phase). A sample was taken prior to PD-10 column loading (named pre 
PD-10) and 25ml of Lonza formulation buffer (10mM sodium phosphate/40mM 
sodium chloride pH 7.0) was used to equilibrate the column. 2.5ml of PA purified 
IgG sample in either upper phase or water was applied to the column. The flow 
though that eluted was collected. Anything that eluted in the flowthrough was 
assumed to be PEG or salt, as the IgG was thought to be retained inside the column 
pores The PD-10 column was then washed once with 3.5ml of formulation buffer 
(Eluate 1) and then subsequently with another 3.5ml of formulation buffer (Eluate 2), 
these samples were collected separately. Formulation buffer was applied to the 
column to prompt the elution of IgG retained in the column pores.  
 
Figure 8.3.1.1: Schematic overview of the PD-10 column sample cleanup process. Buffer 
exchange was used to swap the phase system non synchronous CCC IgG samples into Lonza 
formulation buffer. Sample clean up was conducted to avoid any interference to QC assays.  
 
 
 All collected samples were subject to protein A HPLC and the HPLC peak 
areas can be seen in Figure 8.3.1.2. The results shown list changes in HPLC peak area 
following PD-10 treatment of IgG in water and the upper phase. It was seen in both 
samples when IgG peak area for flow through and eluate fractions were compared to 
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that of the pre PD-10 column, a considerable loss in IgG was seen. For the water 
control this was less than 2% and the upper phase sample <6%.  
 
  
HPLC peak area 
Water control Phase sample (upper) 
Non-
binding IgG 
% IgG 
of initial 
sample  Non-binding IgG 
% IgG of 
initial 
sample  
Pre PD-10 4768 1852955   360246 1904686   
Flow through 32629 31423 1.70 24201 102518 5.38 
Eluate 1 133166 27094 1.46 165986 113562 5.96 
Eluate 2 164579 25286 1.36 397144 27788 1.46 
 
Figure 8.3.1.2: Triplicate HPLC peak area of PA binding IgG and PA non-binding IgG at 
varying stages of PD-10 column sample clean up. PA purified IgG was applied to the column 
in upper phase and water as a control. The % IgG of initial sample was calculated with flow 
through and eluate samples as a percentage of the pre PD-10 HPLC peak area.   
 
 
It was thought with the water control that the IgG had not eluted and was 
subsequently stuck within the column. Several further rounds of washing steps were 
thought to be required to allow elution, however the resulting peak would be diluted 
over several fractions.  It was also noted that the non-binding peak appeared to be 
increasing and perhaps this was due to denaturing within the PD-10 column. This was 
thought unlikely however, as was not seen previously by gel electrophoresis.  
 With respect to the upper phase sample, it was seen that nearly 60% 
of the IgG came straight out in the flow through and wasn‘t retained in the pores of the 
column. It was considered that when the IgG was loaded onto the PD-10 column in 
PEG, the PEG was displacing the IgG. 
 Ultimately this work showed that the PD-10 columns were not 
suitable for buffer exchange of these samples due to the adverse effect of the presence 
of PEG. Possibly these filters were more suitable for globular proteins rather than the 
more complex IgG structure.  
 
8.3.2 Investigation of ultrafiltration columns for sample clean up 
 
The PD-10 columns based on size exclusion chromatography were seen inappropriate 
for IgG sample clean up post non synchronous CCC processing. A differing mode of 
sample clean-up was thus investigated with ultrafiltration columns from Sartorius 
known as Vivaspin columns. The Vivaspin columns were investigated over a range of 
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sample cut off values, ranging from 5-100 kDa. Samples were prepared as previously 
described (section 8.3.1.2) with PA purified IgG in water and upper phase. The residue 
was termed as the material retained by the filter and was re-suspended with 
formulation buffer to a final volume of 500µl. These samples were then subject to 
Protein A HPLC analysis. All experiments were carried out once at each filter size. 
The results are shown in Figure 8.3.2.1 where IgG in water and upper phase is 
subject to ultrafiltration using varying cut off size filters. Results are tabulated for 
filtrate and residue samples.  The filtrate was termed as all material eluted from the 
column, which would be predicted to contain the PEG. A control sample was prepared 
of PA purified IgG in either water or the phase system that had not been subject to 
ultrafiltration. Mass recovery of the IgG was calculated by determining the HPLC 
peak area of the IgG in upper phase post ultrafiltration as a percentage of the control 
IgG.  It can be seen in Figure 8.3.2.1 that as ultrafiltration cut off size increases the 
amount of IgG retained in the residue decreases. Hence the mass recovery of IgG 
decreases as cut off value kDa increases. Figure 8.3.2.2 is a diagrammatic 
representation of Figure 8.3.2.2 and the results show percentage IgG plotted against 
ultrafiltration filter size. A downward slop of IgG recovery in residue samples is 
shown when filter size increases. An increase in IgG recovery in filtrate sample can 
only be seen at 100 kDa. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3.2.1: Investigation of a number of ultrafiltration cut off sizes. HPLC peak areas of 
PA binding IgG and PA non-binding IgG with the differing filters are listed. PA purified IgG 
was applied to the column in upper phase and just in water as a control and the mass recovery 
determined.   
 
Sample 
Cut off 
value 
(KDa) 
HPLC peak area 
Mass IgG 
recovery (%) 
Water control Upper phase 
Non-binding IgG Non-binding IgG 
residue 
5   40025 1207180 110.00 
10   564498 783657 71.41 
30 4446 2048461 709815 403967 36.81 
50 1203089 23904 542124 324988 29.61 
100 788430 71524 243350 64321 5.86 
Filtrate 
5   611937 30169 2.75 
10   636263 29448 2.68 
30 10775 75979 617652 17344 1.58 
50 11147 50316 660826 26060 2.37 
100 25414 39262 584091 398046 36.27 
Control 5978 2104346 711248 1097420  
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Figure 8.3.2.2: Diagrammatic representation of Figure 8.3.2.1. Effect of increasing 
ultrafiltration cut off size on IgG mass recovery in both residue and filtration samples.  
Starting sample of PA purified IgG in upper phase used.  
 
 
As shown in Figure 8.3.2.2, as the ultrafiltration cut off size increased (kDa) the IgG 
mass recovery (calculated in relation to the control) decreased. Interestingly, using the 
5kDa filter, greater than 100% IgG recovery was seen. Further to this, the non-binding 
peak was greatly reduced when compared to the control by around 94%, which was 
assumed to be the removal of the PEG. These results showed ultrafiltration with a 5 
kDa filter had some potential and was therefore used for sample clean up post non 
synchronous CCC processing.  
 
8.3.3: Triplicate non synchronous CCC run with sample clean up using a 5kd 
ultrafiltration column. 
 
A triplicate non synchronous CCC run at a Pr ratio of 0.33 was conducted, with 
samples subject to 5kDa clean, prior to delivery to Lonza for a range of QC assays. As 
the previously used batch of CCS had finished, an older batch that was still available 
was used (465668/47). As this IgG4 batch produced at Lonza was used for research 
purposes only, no more was available in their storage. The CCC processing conditions 
as detailed in Figure 8.3.3.1 were used and repeated in triplicate.  
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Non synchronous CCC separation 
ATPS…17.5/17.5% w/w..…PEG/Salt, pH…7.42  
PEG……1000…Salt …Sodium citrate 
Coil volume……475ml 
Sample loop……29.8ml 
Operating mode…Forward flowing from head to tail 
Stationary phase………Lower phase 
Column filled at ……50ml/min 
Injected mAb: 
1) CCS……… (Batch number …465668/47/47) 
       Volume…........32.5ml diluted with:  
        …..8.75g sodium citrate 
        …..8.75g PEG 
Spin speed…800rpm, temperature….20°C, flow rate…..…10ml/min 
Equilibrated at……10ml/min,  
Stationary phase displaced.….425.…..ml            % stationary phase retention……..10.5% 
Figure 8.3.3.1: Non synchronous CCC conditions used for the production of triplicate samples 
for QC testing. 
 
Results from each separate run and the samples chosen for QC testing are 
highlighted in Figure 8.3.3.2. The table lists HPLC peak area, concentration of IgG in 
mg (obtained using the calibration curve in Figure 7.4.2.1) and mg per fraction 
(obtained by multiplying the IgG concentration by the sample volume). The HPLC 
peak area of the impurities (from the 0.1 minute peak following protein A HPLC 
analysis) is also noted with background corrections made.  It can be seen for all runs 
that the majority of the IgG eluted at 54 minutes. Furthermore the recovery of 
functional IgG in all runs was > 95%. The peak area of the impurities that is also listed 
showed the majority of elution was around 40-52 minutes, which was before the 
elution of the IgG. Figure 8.3.3.3 is a diagrammatic representation of Figure 8.3.3.2 
where HPLC peak area is plotted against elution time in minutes. The clear separate 
elution of IgG from impurities in all three runs can be seen. The impurities elute as a 
large heterogeneous peak in comparison to the smaller sharper elution of the IgG peak.  
Moreover the elution profiles of the three runs showed reproducibility. 
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Figure 8.3.3.2: Triplicate non synchronous CCC data for preparation of sample for Lonza quality assurance assay. PEG 1000 17.5%/17.5% sodium 
citrate system used. Fractions highlighted in red were selected and subject to samples clean-up to remove PEG by use of 5kDa ultrafiltration column.   
Fraction Time 
(minutes) 
Volume 
of sample 
(ml) 
Run 1 Run 2 Run 3 
PA binding 
IgG HPLC 
peak area 
PA 
binding 
IgG conc/ 
mg/ml 
PA 
binding 
IgG mg 
per 
fraction 
Impurities 
HPLC peak 
area 
PA 
binding 
IgG HPLC 
peak area 
PA binding 
IgG conc/ 
mg/ml 
PA 
binding 
IgG mg 
per 
fraction 
Impurities 
HPLC peak 
area 
PA binding 
IgG HPLC 
peak area 
PA binding 
IgG conc/ 
mg/ml 
PA 
binding 
IgG mg 
per 
fraction 
Impurities 
HPLC 
peak area 
Control  29.8 755793 0.20 5.96 8233613 731598 0.20 5.87 8278239 342884 0.19 5.71 8015167 
Control   29.8 758330 0.20 5.96 8555857 766446 0.21 6.16 8211093 322611 0.19 5.71 8423940 
Control  29.8 726270 0.20 5.96 8895632 696503 0.19 5.58 8108793 333196 0.19 5.72 8321759 
1 5 50 0   0 0  0.00 0 0   0 
2 10 50 0   0 0  0.00 0 0   0 
3 15 50 0   0 0  0.00 0 0   0 
4 20 50 0   0 0  0.00 0 0   0 
5 25 50 0   0 0  0.00 0 0   31421 
6 30 50 0   0 0  0.00 0 0   55017 
7 35 50 0   0 0  0.00 0 0   67381 
8 40 50 0   139500 0  0.00 158926 0   162380 
9 45 50 0   1266601 0  0.00 1470564 0   1334060 
10 50 50 0   2449688 0  0.00 2620642 0   2823823 
 
51 10 0   1229256 0  0.00 1300349 0   1481684 
52 10 0   630054 0  0.00 500462 74609 0.01 0.13 624007 
53 10 0   23978 98611 0.02 0.19 0 137229 0.03 0.30 62384 
54 10 1529092 0.42 4.21 0 1367580 0.38 3.75 29249 1369268 0.42 4.18 19889 
55 10 576438 0.15 1.53 0 525643 0.14 1.39 49522 462282 0.12 1.21 0 
56 10 133620 0.03 0.29 0 316663 0.02 0.25 11567 0   0 
57 10 0   0 0  0.00 117213 0   0 
58 10 0   0 0  0.00 97238 0   0 
59 10 0   0 0  0.00 66126 0   0 
60 10 0   0 0  0.00 36122 0   0 
Total mg of functional IgG in 
fractions 
6.03 5.58 5.82  
Total mg in functional IgG in 
injection load 
5.96 5.87 5.71  
% recovery of functional  IgG 101.22 95.17 101.93  
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Figure 8.3.3.3: Non synchronous CCC separation at a Pr ratio of 0.33 reconstructed from protein 
A HPLC analysis chromatograms. 6mg IgG sample load used, 29.8ml sample loop at a flow rate 
of 10ml/min.  The elution profiles of the IgG and impurities from different runs showed 
similarities.  
 
 
8.3.4 Child’s assay for the removal of PEG from samples post ultrafiltration 
 
As PEG did not have absorbency at 280nm, it was hard to prove that it had been removed 
from samples post ultrafiltration by protein A HPLC. It had been seen previously that the 
presence of PEG caused interference to assays with band smearing. To observe that PEG 
had been removed in samples post ultrafiltration, before they were sent to Lonza for QC 
testing, the Child‘s assay was conducted. The Child assay developed in 1975 allows the 
determination of PEG removal in gamma globulin solution. Proteins are treated with 
barium and iodine producing a barium-iodide complex with the glycol allowing detection 
at 535nm (Child, 1975).   
 The Child‘s assay was used to quantitate the amount of PEG present in 
sample. 0.5ml samples of the IgG post ultrafiltration was mixed with 1.5ml of water.  2ml 
of 10m trichloroacetic acid (TFA prepared in water) was added to the IgG solution and 
allowed to stand for 15 minutes. A standard solution was then prepared with 0.5ml of 
BaCl2 solution and 0.25ml of 0.1 N iodine solution added to the IgG. Standard dilution of 
the PEG was made equalling samples of 10, 20, 30 and 40µg PEG (i.e. 0.5, 1, 1.5 and 2ml 
of standard solution to 1.5, 1, 0.5 and 0 ml of water). The sample preparation was repeated 
for ultrafiltration samples and 0.5ml of BaCl2 solution and 0.5ml iodine was added to each 
Elution time graph: Non synch Pr=0.33, flow rate 10ml/min, CCS batch 
number 46568/47(older), 29.8ml sample loop, flowing from centre to 
periphery, upper phase salt
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sample. The samples were then subject to a 100 times dilution and 250µl were then added 
to a multiwall plate and read at 562nm. The results can be seen in Figure 8.3.8.1 and the 
calibration curve in Figure 8.3.8.2.  It was determined that the starting PEG control had 
210µ/g of PEG present, following ultrafiltration Fraction 1 had 10.91µ/g of PEG, Fraction 
2 had 4.38µ/g of PEG, Fraction 3 4.99µ/g of PEG and Fraction 4 4.59µ/g of PEG present. 
Overall it was demonstrated that 97.82% of the PEG had been removed by ultrafiltration.  
 
x100 dilution Average 
Control: PEG 0.497 0.626 0.549 0.557 
STD 1 0.155 0.149 0.161 0.155 
STD 2 0.221 0.286 0.241 0.249 
STD 3 0.302 0.311 0.308 0.307 
STD 4 0.332 0.327 0.341 0.333 
UF1 0.046 0.039 0.42 0.168 
UF2 0.054 0.049 0.041 0.048 
UF3 0.071 0.064 0.059 0.065 
UF4 0.061 0.052 0.048 0.054 
Figure 8.3.4.1: Absorbency values using Child’s assay obtained with readings at 562nm with 
standard and ultrafiltration samples. The ‘STD’ sample was prepared following the heating of 
PEG to 60ºC and mixing with the appropriate amounts of barium and iodine. The same protocol 
was followed for the ultrafiltration samples labelled UF1-UF4 where the same standard dilutions 
were carried out. All samples were diluted 1 in 100 in water and read on the spectrophotometer.  
 
 
Figure 8.3.4.2: Calibration curve used to quantitate PEG following Child’s assay with the 
measurement of absorbance at 562nm.  
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8.3.5 QC assays conducted at Lonza by purification scientist Samit Patel 
 
A range of QC assays were conducted with the non-synchronous CCC fractions 
highlighted in Figure 8.3.3.2. The samples were subject to buffer exchange by the use of a 
5kDa ultrafiltration column. The concentration of the samples as determined by Protein A 
HPLC was 0.4mg/ml. The results for each assay are separately listed below.  
 
1) Removal of Host cell protein:  ELISA and dual stain Western blot 
 
The CHO cell line used to produce the mAb is derived from mammalian species than 
contain thousands of host cell proteins. During fermentation, additional proteins can also 
be produced that have the potential to contaminate the end product. Host cell protein 
removal assays are used to observe the clearance of HCPs present in the CCS starting 
material, that can ultimately affect the overall quality of the end product. It is a regulatory 
requirement to obtain the lowest level of HCP possible as they have the potential to cause 
adverse immune responses in patients or reduced drug efficacy.   
 A HCP ELISA and a dual stain Western blot were carried out. Each 
assay despite providing the same indication with an anti HCP antibody is very different.  
The ELISA for HCP removal is more sensitive when compared to the Western blot and 
quantitative. It measures the whole HCP and does not require any denaturation. The 
Western blot however is a very powerful tool to qualitatively determine HCP protein 
removal. Furthermore the Western blot can show the presence of product related band and 
confirm that no major structural changes have occurred. With the Western blot method 
however, denaturation with the use of a detergent is needed during electrophoresis, which 
can potentially destroy some antigenic determinants. Additionally some variants can be 
lost during the blotting protocol e.g. not transferred onto the membrane. Nonetheless the 
Western blot does allow the detection of multiple components with their relative molecular 
weight (Hoffman, 2000). As results are subject to individual user interpretation however a 
combination of both techniques (ELISA and Western blot) with the ELISA providing 
quantitative end point results is necessary.  
 An initial Western blot was carried out to show the removal of host cell 
proteins, seen in blue in Figure 8.3.5.2. A dual stain Western blot can subsequently be seen 
in Figure 8.3.5.3 with the retention of product specific functional IgG bands shown in red.   
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Sample ID 
Product 
Concentration 
(mg/ml) 
HCP 
Concentration 
(ng/ml) 
HCP 
Concentration 
(ng/mg) 
HCP removal 
(%) 
CCS 2.29 114004 261069  
CCS Post UF 0.38 89022 33828 
CCC Post UF Run 1 0.36 27944 10060 96.11 
CCC Post UF Run 2 0.32 25305 8098 
CCC Post UF Run 3 0.41 30064 12326 
Protein A IgG Std 15.12 <88.2 1323 99.49 
 
Figure 8.3.5.1: HCP ELISA removal results using samples post non synchronous CCC with 
sample clean up using 5 kDa ultra filtration columns.  
 
 
HCP removal by 96.11% post non synchcronous CCC and ultrafiltration was seen 
compared to a 99.49% HCP removal with the protein A purfied IgG control.  
 
 
 
Figure 8.3.5.2:   Western blot, showing in’ blue’ the removal of HCPs. Samples  following non 
synchronous CCC run at a Pr of 0.33. CCC samples that had not undergone sample clean up with 
5KDa ultrafiltration column can be seen to appear smeared and are not clear showing interference 
with the assay.  
 
 
 
 
 
 
 
 
 
 
 
 
Lane Sample ID 
Lane 1 
Molecular weight 
markers 
Lane 3 BSA / IgG IAC 
Lane 5 CHO HCP IAC 
Lane 7 Cell culture supernatant 
Lane 8 CCC Run 1 
Lane 9 CCC Run 2 
Lane 10 CCC Run 3 
Lane 11 
Cell culture supernatant 
(post UF) 
Lane 12 CCC Run 1 (post UF) 
Lane 13 CCC Run 2 (post UF) 
Lane 14 CCC Run 3 (post UF) 
Lane 15 
Protein A purified IgG 
standard 
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Figure 8.3.5.3: Dual western blot, showing ‘red’ product related bands and the presence of any 
host cell proteins seen by the ‘blue bands’. Samples following non synchronous CCC run at a Pr of 
0.33. CCC samples that had not undergone sample clean up with 5KDa ultrafiltration column can 
be seen to interfere with the assay.  
 
Following the Western blot to show the removal of HCP (Figure 8.3.5.2) it appeared that 
the CCC samples that had not undergone buffer exchange using ultrafiltration (lane 7 to 
10) interfered with the assay. The phase system appeared to mask the IgG and smearing of 
the HCP band was evident. CCC samples post ultrafiltration however (lane 12-14) did not 
interfere with the assay and had a distinct banding profile. The necessity for sample clean 
up post CCC with ultrafiltration was demonstrated, to allow QC testing without any 
interference.  
 Results from the dual stain western blot (Figure 8.3.5.3) showed the 
presence of similar product related bands as shown in red, that was comparable to the 
Protein A purified IgG control. However it also showed the presence of many additional 
HCP bands (blue) that had not been removed by CCC processing, but were removed in the 
Protein A purified IgG control. Most specifically this was evident at 6kDa, additionally 
existing HCP could also be seen around 31-66kDa, this demonstrated that HCP proteins 
had not been removed to a comparable level to that of the Protein A purified IgG control.  
2) Gel permeation HPLC  
 
Gel permeation HPLC is used for the estimation of monomers and aggregates in IgG 
samples post purification. Structurally altered proteins which can arise during purification, 
processing and storage can lead to the formation of aggregates and precipitation. Stability 
Lane Sample ID 
Lane 1 
Molecular weight 
markers 
Lane 3 BSA / IgG IAC 
Lane 5 CHO HCP IAC 
Lane 7 Cell culture supernatant 
Lane 8 CCC Run 1 
Lane 9 CCC Run 2 
Lane 10 CCC Run 3 
Lane 11 
Cell culture supernatant 
(post UF) 
Lane 12 CCC Run 1 (post UF) 
Lane 13 CCC Run 2 (post UF) 
Lane 14 CCC Run 3 (post UF) 
Lane 15 
Protein A purified IgG 
standard 
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of proteins post purification is vital to avoid any major safety concerns in patients e.g. 
anaphylactoid reactions (Arakawa et al., 2006).  
 Gel permeation HPLC is based on the separation of molecules by their 
size or hydrodynamic volume, as opposed to their molecular weight. The column is packed 
with porous beads and molecule elution time is based on size. An example is shown in 
Figure 8.3.5.4, molecules of a larger hydrodynamic volume will elute first i.e. the 
aggregates followed by the monomer. The smaller anaylets i.e. fragment will be retained in 
the pores, thus eluted last with prolonged retention time. All components of the sample can 
consequently be separated out and the differing proportions of the sample calculated 
(aggregates, monomers and fragments). 
 The results of the non-synchronous CCC samples following gel 
permeation chromatography can be seen in Figure 8.3.5.5. The Protein A standard is 
compared to that of the CCS sample pre and post CCC. Samples are divided into the 
respective percentage of fragment, monomer and aggregates they contain. It can be seen 
that post CCC processing samples contained 84.01% monomers; this is compared to 
99.45% seen with the protein A purified IgG standard. Post CCC processing samples also 
contained 2.04% of fragments. Aggregates levels however were higher than that of the 
protein A control at 10.96% following CCC processing, this compared to 0.55% with the 
protein A purified IgG control.  
 
Figure 8.3.5.4: Example gel permeation HPLC chromatogram seen for CCC run 3 purified sample 
and the protein A purified IgG standard.  
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Sample name Average (%) 
Total fragment Total monomer Total aggregate 
Protein A purified IgG standard 0.00 99.45 0.55 
Control pre CCC 27.94 66.82 5.25 
CCC purified sample post UF clean up 5.04 84.01 10.96 
Figure 8.3.5.5: Gel permeation HPLC results averaged from triplicates from all samples tested 
post non synchronous CCC processing. Samples broken down into the respective percentages they 
contained of fragments, monomers and aggregates.  
 
 
It could be seen that the CCS control prior to CCC had a low monomer percentage of 66.82 
which could actually be due to the age of the sample. Ultimately it was seen that CCC 
processing, when compared to that of protein A HPLC, was producing aggregates and 
fragments not typically seen. The results were either due to the age of the samples or more 
likely the mixing and settling associated with CCC and the high PEG and salt 
concentrations.  
 
3) Isoelectric focussing 
Isoelectric focusing was used to determine if any structural changes had occurred during 
CCC processing which would be evident from the resulting banding pattern.  With 
isoelectric focusing proteins are separated on the basis of their isoelectric point (pI), which 
is the pH at which the protein has no net charge.  
 To enable isoelectric focussing, proteins are loaded onto a 
polyacrylamide gel and an immobilised pH gradient strips containing a fixed pH gradient 
is affixed to the gel. By the use of an electrical field migration of proteins through the pH 
gradient is possible, until they reach their pI. The resolving power of isoelectric focusing 
has been demonstrated as much higher than normal electrophoresis, where proteins of the 
same size would be resolved as a single band (Maguire, 2006).  
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Figure 8.3.5.6:  Isoelectric focusing results using non synchronous CCC samples post 
ultrafiltration sample clean up from runs 1, 2 and 3. Samples separated according to their pI as 
labelled on the left hand side of the gel. 
 
Isoelectric focussing results and the respective pI range for each sample can be seen in 
Figure 8.3.5.6. With the CCC samples (Lane 4, 5 and 7) additional bands are present when 
compared to the PA purified IgG control. The pI range spans 5.20-8.45 with the CCC 
samples while only from 6.55-8.15 with the protein A purified IgG control. The presence 
of these additional bands seems to suggest that a structural change has occurred during the 
CCC purification run. A modification of amino acid residues on side chains, affecting 
protein charge could also have occurred.   
 
4) qPCR 
Quantitative PCR (qPCR) is used to demonstrate the removal of free DNA.  Monoclonal 
antibody production is by recombinant DNA technology, where therapeutic proteins are 
secreted outside of mammalian cells into the surrounding culture medium. It is therefore a 
regulatory requirement to obtain a final product with less than 100 pg of cellular DNA per 
dose (as stated at Lonza). This is especially important as mAb are taken over prolonged 
periods of time with repeat injections. CCC samples were subject to qPCR and the 
resulting free DNA in corresponding samples is listed in Figure 8.3.3.8. The results 
showed that for all three runs the CCC samples showed the removal of free DNA to similar 
levels. 
Lane Sample ID pI range 
2 pI Markers n/a 
3 CCS 3.50-8.15 
4 CCC post UF Run1 5.20-8.45 
5 CCC post UF Run2 5.20-8.45 
6 Blank n/a 
7 CCC post UF Run3 5.20-8.45 
8 Protein A Standard 6.55-8.15 
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Sample 
Protein Conc 
mg/ml 
Results 
pg/ml Results pg/mg 
CCS Post UF 0.38 6949.7 18288.7 
CCC Post UF Run 1 0.36 735.2 2042.2 
CCC Post UF Run 2 0.32 1156.5 3614.2 
CCC Post UF Run 3 0.41 1152.5 2811.1 
STD error: CCC Post UF  0.03 139.77 453.83 
Protein A IgG Standard 43.00     
Figure 8.3.5.7: qPCR results for the removal of free DNA post non synchronous CCC processing. 
The samples are compared to that of the protein A purified IgG standard.  
 
Post CCC processing a tenfold drop in free DNA was seen (Figure 8.3.5.7). However when 
compared with the protein A purified IgG control (43pg/mg of free DNA) the CCC 
processing (average of 2822.5pg/mg of free DNA) had a difference of removal of >65 fold.    
8.3.6   Summary of results  
 
Results from the QC testing conducted for the non-synchronous CCC samples are 
tabulated in Figure 8.3.6.1 and compared to those routinely achieved for samples following 
Protein A purification. The table is listed such that each QC assay is described in terms of 
the reason for investigation and then the results achieved by both purification methods.  
 The non-synchronous CCC samples appeared out of the QC assay 
specification set by Lonza for samples tested following Protein A purification. The CCC 
samples had > 7 fold more HCP (measured in ng/ml) presents with those of a lower 
molecular weight (6kDa) persisting. By isoelectric focusing it was seen that the pI range of 
the CCC samples had been extended. By gel permeation chromatography monomer levels 
were at 84.01% as compared to the expect 98% seen post PA HPLC purification, 
furthermore a degree of aggregation was seen in samples (10.96%). Whilst a >281 fold 
difference in the removal of free DNA was seen when the samples were compared post 
qPCR.  
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QC assay Investigation 
of 
Non synchronous CCC 
QC results  
Specification  set at 
Lonza following protein 
A purification 
HCP ELISA Removal of 
host cell 
proteins 
(HCP) 
 27771 ng/mg  ≤ 50 ng/mg 
HCP western 
blot 
Removal of 
host cell 
proteins 
(HCP) 
 Removal of most HCP 
but low 6kDa HCP 
proteins still present. 
 4 HCP bands still 
present 
 Removal of all HCP 
bands 
Isoelectric 
focussing 
Structural 
changes 
 pI range extended to 
5.20-8.45 with the CCC 
sample from that of 6.55-
8.51 for the PA purified 
IgG control.  
 Additional bands 
present suggest structural 
change had occurred. 
 PI range from 6-8.5 
Gel permeation 
chromatography 
Aggregation  Monomers: 84.01% 
 Fragments: 5.04% 
 Aggregates: 10.96% 
 Monomers:  98% 
 Aggregates: 2% 
qPCR Removal of 
free DNA 
 2811.1 pg/mg 
remaining 
 10pg/ml 
Figure 8.3.6.1: Comparison of QC results following non synchronous CCC processing to that of 
protein A purification.  
 
 Despite the clear need for optimisation of CCC samples to reach the 
required industry quality level, the results were promising. They showed a positive 
indication for the non-synchronous CCC for the separation of biologics. The reduction of 
aggregates formation during CCC runs however is critical. The focus of work now needs to 
be on assessing how CCC could be aligned with other techniques and then a re-evaluation 
of QC testing. As these non-synchronous CCC conditions have only been optimised to 
allow a separation that retains IgG biological activity many other lines of investigation e.g. 
use of differing phase systems such as ionic liquids etc must be considered, which may 
impact on QC data.  
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8.4 Conclusions 
Following the development of fundamental operating parameters (Chapter 7) purified non 
synchronous CCC samples were characterised by a range of Lonza quality assurance 
assays. CCC fractions were prepared in triplicate and reproducibility was noted. 
 Sample clean up by the PD-10 columns, which function based on size 
exclusion, were seen to be unsuitable for the mAb and perhaps more suited to globular 
proteins. The PEG was seen to displace the IgG, resulting in the IgG being lost in the flow 
through rather than being retained by the pores and collected with elution buffers. A more 
suitable method of sample clean-up was found following investigation with Vivaspin 
ultrafiltration columns. These allowed buffer exchange of the IgG from the phase system to 
Lonza formulation buffer. Furthermore they also allowed > 100% IgG mass recovery when 
a 5kDa cut off size was used. These columns were demonstrated to sufficiently removed 
PEG as seen by Child‘s assay.  
 When CCC samples were analysed by QC assays, 96.11% of the HCP 
had been removed as demonstrated by the ELISA. The presence of the HCP bands that had 
not been removed during CCC processing were evident with the Western blot, most 
specifically a prominent band at 6kDa. In total 4 HCP bands were still present in the CCC 
samples, compared to all HCP being removed in the Protein A purified IgG control. A 
tenfold removal of free DNA was demonstrated by qPCR with the CCC samples (2811.1 
pg/ml) as opposed to only 43pg/mg of free DNA being present in the Protein A purified 
IgG control. 
 Isoelectric focussing was used to detect any structural changes post CCC 
processing; the pI range for the CCC samples had been extended to 5.20-8.45 from that of 
6.55-8.51 of the Protein A purified IgG control. The presence of these additional bands 
suggested structural changes had occurred. These results were further confirmed by gel 
permeation chromatography which showed the monomer levels (usually > 98% with 
Protein A HPLC purified IgG) was only 84.01% with the CCC samples and as a result 
gave rise to 10.96% aggregates and 5.04% fragments.  
 The initial QC assay data showed that impurity reduction is possible; 
however significant future optimisation work is required. The work within this project has 
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culminated in finding a biological operating condition that allows both IgG purification 
and the retention of biological activity. Further work is required to optimise these 
conditions such that purity can be increased. These fundamentals must primarily be 
addressed to allow the industrial uptake of the technique and future comparison with PA  
purification to be drawn.  
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CHAPTER 9: General discussion, 
conclusions and future work 
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9) General discussion, conclusions and future work 
The work detailed within this thesis demonstrates for the first time the separation of 
monoclonal antibody from crude cell culture supernatant by CCC. Moreover the ability to 
attain a high resolution separation with the full retention of mAb biological activity has 
been shown. This fundamental work for the separation of biologics by CCC has allowed 
the determination of the required critical operating parameters. Furthermore the removal of 
most impurities has been demonstrated. Positive indications have been seen that further 
future optimisation would allow CCC purified samples the potential to approach industry 
standard. Ultimately CCC does not have to match Protein A purification, modification of 
the whole purification process would allow other remaining impurities to be removed. 
CCC also demonstrates a clear benefit compared to PA purification in terms of cost of 
goods. Protein A resin is currently priced around £10,000/L, with a maximum of 100 reuse 
cycles possible. Once the initial purchase and implementation cost of CCC had been 
considered all further expenditure would just be on consumables (e.g polymers and salt), 
that are considerable cheaper than the Protein A resin.  
Key to a successful biological separation by CCC is the choice of phase system 
employed. The systematic and logical approach offered by a liquid handling program was 
used in this work, allowing the creation of an array of various ATPS, with the mAb 
incorporated. In comparison to previous robotic work with aqueous organic systems 
(Garrrard, 2005), significant changes were made to robotic programming, mainly due to 
the nature of the ATPS. A Protein A HPLC analytical method was developed to tolerate 
the phase system, allowing the respective partition coefficients (K) of the mAb within 
phase systems to be calculated. Partition coefficients (K) were calculated for each ATPS, 
by the ratio of the mAb partitioning between upper to lower phase.  The PEG 1000 
17.5%/17.5% sodium citrate system was highlighted  as the most appropriate based on a 
high IgG recovery (>85% of that of the Protein A purified IgG control) and a partition 
coefficient in the range of 0.5-2.  
 It was previously highlighted in the literature review that column design 
was vital to permit high g force, high vigour mixing and sufficient stationary phase 
retention. These factors were thought imperative to accomplish protein separation by CCC. 
The majority of protein separation successes were therefore seen with hydrostatic 
machines, that permitted more vigorous cascade mixing. However, surprisingly and 
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completely against conventional wisdom, it was uncovered within this project that the 
choice of CCC machine affected the recovery of functional mAb.  Hydrostatic CCC 
columns (CPC and TC CCC) with different degrees of mixing vigour were seen to cause 
IgG degradation. The highest IgG recovery seen with the hydrostatic machines was only 
70%, despite separation from impurities being achieved, as shown by SDS PAGE and 
silver stain. A relatively higher recovery of 80% of IgG biological activity was seen with 
the hydrodynamic Mini CCC, however resolution of the IgG from impurities was lost with 
this wavelike mixing. Essentially a loss in the ability of IgG to bind to Protein A post CCC 
purification (in both hydrostatic and hydrodynamic machines) was seen. The CCC machine 
appeared to adversely affect IgG functionality, creating an unfunctional form termed 
Protein A non-binding IgG.   
 Auxiliary quantitative confirmation of the loss in IgG functionality by the 
use of Biacore analysis was obtained. Purified IgG following CCC had a reduced binding 
affinity to Protein A. The results indicated that only a weak binding association existed 
post CCC, rendering the IgG partially functional. In addition the degradation of model 
protein Myoglobin was seen post CCC with the production of Apomyoglobin, which was 
Myoglobin missing its haem group. The damage was thus confirmed and evident in more 
robust small protein molecules. Following a review of the literature, it appeared that 
biological recovery post CCC was frequently just assumed, and even those that did 
investigate it suffered losses.   
 Attempts at reversing or ceasing the production of this non-functional 
form by temperature, pH and sonication were not successful.  Investigation into a number 
of stages of CCC processing was conducted including IgG phase system incubation and 
mixing within the machine itself. No loss in the IgG biological activity was seen following 
phase system incubation (up to 50ºC) and when samples were subject to spinning at a 
constant g force. A custom built shaker was designed and investigated to emulate the 
mixing occurring in a CCC machine. It allowed the relationship between the phase system, 
the shearing effect, mixing vigour and the sample itself (PA purified IgG and CCS) to be 
investigated without the additional complications of stationary phase retention and flow 
rate in a CCC machine. Loss in IgG functionality was seen to involve a combination of 
factors rather than a single underlying cause. The presence of other protein components 
(anti-foaming agents, host cell proteins) in the CCS, which increased the total protein 
concentration were seen to affect the retention of IgG functionality. The interface of the 
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phase system was also highlighted to cause a loss of the IgG functionality. Losses however 
were still seen when the IgG was processed in a single phase (most greatly in the salt 
phase), however not to the same level of degradation as in the phase system. The motion of 
mixing or agitation even within one phase was hence suggested sufficient to cause IgG 
damage, which would be exacerbated when both phases were mixed together.  
Flow rate was determined as a foremost parameter in affecting IgG functionality. 
Increased flow rates allowed shorter CCC run times, consequently reducing the transit time 
of the IgG within the machine and significantly increasing the retention of functional IgG. 
However this increased flow rate conversely reduced IgG resolution from impurities. A 
reduction in rotational speed also improved the retention of IgG activity, but again to the 
detriment of the IgG peak width.  
Such losses in IgG biological activity could not gain regulatory acceptance or be used 
to exhibit the potential of CCC processing for industrial uptake. The need for a 
modification in CCC design was demonstrated as crucial within this work. The instruments 
had clearly been designed for more robust small molecule separation, as opposed to fragile 
larger biologics. An optimal CCC mode, to allow the retention of IgG biological activity 
whilst attaining a separation, was found to be the non-synchronous CCC machine. The 
novel machine, when operated in a hydrodynamic mode, allowed the independent control 
of mixing and settling, which was exploited to allow increased rotor to bobbin rotations (Pr 
ratio).  With a J type Mini CCC the Pr ratio is fixed at 1; with non-synchronous CCC this 
Pr ratio can be changed. As constraints were seen with this 1:1 ratio with the use of ATPS 
for protein separations, the Pr ratio was reduced to 0.33, allowing reduced mixing and 
increased settling time.  Retention of IgG biological activity was seen with sharp, high 
resolution separation of the IgG from impurities. This was the first time this had been 
achieved with any CCC machine tested thus far. Improvements of loading capacity from 
1.34mg to 20.26mg (tenfold) was additionally demonstrated with the maintenance of purity 
(>85%).  
  The most critical parameters noted in the study of this mAb separation 
and resulting CCC operational mode was settling time. Vigorous mixing was seen to be 
secondary to settling, despite mixing previously being considered in the literature as key, 
to allow sufficient mass transfer between the ATPS. Work within this project has shown 
vigorous mixing is not required due to the low interfacial tension, resultant from a minimal 
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density differences between phases. For aqueous organic systems, however, this is a 
critical requirement. However, adequate settling time, where IgG can experience mass 
transfer is vital. Which was further highlighted at a Pr ratio of 0.67, this level of settling for 
the amount of mixing offered was not sufficient. A loss in both IgG biological activity and 
resolution from impurities was seen. The use of the correct 0.33 Pr ratio, in the case of this 
mAb, has been seen to underpin the whole CCC separation. As a result the varying g force 
range associated with this machine was relatively much lower.  
 The clear relationship of increased g force ranges created by various 
machines (both hydrostatic and hydrodynamic) and degradation to IgG functionality were 
highlighted by the use of a g force program. A significantly lower g force was created with 
the non-synchronous machine especially at a Pr ratio of 0.33. IgG degradation was not 
resultant on a single parameter; however g force created within the machine itself was 
clearly a major factor. 
 Ultimately purified non-synchronous CCC samples using fundamentally 
determined operating parameters were characterised by a range of Lonza quality control. 
The necessity for sample clean up prior to the quality control analysis was seen and 
ultrafiltration columns at a cut off of 5kDa were used. The removal of PEG was further 
confirmed by the Child‘s assay.  The QC assays demonstrated the removal of 96.11% of 
host cell protein (HCP) by ELISA. By Western blot, results were observed qualitatively, 
four HCPs post CCC processing were not removed. Most specifically a prominent band at 
6kDa remained; this was in comparison to the Protein A purified IgG control where all 
bands were removed. A tenfold removal of free DNA was demonstrated by qPCR with the 
CCC samples (2811.1 pg/mg) as opposed to only 43pg/mg of free DNA being present in 
the Protein A purified IgG control. Structural changes in CCC purified IgG were also seen 
by isoelectric focussing, by the presence of additional bands. The pI range for the CCC 
samples had been extended to 5.20-8.45 from that of 6.55-8.51 of the Protein A purified 
IgG control. These results were further confirmed by gel permeation chromatography 
which showed monomer levels (usually > 98% with Protein A HPLC purified IgG) was 
84.01% with the CCC samples and as a result gave rise to 10.96% aggregates and 5.04% 
fragments. The initial QC assay data has shown that impurity reduction is possible; 
however significant future optimisation work is required to allow purification of product to 
the required level.   
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All the aims and objectives outlined in Chapter 1 have been met. A multiprobe 
robotic programme was developed to allow the investigation of mAb partitioning in a 
number of varying ATPS. Furthermore by the development of a Protein A HPLC analysis 
method, for mAb partitioning in a variety of phase systems was analytically determined.  
The completely unexpected loss in IgG functionality by various CCC machines resulted in 
the initially predicted hydrostatic CCC machines for protein separation being 
inappropriate. An optimal non-synchronous CCC machine was found. With significant 
optimisation and insight obtained from previous CCC runs, operating conditions were 
determined. These optimal operation conditions culminated in developing a CCC mode 
that allowed the retention of IgG biological activity whilst attaining high resolution 
separation. Furthermore, this proof of concept work has been seen via Lonza quality 
control testing to allow the removal of some impurities. Further work is required to 
optimise these conditions such that purity can be increased and structural changes avoided. 
The resulting verdict from the studies in this chapter showed indications of promise for the 
non-synchronous CCC mode in monoclonal antibody separation from bioreactor cell 
culture supernatant.   
 Future work is required to focus on preventing the structural changes that 
have been indicated by CCC. These fundamentals must be studied primarily to allow 
industrial uptake of the technique and furthermore any future comparison with PA 
purification to be conducted.  
Another area of future work is the sample loading capacity of the non-synchronous 
CCC. A major limiting factor with CCC is the requirement for the sample to be prepared in 
the ATPS, so as to not perturb the running of the machine. Consequently  this adds a 
dilution effect and must be balanced with the effect this had on resolution of the IgG from 
impurities. However from an engineering stance, the non-synchronous CCC coils can be 
tailored to this particular separation to allow the efficient use of the coil, resulting in 
increased throughput. The non-synchronous CCC coils used for the studies in this thesis 
were based on an academic model. The beta values of the coil could be changed depending 
on the Pr ratio. Therefore it was estimated that currently with the use of this non- 
synchronous CCC at a Pr ratio of 0.33, that only one third of the coil was being actively 
used, the remaining coil was filled with mobile phase. By an engineering change, where 
the coils are constructed based on a specific Pr ratio such that the beta values are continual 
and not variable, all of the coil could be efficiently used. Future work would allow 
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consideration of this, such that future to maximum coil volume usage is possible, which 
will ultimately increase the sample throughput. 
 A key benefit of the non-synchronous CCC, when compared to that of the 
Protein A chromatography is the cost reduction it offers. After the initial purchase of the 
machine and implementation into a manufacturing facility the only major costs that will be 
incurred are the purchase of the PEG and salt components. When this is compared to the 
cost of the Protein A resin it is much more economical. Additionally, future work can be 
conducted into polymer recycling, thermo separating polymers and also the use of ionic 
liquids, to further reduce the cost. As this work has shown, this technique could be useful 
on a small scale for the purification of high value product such as growth hormones or 
factors.  
 In conclusion, this work has indicated that monoclonal antibody purification 
by CCC is possible and an economically feasible alternative to Protein A purification. 
Significant future work however, is needed to allow samples to reach industry standard.  
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Appendix 
 
The presentation of aspects of this thesis at various conferences is detailed: 
 
1) Bioprocessing UK, Glasgow, Dec 2011 (Poster, bursary prize winner) 
Finding the balance between the retention of monoclonal antibody (mAb) biological 
activity and attaining a separation using Counter Current Chromatography (CCC) 
 
2) Biopartitioning and purification, Mexico, Sept 2011 (Oral platform presentation) 
Finding the balance between the retention of monoclonal antibody (mAb) biological 
activity and attaining a separation using Counter Current Chromatography (CCC) 
 
3) CCC 2010, Lyon, France, Jul 2010 (Poster) 
Monoclonal antibody purification using robotic phase system selection coupled with 
counter current chromatography (CCC) 
 
4) Bioprocessing UK, York, Nov 2009 (Poster, bursary prize winner) 
Monoclonal antibody purification using robotic phase system selection coupled with 
counter current chromatography (CCC) 
 
5) Biopartitioning and purification, London, 2008 (poster) 
Rapid ATPS selection method based on a liquid handling robot 
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